



Cite this: *Biomater. Sci.*, 2022, **10**, 6077

Current knowledge on the tissue distribution of mRNA nanocarriers for therapeutic protein expression

Matthias Zadory, Elliot Lopez,  Samuel Babity, Simon-Pierre Gravel and Davide Brambilla *

Exogenously delivered mRNA-based drugs are emerging as a new class of therapeutics with the potential to treat several diseases. Over the last decade, advancements in the design of non-viral delivery tools have enabled mRNA to be evaluated for several therapeutic purposes including protein replacement therapies, gene editing, and vaccines. However, *in vivo* delivery of mRNA to targeted organs and cells remains a critical challenge. Evaluation of the biodistribution of mRNA vehicles is of utmost importance for the development of effective pharmaceutical candidates. In this review, we discuss the recent advances in the design of nanoparticles loaded with mRNA and extrapolate the key factors influencing their biodistribution following administration. Finally, we highlight the latest developments in the pre-clinical and clinical translation of mRNA therapeutics for protein supplementation therapy.

Received 30th May 2022,
Accepted 6th September 2022

DOI: 10.1039/d2bm00859a

rsc.li/biomaterials-science

1. Introduction

Messenger RNA (mRNA) therapeutics can be used to replace proteins, produce antigens that raise an immune response, or transiently express components of gene-editing machinery. Because of this versatility, mRNA acts as a promising class of therapeutics, particularly for Mendelian disorders with established deleterious mutations, infectious diseases, immunological disorders, and cancer. Notably, as 85–90% of the protein-encoding portion of the human genome remains undruggable with current small chemical entities, mRNA approaches provide great hope for efficient treatments.^{1,2} Initial preclinical trials of local *in vitro*-transcribed (IVT) mRNA injections in the early 1990s demonstrated the potential of this technology for diverse protein replacement and vaccination applications, but a poor pharmacokinetic profile, along with rapid clearance and a short expression profile, hampered its breakthrough into clinics.^{3,4} The therapeutic use of mRNA is indeed challenging because of its unfavorable physicochemical characteristics, such as high molecular weight, negative charge, and susceptibility to ribonucleases (RNases), which prevent efficient uptake of mRNA into cells and subsequent translation.⁵ The design of efficient delivery strategies to resolve these shortcomings has thus been a very active research field, with nanoparticles showing promising results. As early as

1989, Malone and co-workers described the use of the cationic lipid *N*-[1-(2,3-dioleoyloxy) propyl]-*N,N,N*-trimethylammonium chloride (DOTMA) for *in vitro* transfection, and by 1993 the first liposomal mRNA vaccine was tested in mice, highlighting the potential of nano-formulations for the development of mRNA therapeutics.^{6–9}

From a delivery perspective, mRNA can be efficiently translated within the cytoplasm and does not require transport into the nucleus, a key advantage over DNA-based approaches.¹⁰ Years of research on the design of delivery tools have focused on both viral and non-viral technologies, with the former demonstrating more rapid success, but carrying potential hurdles such as unwanted genomic integration, immunogenicity, and costly vector production.^{11,12} Concurrently, the adaptation of biomaterials platforms for the encapsulation of mRNA for safer delivery has invigorated research on synthetic materials, such as polymers and lipids, and has recently led to the development and approval of two COVID-19 vaccines.¹³ Despite these improvements, there remains a critical challenge facing the therapeutic use of mRNA, namely the difficulty of delivering mRNA molecules to target cells with high efficiency and specificity. This is particularly important in the context of a deficient or defective intracellular protein that is to be replaced through IVT mRNA expression. In such cases, the total proportion of transfected target cells is most critical, rather than the absolute quantity of protein generated.¹⁴ Furthermore, the nanocarrier should be capable of shuttling a mRNA payload to specific cells, so that the mRNA can be translated and adequately exert its function in the surrounding

Faculté de Pharmacie, Université de Montréal, 2940 Chemin de Polytechnique, Montréal, Québec, Canada, H3T 1J4. E-mail: davide.brambilla@umontreal.ca

tissues or organs. For cell therapy, in which cell transfection occurs *in vitro* in a controlled and optimized environment, this consideration is less important.^{14,15} In contrast, the *in vivo* delivery of mRNA to defined target cell populations in high proportions is challenging, and depends greatly on the accessibility of the target cells and the biodistribution profile of the nanocarrier. By understanding the fate of mRNA nanocarriers upon systemic injection (intravenous, IV) or local administration (*e.g.*, intravitreal, intratracheal, intrathecal), new opportunities can be identified to improve the efficiency of RNA therapeutics and harness their full potential for the treatment of diseases.

To the best of our knowledge, existing reviews primarily focus on therapeutic gene regulation in the liver and provide limited considerations for extrahepatic delivery. Strikingly, no comprehensive overview of mRNA therapeutics for protein expression and the targeted *in vivo* delivery of mRNA to different organs using non-viral technology has been presented. In this review, we thus seek to examine and critically discuss the development of mRNA nanocarriers and related protein expression in diverse tissues. First, we describe the biochemical features of mRNA, as well as specific challenges associated with its delivery. Second, we review the current literature to isolate the key features of lipid-based nanoparticles (LNPs) and polymer nanocarriers which enable delivery of mRNA to specific organs of therapeutic relevance. To conclude, we highlight recent preclinical and clinical advances in the development of non-viral mRNA delivery strategies for a range of protein-supplementation therapies.

2. mRNA as a drug

2.1. mRNA engineering for optimization *in vivo* function

As a drug candidate, mRNA possesses two major advantages over DNA-based approaches, namely that it does not require nuclear access and does not need to integrate into the cell genome, thus mitigating the risk of unwanted genomic alteration.¹⁶ Within cells, mRNA is physiologically degraded through a succession of molecular modifications including deadenylation and decapping, followed by RNase-mediated hydrolysis.¹⁴ These mechanisms ensure that exogenous mRNA therapeutics are expressed transiently, which directly impact their safety profile.¹⁷ Nonetheless, the *in vivo* development of mRNA therapeutics has long been hampered by two major challenges: the poor stability of mRNA (limiting the amount of protein able to be produced by cellular machinery) and the inefficient delivery of mRNA to target cells.

Pioneering efforts have focused on modifying structural elements of mRNA to improve intracellular stability and translational efficiency, achieving protein expression levels up to 10-fold higher than initially observed with unmodified mRNA.^{18,19} In particular, IVT mRNA is designed to mimic mature and processed mRNA in the cytoplasm of eukaryotic cells. Accordingly, IVT mRNA is single-stranded, and has a 5' cap and a 3' poly(A) tail with an open reading frame (ORF)

region encoding the protein of interest flanked by untranslated regions (UTRs) (Fig. 1A).

The 7-methylguanosine cap (m7G) protects mRNA from exonuclease degradation and promotes translation by recruiting the initiation factor 4E (eIF4E).²⁰ Current approaches to mimic the m7G cap on IVT mRNA utilize synthetic m7G and m7G analogues, including phosphorothioate dinucleotide analogues, boranophosphate analogues, and anti-reverse cap analogues, all of which increase mRNA translation efficiency and extend the cytoplasmic half-life of IVT mRNA.^{21–24} In synergy, 5' protection by capping and 3' polyadenylation also contributes to the stability, translational efficiency, and entry of the mRNA into the ribosomal machinery.²⁵ Many studies have explored the influence of the poly(A) tail on translational efficiency, reporting optimal lengths ranging between 100 and 240 nucleotides.^{21,26,27} This variation has been shown to depend on the specific modifications of the mRNA sequence, as well as the target cell line used.²⁶

Another strategy to increase mRNA stability and translational efficiency is the integration of 5'- and 3'-UTRs with optimal length and regulatory elements to influence translational efficiency and stability. In a study performing the rational screening of *de novo* designed UTRs, the authors found that an optimal 5'-UTR length of around 70 nucleotides is required for adequate translation initiation complex assembly and rapid translation, and that the incorporation of positive cis-regulatory elements in the 3'-UTR contributes to a 10-fold increase in protein expression relative to endogenous UTRs.²⁸ Information contained within the UTRs can also regulate the transport and specific subcellular localization of mRNA. Cis-acting RNA elements are specific RNA sequences located in the UTRs that associate with RNA-binding proteins and promote the transport of mRNA to specific regions within targeted cells.²⁹ For example, using the 5'-UTR of a tick-borne encephalitis virus, the inclusion of dendritic targeted cis-acting RNA elements could enable more robust and effective mRNA expression in the neuronal dendrites of mice, in comparison to the control UTR.³⁰ Another feasible way to control the localization of mRNA expression is to insert additional cell-specific microRNA (miRNA) targeting sites (miRTS) within the 3'-UTR of an IVT mRNA scaffold. miRNAs are noncoding RNA sequences ~20 nucleotides in length that, upon binding to specific regions of the 3'-UTR, can both repress translation and initiate mRNA cleavage, leading to rapid clearance.³¹ Because miRNAs exhibit cell-type and disease-specific expression profiles, the inclusion of binding sites for miRNAs can be used to suppress protein expression in off-target tissues and has been tested with viral vectors.³² For instance, miR-122 is specifically expressed in healthy hepatocytes and repressed in hepatocellular carcinoma.³³ Accordingly, inclusion of a miRTS for miR-122 in the mRNA scaffold resulted in preferential mRNA expression in non-hepatocyte tumor cells *in vivo*.³⁴ This demonstrates how the appropriate design of UTRs can play an important role in the expression profile and localization of proteins, though this technique has not yet been sufficiently investigated for its capacity to drive expression in




Fig. 1 Structural elements of *in vitro*-transcribed (IVT) mRNA and delivery vehicles. (A) Chemical structure of common modified nucleotides used in the open reading frame (ORF) and scheme of the mRNA structure. Structural elements include a 5' cap, 5'- and 3'-UTRs, an ORF encoding antigen (s), and a 3' poly(A) tail. The main function of each region is detailed underneath. (B) and (C) graphical representation of a polymer nanoparticle and a lipid nanoparticle, along with the most common chemical structures associated with each type. Made with Biorender.

specific cells, warranting the use of more sophisticated delivery tools.

Finally, a key development to the understanding of mRNA therapeutics has been the discovery of the immunogenic response elicited by mRNA. It has been shown that exogenous mRNA is immunostimulatory and can be recognized by pattern-recognition receptors (PRRs), such as Toll-like receptors (TLRs), which trigger innate immune signaling pathways that restrict protein expression and enhance the clearance of mRNA transcripts within cells.³⁵ Early studies have demonstrated that mRNA recognition by TLRs can be suppressed *via* the modification of nucleotides used in IVT mRNA.¹⁸ The most commonly utilized modifications (Fig. 1A) include 5-methylcytosine (m5C), 5-methyluridine (m5U), 2-thiouridine (s2U), or pseudouridine (ψ) modifications such as 1-methylpseudouridine (m1ψ), which abrogate the immune response by evading the activation of PRRs. The introduction of modified uridines within the mRNA construct is currently the most efficient way to minimize the immune reaction to foreign mRNA. Notably, m1ψ has been used in both the Moderna and BioNTech/Pfizer COVID-19 vaccines.¹³ Though base modifi-

cations have been shown to improve the efficacy of mRNA treatments, other findings have suggested that this effect is not universal. For instance, the presence of pseudouridine modifications demonstrated no significant effect on either protein expression *in vivo* or mRNA immunogenicity, as compared to unmodified mRNA, when delivered systemically using liver-targeting LNPs.³⁶ As such, it could be hypothesized that the variable advantages offered by base modification may relate to the chemistry and formulation of the mRNA delivery vehicles used, and also to the target cells in which mRNA translation occurs. This notion is supported by a recent study, which systematically screened a series of LNPs incorporating five types of mRNA modifications (ψ, m1ψ, m5U, m5C, m5C/ψ, and m5C/s2U) encoding for luciferase (Luc) and four ionizable amino lipids promoting mRNA delivery to different organs.³⁷ It was demonstrated that the m1ψ modification was the most effective for all vehicles, with an increase of protein expression between 1.5-fold and 11-fold observed, depending on the delivery vehicle. In contrast, the m5U modification was shown to be detrimental to efficacy, inducing up to a 90% reduction in total Luc expression. Together, these findings

demonstrate that mRNA modifications ought to be carefully chosen depending on the chemistry of the delivery vehicle and the targeted organ or tissue.

2.2. Delivery of mRNA

Although mRNA sequences can be engineered to limit instability and immunogenicity issues, the *in vivo* administration of mRNA remains hampered by the effects of extracellular RNase-mediated degradation and by the need to cross the negatively charged cellular membrane.¹⁴ Overcoming these effects is where innovations in nanocarrier-based delivery systems are likely to play a crucial role.

Naked mRNA is largely unable to cross the cell membrane and achieve efficient availability in the cytoplasm—the primary pharmacodynamic compartment of mRNA. The size of mRNA (300–5000 kDa, 1–15 kb) is significantly larger than that of small interfering RNA (siRNA) and miRNA (13–15 kDa) and antisense oligonucleotides (4–10 kDa).³⁸ Though some cells are capable of spontaneous internalization of naked mRNA through scavenger-receptor-mediated endocytosis, only a small amount of mRNA is delivered to the cytoplasm through this process.³⁹ As an exception, immature dendritic cells have the specialized ability to constantly engulf extracellular fluid, and can take up mRNA more efficiently through macropinocytosis.^{39,40} Consequently, a suitable carrier is required for the delivery of mRNA into most cell types. Initially, very efficient *in vitro* delivery tools were developed based on permanent cationic lipids such as 2,3-dioleoyloxy-*N*-[2(sperminecarboxamido)ethyl]-*N,N*-dimethyl-1-propanaminium trifluoroacetate (DOSPA), or 1,2-dioleoyl-3-trimethylammonium propane (DOTAP) which, when mixed with phospholipid such as 1,2-dioleoyl-*sn*-glycerophosphoethanolamine (DOPE), can complex with highly negatively charged mRNA, allowing them to overcome the electrostatic repulsion of the cell membrane. Nevertheless, the major limitation of these lipoplexes (LPXs) for *in vivo* applications are electrostatic interactions with negatively charged plasma proteins—these interactions lead to fast clearance and recognition by the immune system as well as cytotoxicity, thus hindering *in vivo* translation.^{41–43} In light of this, various other classes of materials have been proposed for mRNA delivery, primarily consisting of cationic polymers and LNPs, as illustrated in Fig. 1B and C. Because of their ability to electrostatically condense nucleic acids into nanoparticles, cationic polymers have been presented as potential candidates for intracellular mRNA delivery. Examples of cationic polymers used for *in vivo* RNA delivery studies include derivatives of polyethyleneimine (PEI), poly(amidoamine) (PAMAM), poly(lactic-*co*-glycolic acid) (PLGA), and poly(β -amino esters) (PBAEs) (Fig. 1B). Such polymeric structures can be modulated to achieve a high degree of chemical variation in functional groups, allowing for a range of physical properties, which in turn can influence their bio-distribution and mRNA delivery.⁴⁴ However, concerns regarding their limited efficacy and potential toxicity remain, with high net positive charges and their inability to be degraded under physiological conditions potentially leading to hazar-

dous levels of bioaccumulation. In contrast, LNPs have gained popularity in recent years as vehicles for mRNA delivery. It has been determined that four components are generally required for LNP-modulated mRNA delivery: an ionizable lipid, a helper lipid (typically phosphatidylcholine), cholesterol, and a PEG-lipid (as illustrated in Fig. 1C). Ionizable lipids have been widely investigated and display a wide range of structures, yet all share common structural aspects. These include: (i) a headgroup containing tertiary amines with defined pK_a s, enabling protonation at acidic pH for interaction with the negatively charged mRNA, in addition to preserving a positive charge in the acidic endosomal lumen to promote membrane fusion and delivery to the cytosol, while exhibiting a neutral charge at physiological pH, and (ii) lipid tails enabling incorporation into nanoparticles during formation, facilitating membrane fusion and thereby improving endosomal escape. Additionally, modifications to their structures resulting in altered physicochemical properties can influence the selective delivery of mRNA to different organs.⁴⁵ Phospholipids (also called helper lipids) and cholesterol are generally used to provide structure to LNPs, promoting formulation stability and potentially aiding in endosomal escape.^{46–48} Phospholipids such as 1,2-distearoyl-*sn*-glycero-3-phosphocholine (DSPC) display strong bilayer-forming properties and high phase-transition temperatures, which help increase membrane rigidity and reduce membrane permeability. As an alternative to DSPC, DOPE has also been widely used as a helper lipid and has been shown to promote superior potency relative to DSPC for mRNA formulations.⁴⁷ Cholesterol serves to confer stability by preventing the sequestration of endogenous cholesterol within the LNPs while in circulation.^{49,50} Recent findings have underscored the importance of cholesterol derivatives in the endosomal escape of LNPs, with nanoparticles containing a β -sitosterol substitute exhibiting a 10-fold increase in endosomal retrieval of mRNA in the cytosol when compared to standard cholesterol.^{51–53} Thus, cholesterol and its derivatives are important for the overall stability of LNPs in circulation and may aid in endosomal escape, thereby enhancing intracellular mRNA delivery. PEG-lipids reside on the surface of LNPs and serve three main functions, namely: (i) tuning particle size by varying their concentration, (ii) improving shelf-stability by preventing particle aggregation, and (iii) increasing the *in vivo* circulation lifetime of the LNPs. However, it is well established that the shield provided by PEGylation occurs at the expense of transfection efficiency, a problem known as the “PEG dilemma”.⁵⁴

For potential therapeutic applications, mRNA drugs must generate a sufficient level of encoded protein to achieve their intended effect, while also transfecting a high proportion of target cells. Extensive research into the design of LNPs has resulted in very effective mRNA delivery to the liver, leading to the initiation of multiple clinical investigations.⁵⁵ Though mRNA therapeutics remain a very promising approach for the treatment of non-liver genetic disorders, effective mRNA delivery to extra-hepatic tissues remains a meaningful challenge. Accordingly, a robust understanding of the behaviour of

mRNA nanocarriers throughout the body, as well as the identification of key parameters governing specific delivery to target tissues and cells is required. To this end, tools have been used to assess and quantify particle-based mRNA distribution and expression. For the evaluation of biodistribution, mRNA can be labelled using a fluorescent dye (e.g., Cy5) to allow the tracking of mRNA-loaded nanoparticles throughout the body. As a potential alternative, mRNA transcripts can also be quantified using the reverse transcriptase polymerase chain reaction.⁵⁶ Another common method of evaluating mRNA translation is the use of mRNA encoding for luciferase (Luc), which exhibits luminescence in transfected cells upon intraperitoneal administration of its substrate, luciferin. As an elegant alternative, detailed evaluation of mRNA expression at the cellular level can also be performed by using Ai14 'Cre-reporter' mice.⁵⁷ The Ai14 mice contain a *Lox-Stop-Lox-tdTomato* transgene under the control of a Cre promoter, resulting in conditional expression. As a result, cells in these mice only become tdTomato+ when Cre mRNA has been functionally delivered to the cells or successfully edited. Subsequent labelling with specific cell markers followed by flow cytometry allows for quantification of tdTomato+ cells. These tools have enabled the collection of data on the distribution pattern of mRNA, as well as on transfection performance in targeted cells. In the forthcoming sections, we will discuss properties and examples of particle-based therapeutics which have contributed to increased protein expression in primary organs such as the liver, lungs, and spleen, as well as in organs for which mRNA-based therapies represent a feasible treatment approach.

3. mRNA delivery to the liver, spleen, and lungs

3.1. mRNA delivery to the liver

The liver plays a crucial role in the metabolism of endogenous and exogenous compounds, and alterations in its function underly several metabolic disorders representing a global health burden.^{58,59} For most inherited metabolic liver disorders, current treatments offer limited efficacy, often leaving liver transplant as the only viable option and raising issues of donor compatibility, surgical risk, and long-term immunosuppression.^{58,60–62} mRNA therapeutics present an attractive strategy to resolve these issues, owing to their ability to induce efficient gene expression and replace deleterious or missing proteins. The liver is inherently capable of producing secretory proteins, and the administration of mRNA formulations can be used to harness the "liver as a bioreactor", producing either proteins that are missing in inherited metabolic and hematological disorders, or antibodies for the neutralization of pathogens and tumor cells.^{63–66}

Following systemic administration, nanomedicines tend to accumulate in the liver due to discontinuous vasculature, decreased blood flow rates,⁶⁷ and an abundance of phagocytic cell types lining the hepatic sinusoids.⁵⁷ Sinusoid blood vessels display a highly fenestrated epithelium with fenestrae

ranging from 100–150 nm and lacking basal membrane. This allows for the almost unrestricted passage of blood components and therapeutic carriers into the perisinusoidal space, where the parenchymal cells (hepatocytes) are located.⁶¹ Because these cells play a key role in many disorders, their targeting is of great importance. To accomplish this targeting, both active and passive strategies have been proposed. For the active targeting of hepatocytes, the most thoroughly investigated strategy relies on the conjugation of nanocarriers to *N*-acetylgalactosamine (GalNAc), a ligand for the asialoglycoprotein receptor, which is predominantly expressed on hepatocytes.⁶⁸ This strategy has been employed in the hepatic delivery of siRNA to silence gene expression, as well as in mRNA delivery for the enhancement of protein expression.^{69–71} In comparison, passive targeting utilizes the body's existing trafficking systems and endogenous apolipoproteins such as Apolipoprotein E (ApoE), which is a low-density lipoprotein (LDL) and enters cells *via* binding to LDL receptors (LDLRs).⁷²

For the delivery of mRNA to hepatic tissue, both LNPs and polymer nanocarriers have been investigated. Although not as clinically advanced as lipid-based systems, polymers have shown potential for protein replacement, vaccination, and other applications related to mRNA therapeutics.^{38,73,74} Herein, we discuss both types of delivery vehicles, with emphasis on LNPs, as this formulation is clearly dominant in hepatic mRNA delivery (as illustrated in Table 1).

3.1.1 Lipid-based nanocarriers. Though active targeting strategies have been proposed to enhance the specific delivery of LNPs to hepatocytes, so far only one study has reported the targeted delivery of mRNA to hepatocytes using this method, using LNPs complexed with GalNAc-targeted polymer micelles as mRNA carriers.⁷⁵ However, works have demonstrated that—following IV administration—LNPs are capable of binding circulating ApoE, promoting nucleic acid delivery to the liver. Initial studies using siRNA payloads demonstrated that the pre-incubation of a formulation based on the ionizable lipid *N,N*-dimethyl-2,2-di-(9*Z*,12*Z*)-9,12-octadecadien-1-yl-1,3-dioxolane-4-ethanamine (DLin-KC2-DMA) with ApoE resulted in a dramatic enhancement of hepatic gene silencing for LNPs with near-neutral surface charges at physiological pH, but did not improve the activity of formulations using cationic lipids, indicating that the activity of the LNP system is sensitive to the species of lipid used.⁷⁶ This observation has led to intensive research into the identification of lipids displaying optimized *in vivo* gene silencing activity when incorporated into LNPs, resulting in the identification of (6*Z*,9*Z*,28*Z*,31*Z*)-heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate (MC3), a key component in the FDA- and EMA-approved LNP-RNAi drug Onpattro®.⁷² Based on the success of this approach, most mRNA formulations developed in the last decade rely primarily on passive targeting.

In recent years, various ionizable lipids have been designed and evaluated for mRNA delivery *in vivo* (Fig. 2A). The ionizable lipids MC3, 1,1'-((2-(4-(2-((2-(bis(2-hydroxydodecyl)amino)ethyl)(2-hydroxydodecyl)amino)ethyl)piperazin-1-yl)ethyl)azanediy)bis(dodecan-2-ol) (C12-200) and 3,6-bis(4-(bis(2-hydro-

Table 1 Selected list of mRNA delivery systems discussed in this review (grouped by organ)

Delivery systems	Formulation (mol% if not specified)	mRNA payload	Administrative route	Tropism features (targeting ligand)	Reported transfected cells or tissue	Clinical indication	Ref.
<i>Liver tissue</i>							
<i>Active targeting</i>							
mRNA-LNP lipopolyplex	DOTAP : Chol : CHEMS : PEG2000-lipid (+GalNac-targeted diblock polymer)	Luc mRNA, OTC mRNA	IV	GalNac polymer	Hepatocytes	Ornithine transcarbamylase deficiency	75
<i>Passive targeting – LNPs</i>							
mRNA-LNP	MC3 : DSPC : Chol : DMG-PEG 50 : 10 : 38.5 : 1.5	Cre mRNA	IV	MC3 ionizable lipid with pK _a of 6.4	Hepatocytes (50%), ECs (80%), Kupffer cells (60%) Liver	n.d.	57
mRNA-LNP	MC3 : DSPC : Chol : DMG-PEG 50 : 10 : 38.5 : 1.5	EPO, modified with m1ψ and m5C	IV	MC3 ionizable lipid with pK _a of 6.4	Liver	Anemia	81
mRNA-LNP	MC3 : DSPC : Chol : DMG-PEG 50 : 10 : 38.5 : 1.5	EPO mRNA, modified with ψ	IV	MC3 ionizable lipid with pK _a of 6.4	Liver	Anemia	80
mRNA-LNP	3060 ₁₀ : DOPE : Chol : DMG-PEG 35 : 16 : 46.5 : 2.5	Luc mRNA, EPO mRNA modified with m5U	IV	3060 ₁₀ ionizable lipid, surface pK _a of 6–7	ECs (85%), Kupffer cells (85%), hepatocytes (85%)	Anemia	93 and 94
mRNA-LNP	cKK-E12-A6 : DOPE : Chol : DMG-PEG 35 : 16.0 : 46.5 : 2.5	Cre mRNA, Luc mRNA, EPO mRNA	IV	cKK-E12 based LNPs and alkynes, surface pK _a of 6–7	Hepatocytes (73%)	Anemia	91
mRNA-LNP	C12-200 : DOPE : Chol : DMG-PEG 35 : 16 : 46.5 : 2.5	Luc mRNA, EPO mRNA	IV	C12:200 ionizable lipid with pK _a of 6.5	Liver (predominant), spleen	Anemia	36 and 47
mRNA-LNP	cKK-E12 : DOPE : Chol : DMG-PEG 50 : 12.5 : 35 : 2.5	Cre mRNA	IV	cKK-E12 ionizable lipid, pK _a of 6–7	Hepatocytes, ECs, Kupffer cells	n.d.	249
mRNA-LNP	cKK-E12 : Chol : DOPE : DMG-PEG 35 : 46.5 : 16 : 2.5	Cas9 mRNA, sgRNA for PCSK9	IV	Ionizable lipid cholesterol variants	Liver (>80% edited)	Hypercholesterolemia	82
mRNA-LNP	Lipid5 : DSPC : Chol : DMG-PEG 50 : 10 : 38.5 : 1.5	Luc or EPO mRNA	IV	Ionizable lipid 5, surface pK _a of 6.4	Liver	Anemia	89
mRNA LNP	5A2-SC8 : DOPE : Chol : DMG-PEG 23.8 : 23.6 : 47.6 : 4.7	Luc mRNA, FAH mRNA modified with m1ψ	IV	5A2-SC8 ionizable lipid, surface pK _a of 6.5	Hepatocytes (44%)	Hepatorenal tyrosinemia type I	48
<i>Passive targeting polymers</i>							
mRNA-lipopolyplex	TarN3C10 poly (tartaratoamidoamine) : DSPC : Chol : DMG-PEG 5 : 2 : 2 : 1 N/P ratio, 10 : 1 (w/w)	EPO mRNA, Luc mRNA	IV	Polymer structure (73 nm)	Liver, spleen	Anemia	73
mRNA-polyplex	PEG12000-Pasp(DEF) : mRNA N/P ratio, 3 : 1	GFP mRNA, Bcl-2 mRNA modified with m5C and ψ	IV	Polymer structure (50 nm)	Liver	Fulminant hepatitis	110
mRNA-lipopolyplex	A-TD3 : DOPE : Chol : DMG-PEG 50 : 25 : 23.5 : 1.5 N/P ratio, 8 : 1	Luc mRNA	IV	Polymer structure	Liver, spleen	n.d.	111

Table 1 (Contd.)

Delivery systems	Formulation (mol% if not specified)	mRNA payload	Administrative route	Tropism features (targeting ligand)	Reported transfected cells or tissue	Clinical indication	Ref.
<i>Splenic tissue Active targeting</i> mRNA-LNP	Non-disclosed ionizable lipid : PC : Chol : PEG-lipid 50 : 10 : 38.5 : 1.5	Luc mRNA, Cre mRNA modified with m1ψ	IV	Affinity ligand towards CD4	T cells	n.d.	129
<i>Passive targeting – LNPs</i> mRNA-LPX	DOTMA : DOPE RNA-LPX, charge ratio 1.3 : 2	Luc mRNA modified with m1ψ	IV	Negative LPX charge around –30mV	Spleen, dendritic cells	n.d.	121
mRNA-LNP	5A2-SC8 : DOPE : Chol : DMG-PEG : 18PA 16.67 : 16.67 : 33.33 : 3.33 : 30	Luc mRNA modified with m1ψ	IV	Addition of 30 mol% 18PA	B cells (12%), T cells (10%), macrophages (20%)	n.d.	122
mRA-LNP	10A1P16:MDOA : Chol : DMG-PEG 29.1 : 34.9 : 34.9 : 1.2	Luc mRNA	IV	iPhos lipids, alkyl chain linked to the phosphate zwitterionic head	Macrophages (30%), B cells (6%)	n.d.	126
mRNA-LNP	3060 ₁₀ : PS : Chol : DMG-PEG 35 : 22.5 : 40 : 2.5	Luc mRNA	IV	Replacement of DOPE with 40 mol% PS	B cells	n.d.	125
mRNA-LNP	4A3-SC8 : DOPE : Chol. : DMG-PEG : BMP 19.05 : 19.05 : 38.10 : 3.81 : 20	Luc mRNA	IV	Addition of a 20 mol% BMP	Spleen	n.d.	124
mRNA-LNP	OF-Deg-Lin : DOPE : Chol : DMG-PEG 35 : 16 : 46.5 : 2.5	Luc mRNA	IV	Ester groups and surface p <i>K</i> _a < 6	B cells (7%), T cells (<1%)	n.d.	45
<i>Passive targeting – polymers</i> mRNA-polyplex	PE4K-A17-02SC4 : mRNA 30 : 1 (w/w)	Luc mRNA	IV	Hydrophobic side chain length, surface p <i>K</i> _a < 6	Spleen	n.d.	132
mRNA-polyplex	CART-D12 : A14 poly(carbonate)-b- (α-aminoester)	eGFP mRNA, fluc mRNA modified with m5C, ψ	IV	Oleyl CART polymer	CD4+ T cells (1.6%), CD8+ T cells (1.5%)	n.d.	118
mRNA-polyplex	PA6-4P14 stabilized with 2.5% pluronic F127 ZPP : mRNA 20 : 1 (w/w)	Luc mRNA, Cre mRNA	IV	Phospholipidated polymer	Spleen	n.d.	133
mRNA-lipopolyplex <i>Lung tissue – local administration</i> LNPs	BDD3 APE : DOPE : Chol : DMG-PEG 50 : 25 : 23.5 : 1.5	Luc mRNA	IV	Polymer structure (80 nm)	Liver, spleen	n.d.	111
mRNA-LNP	7C1 : Chol : DOTAP : DMG-PEG 35 : 5 : 5 : 5.5	Luc mRNA	Nebulization	Local administration	Lung	n.d.	167
<i>Polymers</i> mRNA-polyplex	Chitosan-coated PLGA : mRNA 25 : 1 (w/w)	hCFTR mRNA, modified with m1ψ, s2U, m5C	IT	Mucoadhesive chitosan coating, local administration	Epithelial cells	Cystic fibrosis	152

Table 1 (Contd.)

Delivery systems	Formulation (mol% if not specified)	mRNA payload	Administrative route	Tropism features (targeting ligand)	Reported transfected cells or tissue	Clinical indication	Ref.
mRNA-polyplex	Chitosan-coated PLGA : mRNA 25 : 1 (w/w)	Z3 nuclease-encoding mRNA modified with s2U and m5C Luc mRNA	IT	Mucoadhesive chitosan coating, local administration	Epithelial cells, ATII cells	SP-B deficiency	150
mRNA-polyplex	PBAEs : mRNA 50 : 1 (w/w)	Luc mRNA	Nebulization	Local administration	Epithelial cells (25%), ECs (4.5%), immune cells (0.4%)	n.d.	153
mRNA-polyplex	Poloxamine T704-peptide : mRNA	Luc mRNA, SB100X mRNA	Nebulization	Local administration	Epithelial cells	Cystic fibrosis	164
mRNA-polyplex	PBAEs : mRNA 50 : 1 (w/w)	Cas13a mRNA	Nebulization	Local administration	Lung	Influenza and SARS-COV-2	165
<i>Lung tissue – systemic administration</i> <i>Active targeting</i> Ab-mRNA-LNP	L319 : DSPC : Chol : DMG-PEG 50 : 10 : 38.5 : 1.5	fluc mRNA, eGFP mRNA modified with m1ψ	IV	Affinity ligand towards PECAMI	Vascular ECs	n.d.	171
<i>Passive targeting – LNPs</i> mRNA-LNP	5A2-SC8 : DOPE : Chol : DMG-PEG : DOTAP 11.9 : 11.9 : 23.8 : 2.4 : 50	Luc mRNA, mCherry mRNA, Cre mRNA	IV	Addition of 50 mol% DOTAP	Lung ECs (65%), epithelial cells (40%), immune cells (21%)	n.d.	122
mRNA-LNP	9A1P9 : DDAB : Chol : DMG-PEG 46 : 23 : 30 : 0.3	Luc mRNA, Cre mRNA	IV	iPhos lipids, alkyl chain linked to the phosphate	Lung ECs (34%), epithelial cells (20%), immune cells (13%)	n.d.	126
mRNA-LNP	ZA3-Ep10 : Chol : DMG-PEG 50 : 38.5 : 1	Luc mRNA, Cas9 mRNA	IV	Zwitterionic amino lipid (ZA3-Ep10)	Lung	n.d.	173
mRNA-LNP	3060 ₁₀ : DOTAP : Chol : DMG-PEG 35 : 40 : 22.5 : 2.5	Luc mRNA	IV	Replacement of DOPE by 40 mol% DOTAP	Lung	n.d.	125
<i>Passive targeting – polymers</i> mRNA-polyplex	Polyester PE4K-A17-0.2C8 Polymer : mRNA 30 : 1 (w/w)	Luc mRNA, Cre mRNA	IV	Surface pK _a 7.5–8.0	Lung	n.d.	132
mRNA-lipopolyplex	L3 co-formulated with DOPE and C18PEG2000 20 : 5, N/P ratio 50 : 1	Luc mRNA, Cre mRNA	IV	Nanoparticle size of 100 nm, PEG-lipid content of 5%, C18 alkyl PEG-lipid	ECs (75%), immune cells (2%)	n.d.	176
<i>Lymphatics</i> mRNA-LPX	DOTMA : DOPE RNA/LPX ratio 1.3 : 2	Luc mRNA modified with m1ψ	IV	Negative charge around –30 mV	Spleen, dendritic cells	n.d.	121
mRNA-LNP	cKK-E12 : DOPE : Chol : DMG-PEG : SLS 15 : 26 : 40.5 : 2.5 : 16	fluc mRNA, Cre mRNA	SC	Administration route, surface charge of –15 mV, size of 50–120 nm	Lymph nodes, dendritic cells (4.6%), macrophages (1.2%), neutrophils (3.3%), B cells (0.06%)	Cancer immunotherapy	188

Table 1 (Contd.)

Delivery systems	Formulation (mol% if not specified)	mRNA payload	Administrative route	Tropism features (targeting ligand)	Reported transfected cells or tissue	Clinical indication	Ref.
mRNA-LNP	MC3-analogue : DSPC : Chol : DMG-PEG 50 : 10 : 38.5 : 1.5	GFP mRNA, VEGFC mRNA modified with m1 ψ	ID	Local administration	Lymphatic vessels	Lymphedema	185
mRNA-Polyplex	PA6-4P14 stabilized with 2.5% F127 ZPP : mRNA 20 : 1 (w/w)	Fluc mRNA, Cre mRNA	IV	Phospholipidated polymer	CD4+ T cells (6%), CD8+ T cells (2%), B cells (<1%), macrophages (6%)	n.d.	133
<i>Brain</i> <i>Active targeting</i> mRNA-LNP	A-L01 : DSPC : Chol : DSPE-PEG maleimide 50 : 10 : 38.5 : 1.5	fluc mRNA, TM mRNA	IV	Active targeting with anti-VCAM antibody	ECs in cerebral vasculature	Brain inflammation	201
<i>Passive targeting – LNPs</i> mRNA-LNP	MC3 : DSPC : Chol : DMG-PEG 55 : 10 : 32.5 : 2.5	Luc mRNA, FXN mRNA	Intrathecal	Local administration	Dorsal root ganglia	Friedreich's ataxia	195
mRNA-LNP	ssPALM : DOPE : Chol : DMG-PEG 30 : 30 : 38 : 1	fluc mRNA modified with ψ , m5C, s2U	Intracerebroventricular injection	Local administration	Neuronal cells, astrocytes	n.d.	197
<i>Passive targeting – polymers</i> mRNA-polyplex	PEG-PAsp(DEF) N/P ratio, 3 : 1	GFP mRNA, NEP mRNA	Intracerebroventricular injection	Local administration	Brain ventricle	Alzheimer's	200
<i>Eyes</i> mRNA-LNP	MC3 : DSPC : Chol : DMG-PEG 50 : 10 : 38.5 : 1.5	fluc mRNA, eGFP mRNA	SR	Local administration	RPE, Müller glia cells	n.d.	204
mRNA-LNP	MC3 : DSPC : Chol : DMG-PEG 50 : 10 : 38.5 : 0.5	fluc mRNA, mCherry mRNA, Cre mRNA	Intravitreal, SR	Local administration	Subretinal: Retinal pigment epithelium Intravitreal: Müller glia, optic nerve and trabecular meshwork	n.d.	208
<i>Heart tissues</i> Naked mRNA	Saline citrate buffer	eGFP mRNA, VEGF mRNA modified with ψ , m5C	Intramyocardial injection	Local administration	Cardiomyocytes	Ischemic injury	220
mRNA-LNP	C14-113 : DSPC : Chol : DMG-PEG 50 : 10 : 38.5 : 1.5	eGFP mRNA, modified with ψ , m5C	Intramyocardial injection and intraventricular injection	Local administration	Cardiomyocytes	n.d.	218

Abbreviations: cholesteryl hemisuccinate (CHEMS), proprotein convertase subtilisin/kexin type 9 (PCSK9), poly[N-[N-(2-aminoethyl)-2-aminoethyl]aspartamide] (PAsp(DEF)), SS-cleavable proton-activated lipid-like material (ssPALM).




Fig. 2 Nanocarriers providing mRNA delivery and protein expression to the liver. (A) Chemical structure of the best performing ionizable lipids and polymers for liver delivery. (B) Transfection efficiency of these compounds for the different liver cell populations. Doses and duration before evaluation: 2 mg kg^{-1} Cre mRNA after 24 h for MC3,⁵⁷ 0.75 mg kg^{-1} mCherry mRNA after 48 h for both cKK-E12 and cKK-E12/A6,⁹¹ 1 mg kg^{-1} Cre mRNA after 72 h for 306O₁₁₀,⁹⁴ and 0.5 mg kg^{-1} mCherry mRNA after 6 h for 5A2-SC8.⁴⁸ (C) Pie charts of the gold standard LNP formulation used for siRNA delivery, compared to an optimized formulation used to deliver mRNA with the 5A2-SC8 ionizable lipid.⁴⁸ (D) Graphical representation of the IV delivery and extravasation of LNPs in the liver to reach hepatocytes.

xydodecyl)amino)butyl)piperazine2,5-dione (cKK-E12)—previously demonstrated to be effective for siRNA delivery to the liver—were used for initial exploration of mRNA delivery in this organ.^{77,78} One important physicochemical factor relevant for delivery to the liver has been the discovery that ionizable lipid bearing amino groups exhibiting pK_a values between 6 and 7 yield the most effective functional delivery to liver tissue.⁷⁹ With a pK_a between 6.4 and 6.5, MC3 has been the focus of initial liver-targeting mRNA delivery studies. Notably, the IV administration of MC3-based LNPs encapsulating mRNA encoding for erythropoietin (EPO) has demonstrated high levels of hematopoiesis in the liver, resulting in an increased serum concentration of EPO in pigs and cynomolgus monkeys.^{80,81} Similar to MC3, the lipids cKK-E12 and C12-200 both display pK_a s around 6.5 and have also been used for effective delivery of mRNA to the liver.^{36,47,82} A recent study evaluated the biodistribution of cKK-E12 and C12-200-based LNPs using Cy5-labeled mRNA, and reported liver accumulation of around 60% and 70%, respectively. Additionally, an assessment of protein expression six hours after administration showed that 90% of protein expression resulting from

the use of these lipids occurred in the liver.³⁷ Related to the pK_a of ionizable lipids, another key parameter for mRNA delivery is the surface pK_a of the LNP (also termed global or apparent pK_a), which has been demonstrated to be a robust predictive value for siRNA activity *in vivo*.⁸³ The pK_a of lipids can differ when incorporated into LNPs; indeed, non-covalent interactions between the ionizable lipid and other constituent lipids of the LNPs, the mRNA payload, and the surrounding medium have all been shown to alter the pK_a .⁸⁴ Supporting this notion, Heyes *et al.* have reported a fluorescence-based approach using 2-(*p*-toluidinyl) naphthalene-6-sulfonic acid (TNS), an acidic small molecule showing higher levels of fluorescence when protonated, to assess the pK_a of LNPs.⁸⁵ This method allows the direct determination of the individual pK_a s of amino lipids in the assembled LNPs, while also serving as an indirect approach to determine the ionization status of the LNPs themselves. Similar to the pK_a s of ionizable lipids, a surface pK_a between 6 and 7—resulting in a neutral surface charge during circulation—has been shown to promote effective gene silencing in the liver, and accordingly this parameter has been used to assess the ability of nanocarriers to

deliver mRNA to the liver.⁸⁶ In one example, surface pK_a has been used as a parameter in the development of Moderna's lead ionizable lipid ("Lipid 5"), which has been successfully used for treatment in therapeutic models of acute intermittent porphyria and methylmalonic acidemia.^{87,88} This lipid was selected based on an *in vivo* screening of a series of amino lipids, which, when incorporated into LNPs, exhibited surface pK_a values ranging from 5.80 to 7.18, as well as distinct protein expression profiles. The optimized "Lipid 5", with a surface pK_a of 6.50, demonstrated a 6-fold increase in protein expression localized in the liver compared to conventional MC3-based LNPs.⁸⁹

Although it had been assumed that MC3- or cKK-E12-based LNPs targeted hepatocytes, recent findings have shown mRNA expression in the liver's endothelial cells (ECs) and Kupffer cells in Cre reporter mice (see Fig. 2B).⁵⁷ This suggests that MC3- and cKK-E12-based formulations also enable functional nucleic acid delivery to other cell types within the liver. These findings clearly demonstrate that transfection efficiency must be thoroughly assessed at the cellular level. In addition to targeting the correct cell type, the nanocarrier must also be able to efficiently escape the endosomal lumen to achieve a therapeutically relevant level of protein production. Endosomal escape is a major limitation for mRNA-based drugs, as studies have revealed that only around 1–4% of internalized nanoparticles are able to be retrieved in the cytosol before degradation.⁹⁰ With this in mind, several works have aimed at identifying strategies to improve the efficiency of this endosomal escape. For instance, a recent study demonstrated that the incorporation of alkyne functionalities, rather than alkenes, in the hydrophobic tails of ionizable lipids could increase the fusogenicity of the resulting particles and facilitate endosomal escape.⁹¹ Specifically, the ionizable lipid MC3 was modified by the inclusion of unsaturated alkyne functionalities and ester groups, then formulated into LNPs. Upon injection, superior liver expression was found when using the alkyne lipid, highlighting improved endosomal escape and functional mRNA delivery. Interestingly, analysis of cellular transfection efficiency using Cre-reporter mice revealed that the percentage of Tdtomato+ hepatocytes increased from 50% to 75% when transfected using alkyne-modified lipids. Concurrently, another group developed a series of polyester-based dendrimer ionizable lipids, among which a highly potent ionizable lipid termed 5A2-SC8 (Fig. 2A) with a surface pK_a of 6.67 was identified following screening.⁹² Biodistribution studies showed time-dependent Luc activity with peak expression observed at 6 h post injection followed by a strong decrease with almost no signal detectable after 48 h. Interestingly, increasing the dosage from 0.1 to 0.2 mg kg⁻¹ induced a more dispersed expression profile throughout tissues, especially in the spleen, suggesting a potential impact of dose on the biodistribution and functionality of the particles. Flow cytometry quantification of mCherry mRNA delivery to hepatocytes revealed that 45% of the total hepatocyte population strongly expressed the protein at 6 h post injection.⁴⁸ This lipid was further investigated for the delivery of fumarylacetoacetate hydrolase (FAH)

mRNA to hepatocytes and was able to produce a therapeutic level of the protein in a FAH^{-/-} mouse model. Another factor influencing endosomal escape is the surface ionization of LNPs;⁹³ this parameter corresponds to the degree of protonation of the nanoparticle at a given pH and is critical for endosomal escape. Investigation of the relationship between the chemistry of the alkyl tails of lipids and their *in vivo* efficacy revealed that ionizable lipids bearing branched tail structures are more strongly ionized at the endosomal pH of 5.0 and are consequently more effective at delivering mRNA than their linear counterparts. A biodistribution evaluation of Cy5-labeled mRNA, however, revealed that small changes in lipid chemistry had minimal impact on particle distribution, with LNPs exhibiting accumulation in the spleen, liver, and lungs, though the resulting protein expression was almost entirely observed in the liver. While an explanation for this discrepancy in biodistribution and protein expression profile remains elusive, it can be hypothesized that although the LNPs are able to travel to the sites indicated by the biodistribution profile, they may fail to deliver their mRNA payload for effective translation (*e.g.*, failure of endosomal escape or internalization). Upon *in vivo* screening, one ionizable lipid termed 3060₁₁₀, containing a branched decanonyl alkyl chain and generating a LNP surface pK_a of 6.40, demonstrated over 90% of its total protein expression in the liver (Fig. 2A). Single-cell flow cytometry analysis revealed that more than 85% of the total population of Kupffer cells, ECs, and hepatocytes were transfected, making this ionizable lipid one of the most potent agents to mediate functional mRNA delivery to the liver.⁹⁴

While alterations to LNPs have canonically been focused on the chemistry of ionizable lipids, modifications to the other components of LNPs have been shown to have an influence on the endosomal escape, biodistribution, and circulation of the particles. For example, a strong correlation has been observed between mRNA expression level and the type of helper lipid used, particularly in cases where DSPC was replaced by DOPE, which led to a 7-fold increase in protein production.⁴⁷ Whereas DSPC contains a quaternary amine headgroup and a fully saturated tail, DOPE contains a primary amine headgroup and a tail with one degree of unsaturation. It has been reported that conical lipids, such as DOPE, tend to adopt the less stable hexagonal phase, while cylindrical lipids, such as DSPC, tend to adopt the more stable lamellar phase.⁹⁵ Another study has shown that the molar fraction of zwitterionic phospholipids must be increased when switching from siRNA to mRNA delivery, and that this change yields higher levels of protein expression.⁴⁸ Following these studies, optimizations of siRNA formulations for mRNA delivery have been proposed including: (i) the molar fraction of zwitterionic phospholipids could be increased, while that of ionizable lipids could be decreased, and (ii) the use of DOPE instead of DSPC should result in increased mRNA expression. An optimized formulation is illustrated in Fig. 2C. A third study used an *in vivo* screening of IV-administered LNPs to demonstrate that those prepared using DOPE preferentially accumulated in the liver, while similar LNPs containing DSPC accumulated primarily in

the spleen.⁹⁶ Using a quartz crystal microbalance with dissipation monitoring, it was found that a DOPE-containing LNP formulation exhibited stronger interactions with ApoE than an identical DSPC-containing formulation, thereby increasing two-fold the extent of mRNA delivery to the liver.

LNPs are commonly formulated with unmodified cholesterol, however, endogenous cholesterol is naturally esterified or oxidized enabling its compact storage and trafficking to several cells including hepatocytes, ECs, and macrophages *via* lipoproteins.⁹⁷ Recently, it has been shown that cholesterol derivatives act as an important factor altering the *in vivo* distribution of LNPs.⁹⁸ An *in vivo* screening of LNPs incorporating oxidized, esterified, and unmodified cholesterol showed that esterified cholesterol variants outperformed their unmodified counterparts for mRNA delivery by 1.4-fold. Moreover, the authors reported for the first time enhanced and more specific gene editing in hepatic ECs mediated by a LNP containing a cholesteryl oleate derivative, leading to a 41% increase in editing as compared to unmodified cholesterol. The delivery of this LNP to liver ECs was also three times more efficient than its delivery to hepatocytes, illustrating the higher specificity of cholesterol oleate esters towards hepatic ECs. Targeting these ECs can be of clinical importance given the active role they play in establishing the liver microenvironment and driving fibrosis, inflammation, primary tumor growth, and metastasis.⁹⁹ In a further study, the same group investigated oxidative cholesterol modifications within the B-ring and the hydrocarbon tail attached to the D-ring (Fig. 1C). Using cKK-E12-based LNP formulations, *in vivo* screening demonstrated that: (i) LNPs containing oxidized cholesterol deliver mRNA more efficiently to all hepatic cells than those containing unmodified cholesterol, (ii) oxidized cholesterol modifications mediated higher mRNA expression in ECs and Kupffer cells than in hepatocytes compared to unmodified cholesterol, and (iii) modifications of the side chain attached to the D-ring (particularly 20- and 25-hydroxycholesterol) yielded stronger protein expression compared to modifications on the B-ring. Notably, variations containing 20 α -OH groups outperformed unmodified cholesterol for all hepatic cells while also demonstrating more robust mRNA delivery to ECs and Kupffer cells. This study highlighted that LNPs containing oxidized cholesterol modifications (especially on the alkyl side chain) can impact mRNA expression in several hepatic cell subtypes, leading to higher mRNA expression in ECs and Kupffer cells than in hepatocytes. Given the role of ECs⁹⁹ and Kupffer¹⁰⁰ cells in the pathogenesis of liver diseases, the use of oxidized and esterified cholesterol in LNP formulations of mRNA could be a feasible strategy to improve targeting to these cells and might be of interest in certain clinical conditions.

Finally, several studies focused on optimizing the PEG-lipid for the enhancement of liver targeting. In particular, it has been shown that diffusible PEG-lipids, which ensure the stability of formulations but dissociate from the LNP upon systemic administration, have been successful for liver delivery.¹⁰¹ Such lipids are generally composed of an acyl chain of 14 carbons conjugated to a PEG polymer such as the predominant

DMG-PEG which has been used in almost all reported studies, as well as in the Onpattro[®] formulation (Table 1).⁷² These diffusible PEG-lipids rapidly dissociate from the nanoparticle with as little as 20% remaining 2 h after systemic administration.¹⁰² In contrast, PEG-lipids with 18-carbon acyl chains are not diffusible and result in LNPs with longer circulation half-lives.¹⁰² However, LNPs that target hepatic tissues do not require such extended circulation lifetimes due to the inherent capacity of the liver to rapidly capture nanoparticles. Accordingly, DMG-PEG is an ideal choice of PEG-lipid for delivery to the liver.

Altogether, mRNA-containing LNPs exhibiting surface pK_as between 6 and 7 result in high levels of accumulation in the liver, associated with high transfection efficiencies reaching up to 85% for the ionizable lipid 3060_{i10} (Fig. 2B). These high transfection rates are very promising for therapeutic applications and have helped overcome barriers to the preclinical and clinical development of treatments for rare genetic liver disorders. Passive targeting using ApoE does not only mediate the functional delivery of mRNA to hepatocytes, but also to ECs and Kupffer cells, with which the LNPs come in contact prior to reaching the space of Disse and the hepatocytes (Fig. 2D). Recent findings have also shown that cholesterol and cholesterol derivatives contribute to greater transfection efficiencies and can shift mRNA expression towards different hepatic cell subtypes, indicating their potential—in combination with ionizable lipid and helper lipid chemistry—to achieve improved mRNA delivery to desired cells.

3.1.2. Polymer-based nanocarriers. As an alternative to LNPs, polymer-based materials have also been investigated for the delivery of mRNA to the liver. Examples of polymeric structures include amino polyesters, PBAEs, PAMAMs, poly(*b*-benzyl-L-aspartate) and PEI, with the latter being the most frequently investigated for gene delivery, and specifically for mRNA vaccine delivery.^{103,104} In circulation, mRNA complexed with polymers (polyplexes) exhibits poor stability, mainly due to electrostatic interactions between the cationic backbone and endogenous serum proteins.¹⁰⁵ Co-formulation with PEG has been shown to have a shielding effect, increasing particle stability in physiological conditions, and most studies using polyplex formulations have chosen PEGylation as a suitable method of stability promotion.^{106–109} In one example, the copolymerization of polyaspartamide cationomers and PEG12000 encapsulating green fluorescent protein (GFP) mRNA resulted in homogenous hepatic protein expression.¹¹⁰ Subsequently, this mRNA polyplex was tested in a murine model of fulminant hepatitis, a disease associated with the massive apoptosis of hepatocytes. mRNA encoding for the anti-apoptotic factor Bcl2 significantly decreased the percentage of apoptotic cells by a factor of 3.5, illustrating the potential of this PEGylated polymeric system to promote mRNA delivery in hepatic diseases. While multicomponent LNPs allow the formulation to be tuned by varying the identity and ratio of the components, polymers offer a vast range of chemical diversity of functional groups and physical properties, which can be used to optimize nucleic acid delivery. Aiming at improving mRNA delivery in

the liver, poly(glycoamido-amines) (PGAAs)—which contain amines and multiple hydroxyl groups along their polymer backbone—have been investigated to induce EPO expression.⁷³ First, the polymeric PGAA backbone was modified using three different hydroxyl structures, namely tartrate, galactarate, or glucarate (linear sugar derivatives) combined with three different amine-containing monomers. Next, alkyl tails of varying lengths were added to the backbone *via* epoxide ring-opening reactions, enabling incorporation of the polymer into LNPs containing DSPC, DMG-PEG, and cholesterol. Evaluation of the structure-activity relationships of these particles revealed that the key structural features of top performing formulations were: (i) more amino groups, which resulted in more favorable expression, (ii) the tartrate series generally displayed increased mRNA delivery relative to the galactarate or glucarate series, and (iii) shorter alkyl tails also resulted in improved delivery. mRNA expression of the lead polymer, termed TarN3C10 (Fig. 2A) revealed strong expression in the liver, though equally strong expression was observed in the spleen. TarN3C10 was able to produce a 6-fold higher EPO concentration than a C12-200 LNP formulation used as a positive control. The same group explored the polymer structure of amino-polyesters (APEs) incorporated into LNPs exhibiting a monodisperse nanoparticle population with sizes below 100 nm.¹¹¹ A biodistribution evaluation of APE-LNPs showed strong accumulation in the liver, where most Luc expression was reported, though significant expression was also detected in the spleen. The structure and properties (lipophilicity, pK_a), while not reported, were thought to influence the organization of mRNA-containing LNPs, subsequently influencing the surface charge of nanoparticles, and their ability to interact with serum proteins, potentially resulting in the observed differences in the uptake and *in vivo* efficacy. mRNA delivery to the liver has also been achieved *via* subcutaneous (SC) injection of polymeric nanoparticles. mRNA-loaded polymeric nanoparticles were prepared by complexation of mRNA to an N-substituted PEG2000-diblock-polyglutamide containing 1,2-diaminoethane groups as side chains.¹⁰⁹ To diminish the toxicity associated with the high positive charge of the prepared polyplexes, their surfaces were modified with a 2 kDa PEG *via* amide bond formation, resulting in a decrease of the zeta potential from +20 mV to +5 mV. Following a single SC injection of GFP mRNA-loaded polyplexes, bright and prolonged GFP fluorescence was observed in the liver, and to a lesser extent in the kidneys. The fluorescent signal was observed in the liver at 4 h post-administration and peaked at 12 h.

Though not as extensively investigated as LNPs for mRNA delivery to the liver, polymers can deliver functional mRNA to liver cells, resulting in high levels of protein production. Materials such as amino-polyesters synthesized *via* ring-opening polymerization of readily available lactones represent a viable approach for mRNA delivery, potentially overcoming the biodegradability-related safety concerns raised for cationic polymers.¹¹² Notably, while data on transfection efficiency in various hepatic cells subtypes is now widely reported for LNP

formulations, such data are missing from reports of polymer-based nanoparticles.

3.2. mRNA delivery to the spleen

The spleen is the largest secondary lymphoid organ, in which antigen presenting cells (APCs) exist in close proximity to T cells, providing an adequate microenvironment for the efficient priming and amplification of immune responses.¹¹³ Leukocytes in the spleen include various subsets of B and T cells, dendritic cells (DCs), and macrophages, and are involved in many functions such as the initiation of innate and adaptive immune responses against pathogens, as well as lymphocyte maturation and recycling (Fig. 3A). Modulation of the activity of immune cells has attracted interest for tumor immunology applications, as highlighted by the rapid growth in the clinical use of immunotherapeutic agents.¹¹⁴ For instance, chimeric antigen receptor T-cell (CAR T) therapy is a technique which relies on the ability of the immune system to fight cancer cells and has achieved clinical approval for the treatment of advanced leukemia and lymphoma.¹¹⁵ While current CAR T cell treatments require the *in vitro* genetic alteration of T cells prior to their clinical use,¹¹⁶ the development of *in vivo* T cell-targeted mRNA delivery systems able to induce robust and transient CAR expression could offer an interesting alternative. Such systems could also be valuable for the treatment of several B cell dysfunctions, given the crucial role of B cells in the modulation of immune responses. As an example, the proliferation of dysregulated mature B cells has been shown to be the origin of non-Hodgkin's B cell lymphoma, and effective genetic modulation of B cell function *in vivo* could have a profound impact on the treatment of this disease.¹¹⁷ Accordingly, improvements to the *in vivo* delivery methods of mRNA therapeutics targeting both B and T cells would be greatly advantageous. In spite of this, there have been few reports on the effective delivery of mRNA to B and T cells, likely due to their limited capacity for endocytosis and subsequently impaired protein translation.¹¹⁸

3.2.1. Lipid-based nanocarriers. Following systemic administration, LNPs have been observed to substantially accumulate in the spleen, which can be attributed to their uptake by splenic macrophages of the mononuclear phagocyte system (MPS) following surface opsonization and protein adsorption.^{47,119,120} Early work by Kariko *et al.* demonstrated that upon IV administration of a pseudouridine-modified Luc mRNA-lipoplex (mRNA-LPX) to mice, the spleen was the primary location of mRNA accumulation, as well as where the greatest expression was observed.¹⁸ Previous works have also investigated the delivery of mRNA to splenocytes, identifying nanoparticle charge as a key parameter governing organ specificity. In a landmark study using mRNA-LPXs consisting of DOTMA (cationic lipid) and DOPE (helper lipid) for the formation of LPXs, variation of the lipid-to-mRNA ratio resulted in alteration of the particle charge (*i.e.* zeta potential).¹²¹ While positively charged Luc mRNA-LPXs predominantly accumulated in the lungs, it was observed that mRNA-LPXs with a lipid-to-mRNA ratio of 1:1.5 and a zeta potential around




Fig. 3 Spleen-targeting nanocarriers. (A) Graphical representation of the spleen cell populations targeted by nanocarriers. (B) Chemical structures of the best performing lipids and polymers for promotion of protein expression in the spleen. (C) Transfection efficiency of these compounds in different splenic cell populations. Doses and duration prior to evaluation: 0.75 mg kg^{-1} Cy5-labeled mRNA, $t = 1 \text{ h}$ for OF-Deg-Lin;⁴⁵ 0.5 mg kg^{-1} mRNA with DiD-labeled LNPs, $t = 4 \text{ h}$ for tB-UC18;¹⁵⁰ 0.3 mg kg^{-1} Cre mRNA, $t = 48 \text{ h}$ for 18PA;¹²² 0.5 mg kg^{-1} Cre mRNA, $t = 48 \text{ h}$ for iPhos,¹²⁶ non-specified for CART13.¹¹⁸ Made with Biorender.

-35 mV generated a signal exclusively in the spleen, with no significant expression observed in the liver. Interestingly, the authors revealed that macrophages exhibited the highest rate of mRNA uptake, whereas the largest translation efficiency was observed in dendritic cells, indicating that these cells are more effective at the cytoplasmic translocation and translation of mRNA into protein. The addition of a fifth permanent anionic lipid to a conventional LNP formulation—leading to an altered surface pK_a of the resulting nanoparticles—has been identified as a feasible strategy for targeting splenic tissue. This strategy, termed Selective ORgan Targeting (SORT), utilizes the incorporation of 30 mol% of the supplementary anionic lipid 1,2-dioleoyl-*sn*-glycero-3-phosphate (18PA) into a liver-targeting LNP, allowing the redirection of mRNA expression to splenic tissue.¹²² Importantly, this formulation demonstrated a remarkable transfection efficiency of $\sim 12\%$ of all B cells, $\sim 10\%$ of all T cells, and $\sim 20\%$ of all macrophages present in the spleen.¹²² The addition of this supplementary anionic headgroup was found to promote the adsorption of plasma proteins with an isoelectric point above physiological pH, in turn resulting in an altered protein corona. A recent study revealed that the tissue tropism of this formulation is governed by the modulation of surface pK_a , with values decreasing from 6.46 to 3.97, far lower than optimal pK_a values identified for

specific liver targeting.¹²³ Interestingly, zeta potential measurements revealed that the overall net surface charge of the resulting LNPs was not significantly altered, indicating that this strategy for spleen-specific mRNA delivery is feasible using LNPs displaying a near-neutral surface charge—an important feature for *in vivo* stability and delivery efficiency. Proteomics studies have also demonstrated that, because of this alteration to the surface pK_a , spleen-targeting LNPs mostly adsorbed β -2-glycoprotein I (β 2-GPI, also known as ApoH), in contrast to liver-targeting LNPs which mostly adsorbed ApoE. The administration of spleen-targeting LNPs to ApoE^{-/-} mice did not impair mRNA delivery, but rather enhanced its delivery to splenocytes, confirming an ApoE-independent intracellular mechanism this class of LNPs. Other negatively charged phospholipids have also demonstrated spleen-specific tropism; for instance, the incorporation of bis(monoacylglycerol)phosphate (BMP) allowed for more than 75% mRNA translation efficiency in the spleen.¹²⁴ When added as a fifth lipid at up to 20% molar ratio in a four-component LNP formulation, spleen-specific mRNA expression was observed, corroborating the results obtained using the aforementioned strategy. A recent study aimed at reproducing this same tissue tropism by maintaining a four-component nanoparticle system and replacing the helper lipid DOPE with the negatively charged helper lipid

phosphatidylserine (PS). The incorporation of 40 mol% of PS in a liver-targeting formulation substantially shifted mRNA expression towards the spleen, supporting the previously established notion that the incorporation of negatively charged lipids into LNP formulations represents a feasible approach to promote mRNA expression in the spleen. As previously noted, no significant change in the zeta potential of the LNPs was observed, and only a moderate correlation between zeta potential and spleen-specific mRNA delivery was found.¹²⁵

The impact of the structure of ionizable lipids and phospholipids on the promotion of spleen selectivity has also been investigated (Fig. 3B). In one example, this was achieved using ionizable phospholipids (iPhos) composed of one pH-switchable zwitterion and three hydrophobic tails, which have been described to adopt a cone shape in acidic endosomal environments, facilitating the release of cargo from endosomes.¹²⁶ Evaluation of the membrane-disrupting activity of iPhos lipids showed that pH-switchable zwitterions exhibited dramatically higher membrane fusion and rupture than simple tertiary amines in a concentration-dependent manner, validating the superiority of zwitterionic structures in endosomal lumen escape. *In vivo* structure activity relationships have also identified the length of the alkyl chain bound to the phosphate group as a key moiety for organ selectivity. Indeed, an alkyl chain of 13–16 carbons attached to the phosphate group of the iPhos lipid combined with the helper lipid *N*-methyl dioctadecylamine (MDOA) led to an optimized spleen-specific LNP formulation achieving nearly 30% transfection of all splenic macrophages and 6% transfection of B cells, suggesting that modifications to the chemical structure of iPhos can result in improved organ selectivity towards the spleen (Fig. 3C). Simultaneously, exploration of the rational design of ionizable diketopiperazine lipids for the delivery of mRNA to B cells has resulted in a lead compound—termed OF-Deg-Lin—which exhibits biodegradable ester bonds and, when formulated into mRNA-LNPs, results in particles with a surface pK_a of 5.7 (Fig. 3B).⁴⁵ Upon systemic injection, the biodistribution of Cy5-tagged mRNA encapsulated in OF-Deg-Lin LNPs demonstrated 100-fold preferential accumulation in the liver over spleen; however, over 85% of total protein production from this formulation was found to occur in the spleen, with very little expression observed in the liver. To further investigate this discrepancy between the distribution and expression of mRNA, a non-biodegradable analogue of OF-Deg-Lin was prepared and tested, demonstrating selective distribution and expression in the liver. However, the mechanism by which OF-Deg-Lin mRNA-LNPs promote mRNA expression in the spleen, despite mostly accumulating in the liver, remains elusive. One explanation could be that the electrophilic ester bonds in OF-Deg-Lin are degraded more rapidly in the liver than in other organs, thus preventing either functional delivery of the mRNA to the cytoplasm of hepatic cells (*e.g.*, during cell internalization or trafficking), or successful endosomal escape due to acidic degradation of the lipid.⁸³ In contrast, OF-Deg-Lin might survive enzymatic degradation in the spleen, such that the nanoparticles retain their ability to

induce functional protein expression following uptake into the resident splenic cells. This highlights the importance of the ester bonds found in OF-Deg-Lin for the delivery of functional mRNA to the spleen. Flow cytometry analysis of Cy5-mRNA-containing OF-Deg-Lin LNPs demonstrated a transfection efficiency of 7% of the total B cell population and around 1% of the total T lymphocyte population. In another study, the investigation of modifications in tail length and linker spacing in OF-Deg-Lin, resulted in the lipid OF-C4-Deg-Lin, containing a longer linker length of 4 carbons, as well as doubly unsaturated tails. Biodistribution evaluation of nanoparticles formulated using this novel lipid containing Cy5-tagged Luc mRNA demonstrated that over 75% percent of the LNPs were distributed to the liver, while more than 85% of Luc mRNA expression was found to occur in the spleen.¹²⁷ Moreover, when compared to the lipid cKK-E12, OF-C4-Deg-Lin promoted ~5-fold higher protein expression in the spleen. Thus, OF-Deg-Lin-based LNPs may be an attractive strategy for targeting splenic B cells *in vivo*.

Also, the identity of the helper lipid has been shown to influence binding affinity to specific serum proteins, as well as trafficking towards the liver and spleen. Indeed, substituting DOPE with DSPC in LNP formulations has been shown to shift the biodistribution from the liver towards the spleen by reducing the strength of interactions with ApoE.⁹⁶ Similarly, Dahlman and colleagues observed that changing the composition of helper lipids in a LNP formulation could alter the cell tropism observed upon administration. Notably, they also showed that using DOPE instead of the helper lipid 18:1 Lysophosphatidylcholine (lysoPC) led to an increase in the ratio of transfected splenic ECs to hepatocytes.¹²⁸ Future combined investigations of charge, surface pK_a , and helper lipid composition could serve to greatly increase the potential selectivity of LNP formulations for splenic delivery.

One study evaluated active targeting to enable efficient T-cell transfection. For instance, surface conjugation of anti-CD4 antibodies to LNPs resulted in a 30-fold increase of splenic T-cell uptake in comparison to non-targeted LNPs.¹²⁹ The localization ratio, calculated as the percentage of initial dose per gram of organ relative to dose per gram of blood, yielded 6-fold higher levels of particles in the spleen compared to conjugated control IgG, confirming that this active targeting platform could outperform the passive uptake usually observed with untargeted mRNA-LNP systems in the spleen. Flow cytometry analysis demonstrated about 60% transfection of CD4+ T cells in the spleen, validating that this formulation can achieve the efficient transfection of T cells.

Overall, most studies have shown that mRNA transfection and translation occur in splenic macrophages and dendritic cells to a greater extent than in B and T cells (Fig. 3C). Typical transfection efficiencies are between 5% and 12% for B cells and around 1% to 10% for T cells.^{45,122} One feasible strategy for the favorable delivery of functional mRNA to the spleen has been the incorporation of negatively charged phospholipids, which in turn result in alterations to the surface pK_a of the LNPs. Optimization of the structure of ionizable lipids—as

illustrated with OF-Deg-Lin-derivatives and iPhos lipids—has also proven to be an effective approach for tuning mRNA delivery to the spleen. A recent study reported remarkable protein expression in splenic tissue, with 61% occurring in macrophages and dendritic cells and around 6% occurring in B and T cells, using a structurally optimized lipid (tB-UC18) based on a tri-substituted benzaldehyde derivative containing primary amines (Fig. 3B).¹³⁰ While the mechanism by which this lipid promotes mRNA expression in the spleen remains unclear, these findings underscore that the exploration of the chemical structures of ionizable lipids might yield potent mRNA delivery vehicles for the spleen. Future investigations of the relationship between helper lipid identity, ionizable lipid structure, surface pK_a , and surface charge are thus of prime importance for the development of relevant and efficient solutions for specific mRNA delivery to splenic cells populations *in vivo*.

3.2.2. Polymer-based nanocarriers. mRNA polyplexes for spleen-targeted delivery have also been investigated. It has been demonstrated that the degree of hydrophobicity of polymer carriers could increase the cellular uptake of polyplexes, as well as endosomal escape.¹³¹ Aiming to optimize mRNA delivery, a group synthesized a library of polyester polymers bearing a range of alkyl- and amino-functional groups varying in length and hydrophobicity. *In vivo* evaluation of Luc expression indicated that mRNA expression between organs (lungs and spleen) could be altered by varying the length of alkyl chains and pK_a .¹³² It was found that for mRNA polyplexes, short alkyl chains (4 or 5 carbons in length) and low apparent pK_a (below 6) tended to promote translation of mRNA in the spleen. Interestingly, however, biodistribution analysis of Cy5-mRNA showed a large accumulation of mRNA-polyplexes in the liver. This discrepancy between biodistribution and protein expression has also been observed with other polymeric mRNA nanocarriers.¹¹¹ As previously discussed regarding LNPs, the incorporation of negatively charged lipids promotes the specific delivery of mRNA to the spleen. Taking into account this strategy, a group explored the influence of zwitterionic phospholipids grafted onto the amine-containing side chains of mRNA polyplexes, with backbones consisting of polymerized glycidyl methacrylate (GMA), along with epoxide-containing side chains, able to react with various amines. Subsequently, a post-combinatorial reaction of the amine side chain with alkylated dioxaphospholane oxide yielded zwitterionic phospholipidated polymers (ZPPs).¹³³ Aside from improving total mRNA delivery compared to non-phospholipidated polymers, the introduction of negatively charged phosphate groups into ZPPs decreased the surface pK_a of the nanoparticles from 8.3 to 7.3 compared to those made from non-phospholipidated polymer, which in turn promoted splenic mRNA delivery and expression, specifically displaying expression orders of magnitude higher than that observed in the liver. Beyond their influence on surface charge and pK_a , it has been shown that the lipid content and chemical structure of the polymers used can greatly influence the uptake of nucleic acids by T cells.^{134,135} By generating a library of

diblock polymers containing: (i) a lipophilic block functionalized with various side-chain lipids, and (ii) a polycationic α -amino ester mRNA-binding block, a group was able to identify a lead polymer (CART13) that efficiently promoted mRNA expression primarily in the spleen. Analysis of the splenic cell population demonstrated a transfection efficiency of about 1.5% in T cells, and 9% in B cells (Fig. 3C).¹¹⁸ Notably, transfection of T cells at this level had not been observed for similar mRNA delivery systems, which are normally limited to sub-1% T-cell transfection.^{45,121} Despite the great chemical diversity offered by polymeric nanocarriers, reports of their use for spleen delivery are far outnumbered by reports using LNP formulations. The key factors described above, including the introduction of alkyl side chains to increase the lipid content of the polymeric structure and the phospholipidation of the amine backbone for decreased surface pK_a , are feasible approaches to mediate mRNA expression in the spleen, and could serve as a basis for future investigations yielding more potent delivery vehicles.

3.3. mRNA delivery to the lungs

Lung diseases are a leading cause of death and disability worldwide.¹³⁶ In particular, genetic disorders leading to functional protein expression deficiencies such as cystic fibrosis (CF), primary ciliary dyskinesia (PCD), α 1-antitrypsin deficiency (AATD), and surfactant protein B (SP-B) deficiency, are diseases for which existing treatments can lead to therapeutic resistance, while displaying low overall effectiveness for certain disease variants.^{16,137,138} In contrast, mRNA-based protein supplementation therapy could act as a viable mutation-independent alternative. The origin of these disorders stems primarily from epithelial cells, which include, among others, goblet cells (which produce mucins and are responsible for regulating the secretion of chloride ions), ciliated cells (which promote mucoclearance), macrophages, and alveolar cells (which monitor gas exchange and the production of lipid surfactants).¹⁶ For the delivery of mRNA therapeutics to the lungs, two routes of administration have been investigated: (i) local intratracheal (IT) or nebulization-based administration, and (ii) systemic IV injection. Upon IV administration, nanoparticles circulate directly to the heart, where they reach the right ventricle, and continue into pulmonary circulation.¹³⁹ Lung capillaries are among the smallest blood vessels in the body, and are comprised mostly of non-fenestrated endothelium, acting as a major barrier for the extravasation of nanoparticles into the alveolar epithelium.¹⁴⁰ Generally, the IV administration of nanoparticle-formulated mRNA has the advantage of circumventing the mucus barrier of the lungs, though this route suffers from limited targeting specificity. In contrast, local administration has the advantage of direct application into the airways, but must cross the pulmonary mucus layer, which presents a formidable barrier for nanocarriers. As such, it is of key importance to expand our knowledge of the relevant features and routes of administration for nanocarriers, in order to enable the efficient delivery of mRNA to lung cells.

3.3.1. Local administration. The local delivery of mRNA presents a feasible route of administration holding potential for the treatment of lung disease, however, nanocarriers must overcome two principal anatomical barriers prior reaching deep alveolar lung structures and delivering mRNA to epithelial cells, namely the architecture of the airways, which restricts the penetration of particles between 1–3 μm into the alveolar region, and the underlying mucus layer.¹⁴¹ While the size of nanocarrier used can be tuned to reach the nanometer range, thus permitting travel through the airways, the pulmonary mucus layer represents a major challenge. In healthy individuals, this mucus has an approximate thickness of 2–5 μm in the bronchi, though in CF patients it can be much thicker and less hydrated, affecting the diffusion and deposition of inhaled nanoparticles through steric obstruction and direct interaction with target epithelial cells.^{142,143} Early studies evaluating the diffusion of nanoparticles across the mucus demonstrated diffusion through the pores of the gel mesh, with smaller objects (100–200 nm) moving more rapidly through the pores than large nanoparticles (200–500 nm).¹⁴⁴ *In vitro* investigations of nanoparticle diffusion through thick and dehydrated sputum collected from CF patients showed that particles above 500 nm were completely blocked by the mucus layer and that only around 0.3% of nanoparticles between 150 and 200 nm in size could diffuse through the mucus.^{145,146} Aside from the meshed structure of the mucus, the presence of free DNA molecules and negatively charged lipids lends a negative charge to the mucus, interacting with positively charged particles to reduce diffusion and gene transfer.^{147,148} In contrast, neutral nanoparticles have shown greater and more rapid (around 3-fold) diffusion compared to charged vehicles, suggesting favorability for the delivery of nucleic acids.¹⁴⁴ When comparing LPXs and polyplexes including PEI and PAMAM dendrimer-based gene delivery systems, polymers have been observed to be more resistant to the effects of negatively-charged pulmonary surfactants than LPXs *in vitro*.¹⁴⁹ One approach that has been explored to overcome the hurdles of the mucus and pulmonary surfactants has been pretreatment with mucolytic agents such as recombinant human DNase (rhDNase) or *N*-acetylcysteine (NAC), which liquifies the pulmonary mucus and lowers its viscosity. Pretreatment of the nasal epithelium with NAC 30 min prior to the administration of plasmid DNA (pDNA)-LPXs resulted in increased gene expression, potentially acting as a feasible strategy for improving gene delivery to the lungs, though this has not been tested with mRNA payloads.¹⁴⁷ There are numerous works describing pDNA and siRNA delivery to the lungs, and though *in vivo* mRNA delivery *via* local administration has received growing interest in the most recent decade, most works have placed an emphasis on polymeric formulations, with few studies using LNPs for IT and nebulization applications.

3.3.1.1. Polymer-based nanocarriers. In an attempt to investigate direct IT delivery of mRNA to the lungs, Dewerth and co-workers administered zinc finger nuclease (ZFN)-encoding chemically modified mRNA in chitosan-coated (for mucoadhesive function) PLGA, achieving protein rescue in lasting over

20 days in SP-B deficient mice.¹⁵⁰ The study also compared the delivery of ZFN encoded by either plasmid DNA or mRNA, finding that the latter achieved a greater rate homology-directed repair (HDR), approximately 9%. For the treatment of SP-B deficiency in humans, the restoration of SP-B levels by 5–10% in the lungs is sufficient to reduce disease symptoms to mild levels, suggesting a potential therapeutic effect if 9% gene transfection can be achieved.¹⁵¹ Given the transient nature of mRNA-induced ZFN expression, this approach presents a safe and attractive approach. In another independent study, the same group compared the IT and IV delivery of mRNA encoding the transmembrane conductance regulator (CFTR) using chitosan-coated PLGA nanoparticles, observing efficient restoration of CFTR channels in a knockout model. Interestingly, the IV route exhibited greater performance for the delivery of such complexes to the lungs.¹⁵² Indeed, to achieve expression at the level reached by delivery of 2 mg kg⁻¹ body weight *via* IV administration, a doubling of IT dosage was required. These findings are likely due to the presence of mucus in the upper airways, as well as mucociliary movements, which promote the clearance of the nanoparticles. While IT administration allows the direct passage of nanoparticles into the airways, this method usually necessitates invasive procedures such as orotracheal intubation—suitable for testing in animals, but impractical for clinical situations requiring multiple doses. Furthermore, IT delivery is limited to the upper airways of the lungs, unlike non-invasive inhalation techniques.¹⁵³ Evaluation of the IT administration to pigs of Luc mRNA polyplexes consisting of a cationic polymer scaffold of poly(acrylic acid) demonstrated that mRNA was mostly found in cranial lobes of the lungs, as revealed by luminescence measurements of the Luc protein.¹⁵⁴ In contrast, inhalation allows deposition throughout the entire bronchiolar and alveolar epithelium, reaching deep lung structure, which could in turn lead to more significant relief of symptoms.¹⁵⁵

Nebulization is a non-invasive procedure in which a device transforms a liquid medicine into a mist that can be inhaled into the lungs. For the nebulization of mRNA, the nanocarrier vehicles must withstand shear forces and must be able to be concentrated at high clinical doses, suggesting the suitability of cationic polymers, due to their capacity to complex large quantities of mRNA.^{156,157} Branched PBAEs (bPBAEs) have been shown to be less toxic than PEI polymers, and polyplexes of this material have been investigated as vehicles for mRNA delivery *via* nebulization, demonstrating efficient delivery of mRNA to lung tissue. An initial study reported that the transfection percentage of endothelial, epithelial, and immune cells achieved through nebulization was around 25% for the total epithelial cell population, including 4.4% for ECs, and 0.4% for immune cells, as determined by flow cytometry.¹⁵³ As these data were generated in healthy mice, rather than in a pathological model, it is difficult to evaluate the potential therapeutic effects resulting from this level of transfection efficiency. It has been suggested that for CF, 5–10% CFTR gene correction in epithelial sheets¹⁵⁸ could mitigate symptoms, and that 15–30% epithelial transfection would be needed for a

50% restoration of CFTR current.¹⁵⁹ To investigate whether PEGylation of the polymer nanocarriers would influence the delivery of mRNA, PBAEs containing an alkyl amine (12 carbons in length) were synthesized to enable coformulation with the PEGylated lipid C18PEG5000, however, it was found that the PEGylated (7.5 mol%) polyplexes did not enhance mRNA delivery *in vivo*. PEGylation of nanoparticles as a strategy for overcoming the mucus barrier has been widely used for the delivery of payloads other than mRNA and represents a gold-standard for the engineering of mucus-penetrating nanocarriers.¹⁶⁰ Additionally, previous studies conducted in pathological and healthy mucus, performed using pDNA-based LPXs and polystyrene beads, reported a positive effect resulting from PEGylation, with the PEG acting as a shield from respiratory fluids and surfactants, thereby facilitating diffusion of muco-inert particles through the mucus.^{161,162} A recent *in vitro* study evaluated the mucus penetration rate of PEGylated and non-PEGylated lipopolyplexes in CF sputum from patients and in an artificial model of healthy sputum. While PEGylation improved mucus penetration in healthy sputum, no impact was observed in pathological mucus when compared to non-PEGylated nanoparticles.¹⁶³ Analysis of sputum composition revealed that the CF mucus contained more mucins (MUC5AC and MUC5B) than the healthy sputum, which strongly interacted with the nanoparticles independent of PEGylation. Nebulization of non-PEGylated mRNA-containing PBAE polyplexes has been successfully achieved *in vivo* in two studies, which conducted evaluations in animal models of CF. In another example, non-PEGylated peptide-poloxamine nanoparticles have shown encouraging results for the restoration of CFTR activity in mice.¹⁶⁴ These vehicles were below 100 nm in size, and the presence of terminal hydrophilic polyethylene oxide blocks from the poloxamine allowed the formation of dense brushes protruding from the nanoparticle surface, resulting in a muco-inert surface that prevented mucoadhesion. Similar results can be seen in a study using polyplexes for the delivery of Cas13 mRNA and guides to target RNA viruses.¹⁶⁵ The PBAE-mRNA polyplexes were nebulized in mice challenged with an influenza viral load, and were found to efficiently degrade influenza RNA in lung tissue when delivered after infection, illustrating the potential of non-PEGylated PBAE polymers for the nebulization of mRNA. Results from these studies highlighted that the addition of PEG on the surface of PBAE- or poloxamine-based polyplexes was not a prerequisite for achieving epithelial transfection in the lungs upon local administration.

3.3.1.2. Lipid-based nanocarriers. Though cationic amine polymers have been shown to be efficient carriers for mRNA in the lungs, nebulized therapies using these polymers have not yet been approved by the FDA. In contrast, the clinical implementation of LNPs is more advanced, making these materials an attractive alternative to polymers for delivery of mRNA to the lungs.¹⁶⁶ A demonstration that LNPs are capable of delivering clinically relevant doses of mRNA to the lungs *via* nebulization would present new avenues as a versatile platform for mRNA delivery. A large *in vivo* screening has yielded inter-

esting insights on (i) the impact of PEG content, and (ii) the impact of helper lipid identity.¹⁶⁷ The best-performing formulation for achieving high mRNA expression in the lungs upon nebulization consisted of 55 mol% DMG-PEG and included the cationic helper lipid DOTAP at 5 mol%. While PEG-lipids are generally known to promote stability and prevent clearance in systemic delivery, their function in nebulization remains unclear. One hypothesis is that the large quantity of PEG serves to improve the stability and integrity of LNPs during the harsh conditions applied during the nebulization process. Inclusion of the cationic helper lipid DOTAP also contributed to higher transfection efficiency. Comparison of this strategy with formulations previously optimized for systemic delivery demonstrated superior performance, mainly due to higher stability of the LNPs during nebulization. This study revealed that the structure of PEG, as well as its molar percentage and the charge of the helper lipid can greatly affect mRNA incorporation and subsequent delivery, suggesting the need for further studies to understand the impact of PEG density and charge on pulmonary administration by nebulization.

Altogether, local administration of mRNA to the lungs has been shown to be feasible with both LNPs and polyplexes. The nebulization of mRNA using non-PEGylated biodegradable PBAE polyplexes, which have been shown to be able to complex up to 0.5 mg mL⁻¹ of mRNA, demonstrated 25% transfection of the total lung epithelial cell population in a healthy mouse model (Fig. 4A). Whether PEGylation provides potential benefits for delivery to pulmonary epithelial cells is controversial. Recent studies using poloxamine-based polymers and PBAEs demonstrated successful delivery of mRNA to the lungs without the need of PEGylation.^{164,165} Further, in a recent study conducted with siRNA, a thorough analysis of comparable PEGylated and non-PEGylated polymer formulations (PEI and PLGA) clearly demonstrated that PEGylation did not enhance gene silencing in CF mucus, corroborating results obtained with non-PEGylated PBAE polyplexes.^{153,163} This phenomenon could be attributed to lower cellular uptake into epithelial cells resulting from the PEG shield. In contrast, PEG has been shown to be crucial for the stability of LNP formulations for nebulization, by preventing aggregation during storage and promoting structural stability within the vibrating mesh nebulizer.¹⁶⁷

3.3.2. Systemic administration. Effective mRNA delivery to lung cells *via* systemic administration has the advantage of avoiding diffusion through the thicker mucus layer seen in CF patients or scarred lung parenchyma.^{148,163,168} Due to the preferential accumulation of LNPs in the liver after systemic administration, the design of LNPs for mRNA delivery to other organs remains an extraordinary challenge. Nevertheless, over the past five years, research on LNP and polymer design has led to important advances towards favorable mRNA expression in the lungs.

3.3.2.1. Lipid-based nanocarriers. Inducing mRNA expression in the lungs upon systemic administration has mostly been evaluated through passive targeting without the use of targeting ligands. Nonetheless, a recent study has inves-




Fig. 4 Local and systemic administration of mRNA via nanocarriers to the lungs. (A) Chemical structures of several polymers used for local administration, or (B) ionizable lipids used for systemic delivery. (C) Graphical representation of the two routes of administration, for the principal classes of nanocarriers represented in the literature. (D) Transfection efficiency of the best-performing nanocarriers both for local and systemic delivery. Doses and duration before evaluation: 1 mg kg^{-1} Cre mRNA, $t = 144 \text{ h}$ for PBAEs;¹⁵³ 0.3 mg kg^{-1} Cre mRNA, $t = 48 \text{ h}$ for DOTAP;¹²² 0.25 mg kg^{-1} Cre mRNA, $t = 48 \text{ h}$ for iPhos;¹²⁶ and unknown dose of Cre mRNA, $t = 48 \text{ h}$ for lipopolyplex A1.¹⁷⁶

tigated the use of active targeting *via* conjugation to the LNP surface of antibodies specific for the vascular cell adhesion molecule, PECAM-1. PECAM-1 is highly expressed in vascular cells (including ECs) and early studies have demonstrated that liposomes targeting PECAM-1 are capable of accumulation in the lung endothelium.^{169,170} Biodistribution evaluation using radiolabeled formulations also revealed that the pulmonary uptake of PECAM-1-targeted-Ab/LNP-mRNA was 16-fold greater than that of control IgG/LNP-mRNA.¹⁷¹ Luc mRNA-induced fluorescent signals showed more specific expression in the lungs, and reduced expression in the liver for PECAM-1-targeted-Ab/LNP-mRNA, but not for the control IgG/LNP-mRNA, with a ~ 25 -fold elevation of the signal in the lungs. Upon assessment, the lung/liver ratio of targeted LNPs was found to be around 2.5, indicating that this approach might constitute another feasible strategy to achieve specific mRNA delivery to the lungs.

By increasing the molar percentage of the permanent cationic lipid DOTAP in LNPs, mRNA expression was shifted from the liver to the lungs, with an optimal formulation containing 50 mol% DOTAP demonstrating near exclusive mRNA expression in lung tissue. The increased quantity of DOTAP induced a gradual augmentation of the LNP surface pK_a from 6.46 to >11 for the optimal lung-targeting formulation, which was capable of transfecting $\sim 40\%$ of all epithelial cells, $\sim 65\%$

of all ECs and $\sim 20\%$ of immune cells in the lungs (Fig. 4B).¹²² Surprisingly, while the surface pK_a of the LNPs was increased, the zeta potential of this formulation showed a surface charge near neutral. A possible explanation might involve the encapsulation of DOTAP within the LNPs alongside the mRNA. Analyses using Cy5-labeled mRNA demonstrated that, despite strong protein expression in the lungs, around 30% of the total mRNA was still delivered to the liver, revealing a discrepancy between the biodistribution and mRNA-induced protein expression profile. The addition of DOTAP and the resulting increase in surface pK_a also had the effect of altering the protein corona of the LNPs, as highlighted in a recent proteomics study.¹²³ The composition of the protein corona of lung-targeting LNPs was primarily enriched in vitronectin, in contrast with liver-targeting LNPs, where the corona was mostly enriched in ApoE. In another study, the inclusion of DOTAP at 60% mol in liver-targeting LNPs supported the previous findings, achieving lung-specific gene editing, as indicated by strong fluorescence in the lung tissue of Ai14 Cre-reporter mice upon administration of Cas9/sgTOM mRNA LNPs.¹⁷² Replacement of the lipid DOPE with DOTAP in a four-component LNP system was also shown to promote lung-specific mRNA delivery. Specifically, the incorporation of 40 mol% DOTAP substantially shifted mRNA expression to the lung, further supporting that the incorporation of a positively

charged lipid into LNP formulations represents a feasible approach to promote selective mRNA expression in lung tissue.¹²⁵ Interestingly, lung specificity was found to strongly correlate with LNP surface pK_a , but correlated poorly with zeta potential. While both of these parameters provide information on the surface charge of the nanoparticles, the absence of a shift in zeta potential is surprising. A complete understanding of this phenomenon remains elusive and future work is required to acquire mechanistic understanding of this discrepancy. The ionizable phospholipid iPhos was also found to be able to promote lung-selective mRNA delivery;¹²⁶ *in vivo* evaluations revealed that the presence of a 9-carbon alkyl chain attached to the phosphate group was able to mediate lung-specific mRNA localization. Further, the incorporation of the cationic helper lipid dimethyldioctadecylammonium bromide (DDAB) resulted in an optimal lung-targeting LNP formulation with a surface pK_a of 7.15, achieving a transfection efficiency of nearly 34% of all ECs, 20% of all epithelial cells, and roughly 13% of immune cells, enabling effective gene editing in the lungs (Fig. 4B and D). This suggests that the inclusion of an optimized ionizable lipid structure, coupled with the insertion of a cationic helper lipid, can promote lung-specific mRNA delivery. Though the surface pK_a values for the iPhos formulations were not as high as those exhibited upon the incorporation of 50 mol% DOTAP, both formulations achieved comparable transfection efficiencies in lung cells, suggesting that while the surface pK_a of LNPs is relevant, other factors—including the structure of the ionizable lipids—may contribute to the success of lung-specific mRNA expression. Based on the same design principles used for iPhos lipids, zwitterionic amino lipids (ZALs) have been developed, comprising a zwitterionic sulfobetaine headgroup, an amine-rich linker region, and a range of hydrophobic tail structures. These lipids combine the chemical and structural features of zwitterionic and cationic lipids into a single compound, which in turn allows the enhanced delivery of longer RNA sequences, such as Cas9 mRNA. Among the lead ZAL structures prepared, the best performing compound (ZA3-Ep10), resulted in expression of Luc in the lungs, though substantial expression was also observed in the liver and spleen 24 h post-injection (Fig. 4B).¹⁷³ A further study analysed the biodistribution of the ZA3-Ep10-based LNP formulation and the level of mRNA-induced protein expression 6 h after injection.³⁷ Interestingly, the data showed a wide distribution profile, with mRNA accumulation mostly observed in the liver (66%) and lungs (21%), though protein expression was primarily found to occur in the lungs (>70%).^{108,111} Thus far, no extensive explanation has been proposed for this discrepancy, and more investigations are required to explore cell-specific differences in nanoparticle internalization, endosomal escape, and translational kinetics, all of which may contribute to better understanding the disparities between biodistribution and mRNA expression.

3.3.2.2. Polymer-based nanocarriers. Systemic mRNA delivery to the lungs has also been investigated using polymeric structures, such as PBAEs and polyester derivatives.^{132,174,175}

In one example, a set of PBAE polymers were synthesized *via* the Michael addition of three monomers (diacrylate, secondary or tertiary amine, and C12-dodecyl amine), forming random copolymers defined as terpolymers. Nanoparticles were then generated by the incorporation of DMG-PEG (7 mol%) through hydrophobic interactions, promoting particle stability for over 2 hours in phosphate buffered saline (PBS) spiked with 10% fetal bovine serum (FBS). An *in vivo* evaluation of the best-performing of these polymers resulted in Luc expression primarily in the lungs.¹⁰⁸ Similar to previous studies, this work revealed a strong discrepancy between mRNA biodistribution and protein expression. Notably, while the greatest protein expression was detected in the lungs, with no substantial signal recorded in other organs, fluorescently labeled mRNA polyplexes were found to be distributed evenly among the organs, with the strongest signals observed in the spleen and lungs. While the mechanism by which mRNA translation in the lungs is favoured remains unclear, it has been suggested that the surface charge of the lipopolyplexes, ranging from +10 to +15 mV, may result in altered interactions with serum proteins or surface receptors in the lung endothelium, and may account for the level of lung-specific expression observed. Subsequent work on the same terpolymers demonstrated that optimization of the alkyl chain length of the PEG-lipid, alongside the molar % of PEG-lipid, can confer a high degree of lung-specific mRNA expression.¹⁷⁶ The *in vivo* screening of a series of non-covalent polymer formulations made from terpolymers and PEG-lipids containing alkyl chains varying in length between C14 and C18, at proportions ranging from 1–7 mol%, yielded a lipopolyplex formulation comprising PBAE terpolymers + 5% C18PEG2000 complexed with mRNA at a nitrogen to phosphate (N/P) ratio of 50:1, which outperformed previous formulations containing 5.5 mol% DMG-PEG. As such, optimization of the PEG-lipid structure and mol% could present another feasible approach for improving mRNA expression in the lungs. Furthermore, this mol% of PEG-lipid yielded particles with sizes of ~100 nm (within the optimal range), a factor which has been strongly correlated with effective lung-specific mRNA delivery in other studies.¹²⁵ Flow cytometry analysis in Cre-reporter mice revealed that this formulation primarily transfected lung ECs (75% of the total EC population) and, to a lesser extent, immune cells (2% of the total immune cell population). Aside from surface charge and PEGylation, the surface pK_a of polyplexes has also been identified as an important parameter for mRNA delivery to the lung. A recent study performed a screening of a series of cationic polyester polymers containing varied amino groups and modified hydrophobic side chains, to evaluate the size, surface charge, and pK_a of polyplex nanoparticles for the selective delivery of mRNA to the lungs.¹³² No correlation was found between the size and charge of polyplexes, as the lead polymer with the strongest signal in lung tissues showed nearly neutral surface charge. Interestingly, surface pK_a correlation assessment illustrated a strong relationship between selective mRNA delivery to lung tissue and pK_a , with optimal values for lung delivery ranging from 7.5 to 8, in line with the data observed

for LNPs. Biodistribution studies also revealed a disperse Cy5-labeled mRNA distribution throughout the body, with strong accumulation in the liver illustrating once more that mRNA distribution does not correlate with mRNA translation.

Altogether, lung-targeted mRNA delivery has been found to be achievable *via* systemic administration, using both polymeric and lipid-based formulations (Fig. 4C). Interestingly, when comparing transfection efficiency at a cellular level, it appears that transfection in ECs is higher upon systemic administration than upon local administration, suggesting that this administration route could represent a more viable approach for the treatment of acute lung injury/acute respiratory distress syndrome. Transfection efficiency of lung epithelial cells has been reported to range between 20–40% for LNP systems, and up to 75% when using PBAE polymers (Fig. 4D). A common feature of lung-targeting formulations is the introduction of positively-charged lipids into LNPs, resulting in surface pK_a values above 7 and consequently altered protein interactions.^{93,123} In addition, modifications to the side chains of polymers used for mRNA delivery led to similarly altered surface pK_a , suggesting that this parameter is critical for achieving lung tissue-specific delivery of mRNA.

3.4. Highlights on the biodistribution of mRNA nanocarriers

As described above for both LNPs and polymeric structures, several parameters must be considered in order to achieve tissue-specific mRNA expression. Here, we underline two key points playing a crucial role in mRNA biodistribution which might provide inspiration for future works aiming to develop more efficient tissue-specific delivery vehicles for mRNA.

Thus far, it has been difficult to accurately predict the biodistribution of nanoparticles based on their physicochemical parameters. The surface pK_a , corresponding to the pH at which the proportion of charged and uncharged ionizable lipids at the surface of the particle is equal, has been assessed in various studies and is thought to be a key factor. Although this seems persuasive, particularly for liver-targeting formu-

lations, recent findings have revealed that other parameters are also involved. Indeed, surface pK_a values above 11 have been reported to promote almost exclusively lung-specific mRNA delivery when using the ionizable lipid 5A2-SC8 and 50 mol% DOTAP, whereas a surface pK_a of 7.2–8.0 was sufficient to mediate mRNA delivery to the lungs using iPhos LNPs or the polymer PE4K-A17-0.2C8.^{122,126,132} This suggests that the surface pK_a may depend on the type of ionizable lipids and/or charged helper lipids used in the nanoparticle formulation, and accordingly, the biodistribution profile must be extrapolated from these predictive values keeping in mind the associated formulation. Additionally, only a poor correlation between surface pK_a and zeta potential has been reported, which is surprising, given that both parameters provide information regarding the charges present at the surface of LNPs.¹²⁵ While the underlying mechanism remains unclear, a possible explanation for this lack of alteration of the zeta potential could be due to an internal restructuring of the LNPs when permanently charged lipids are added, resulting in changes to the surface pK_a and leaving the zeta potential unaltered. With this in mind, surface pK_a appears to have an influence on mRNA biodistribution, but this may need to be thoroughly assessed alongside other parameters, such as the type of ionizable lipids and helper lipids used in the formulation, overall LNP structure, and mRNA-to-lipid ratio, in order to be efficiently used in screening process.

When comparing biodistribution profiles and mRNA-induced protein expression, there is no clear evidence that the massive accumulation of nanocarriers in a given organ will necessarily lead to a high degree of protein expression. Indeed, meaningful discrepancies have been reported for both LNPs and polymeric nanocarriers (Fig. 5).^{37,94} As an example, the previously described Of-Deg-Lin lipid resulted in over 85% of total protein expression in the spleen, despite the LNPs being primarily distributed to the liver.⁴⁵ Consequently, biodistribution alone cannot predict the functional delivery of mRNA to a particular tissue. The reasons certain formulations fail to




Fig. 5 Discrepancies between mRNA biodistribution and resulting expression. (A) mRNA biodistribution and functional delivery for three polymeric formulations, with a dose of 0.6 mg kg^{-1} of either Luc mRNA or Cy5-labeled mRNA, after 6 h.¹¹¹ (B) mRNA biodistribution and functional delivery for three lipid-based formulations, with a dose of 0.75 mg kg^{-1} of either Luc mRNA or Cy5-labeled mRNA, after 6 h.³⁷

mediate protein expression in certain tissues remain elusive, but possible explanations may lie in endosomal composition, which differs between various cell types, and changes to the formation of the protein corona, which is thought to govern cellular uptake and the fate of nanoparticles in circulation.^{177,178}

4. mRNA delivery to other relevant organs

4.1. mRNA delivery to the lymphatic system

4.1.1. Local administration. The lymphatic system regulates interstitial fluid homeostasis and coordinates the trafficking of antigens and immune cells, while also contributing to the dietary uptake of lipids.¹⁷⁹ Importantly, the role of lymphatic vessels has been identified in the pathogenesis of various diseases such as lymphedema, inflammatory bowel disease, and the metastasis of solid cancers.^{180,181} While the lymphatic system is not easily accessible *via* IV injection, intramuscular (IM), intradermal (ID) and SC administration routes have been more successful, mainly due to the increased interstitial pressure resulting from these forms of injection, leading to the natural drainage of excess interstitial fluid through the lymphatic vessels.¹⁸² Imaging analysis has shown that, upon IM injection, radiolabeled mRNA-LNPs were trafficked to lymph nodes (LNs) within 4 h.¹⁸³ Data collected at 4 h and 28 h post-injection revealed a decrease in signal of around 45% at the site of injection, whereas an average increase of two-fold was found in the LNs. The transport of nanocarriers to LNs can occur either in a passive manner, taking place within minutes to hours of administration, or through active transport driven by APCs, which travel through the lymphatic system, a process requiring more time.¹⁸⁴ Flow cytometry analysis in the LNs after 28 h suggested that most transfected cells were APCs, supporting the proposed active transport mechanism in addition to the more rapid passive drainage indicated by the strong signal at 4 h. Local administration of mRNA encoding for vascular endothelial growth factor (VEGF) has been investigated as a means to induce local lymphatic growth and subsequently activate lymphatic function in newly formed lymphatic vessels in mice.¹⁸⁵ ID administration of mRNA encoding for GFP demonstrated expression only at the injection site, thus excluding potential off-target effects in other organs following ID delivery. VEGF-induced lymphangiogenesis was limited to the injection sites in the paws of mice, and resulted in reduced paw thickness (*i.e.*, alleviation of symptoms) in a mouse model of secondary lymphedema, indicating that this mRNA-LNP platform could represent a feasible alternative to current approaches such as manual lymph drainage or compression therapy.

Nanoparticle size and charge have both been identified as factors governing drainage through lymphatic vessels. Drainage has been reported for nanoparticles with sizes ranging from 20–200 nm, with optimal lymphatic uptake observed for particles between 20–80 nm.^{180,186,187} Similarly, it has been reported that following SC injection, mRNA-LNPs

with diameters of 150 nm and zeta potentials between –15 and –3 mV could efficiently be drained to the LNs.¹⁸⁸ In Cre reporter mice, flow cytometry revealed that 4.6% of DCs, 1.2% of macrophages, 3.3% of neutrophils, and 0.06% of B cells were efficiently transfected. Antitumor function evaluation after a single SC injection of LNPs containing mRNA coding for the tumor-associated antigens gp100 and TRP2 in an aggressive mouse model of melanoma revealed strong CD8+ T cell activation, tumor size reduction, and extended overall survival of the treated group. Direct percutaneous injection into the LNs has also been investigated for immunotherapy applications, specifically for the delivery of mRNA vaccines without the use of nanoparticles.¹⁸⁹ Vaccine-induced T cell infiltration and killing of autologous tumor cells was shown in resected post-vaccination metastases. The cumulative rate of metastatic events was highly significantly reduced after the initiation of vaccination, resulting in sustained survival without further disease progression.

4.1.2. Systemic administration. mRNA delivery to the lymphatic system *via* systemic IV administration has been achieved by altering the particle charges of LPXs and ZPP polymers, as well as through active targeting. Specifically, it was shown that mRNA-LPXs exhibiting a negative charge of ~–25 mV could reach LNs as well as splenic APCs through the initiation of a strong type-I interferon (IFN)-driven immunostimulatory response.¹²¹ Systemic injection demonstrated a 60-fold higher CD8+ T cell priming effect compared to SC administration, allowing mRNA-based delivery of encoded antigens to APCs located throughout the lymphatic system, including in the axillary and inguinal LNs. This suggests that systemic administration approaches could be capable of greater T cell transfection than local vaccine delivery, yielding great promise for cancer immunotherapy. This approach has recently been tested in a first-in-human study in melanoma patients, yielding promising results either alone or in combination with a programmed cell death protein 1 (PD1) inhibitor in patients with unresectable melanoma.¹⁹⁰ The high-magnitude induction of the T-helper-1 phenotype generated a synergistic effect when coupled with anti-PD1 therapy and resulted in a tumor regression rate of 35% in checkpoint inhibitor-experienced patients. Additionally, IV administration of the optimized PA6-4P14 ZPP polymer nanocarriers efficiently induced mRNA delivery to diverse LNs, including iliac, axillary, and mesenteric LNs, resulting in transfection of nearly 6% of all CD4+ T cells.¹³³

4.2. mRNA delivery to the brain

mRNA therapeutics could represent a promising approach for the treatment of brain disorders caused by genetic defects.^{191,192} However, the effective delivery of large hydrophilic drugs, including mRNA, to the brain following systemic administration is hampered by the blood-brain barrier (BBB).¹⁹³ Thus, most studies on mRNA delivery to the brain utilize local administration routes, with only one work evaluating the delivery of mRNA to the brain endothelium *via* IV administration.

4.2.1. Local administration. Intrathecal administration allows direct access to the central nervous system (CNS) through direct injection into the spinal canal, and has been used for the delivery of frataxin (FXN) mRNA to the CNS as a potential treatment for Friedreich's ataxia, an autosomal recessive neurodegenerative disease.^{194,195} Upon intrathecal injection of mRNA-LNPs, FXN expression was observed in the dorsal root ganglia (DRG), and to a lesser extent in the spinal cord and cerebellum. When administered intravenously, however, no expression was observed in the brain, demonstrating the inability of the LNPs to cross the BBB. As an alternative, intracerebroventricular administration has been proposed, which consists of the injection of substances directly into the cerebrospinal fluid through the cerebral ventricles.¹⁹⁶ Using this route of administration, enhanced green fluorescent protein (eGFP) and Luc mRNA encapsulated in neutral LNPs could be delivered to astrocytes and neuronal cells in the corpus callosum of mice.¹⁹⁷ While the mechanism of cellular uptake in these cells remains unidentified, astrocytes and neurons express LDLRs and the cerebrospinal fluid is known to be rich in ApoE, suggesting a possible ApoE-LDLR-mediated uptake mechanism of LNPs into these cells.^{198,199} Similarly, PEGylated polyplexes have been delivered by intracerebroventricular injection in mice.²⁰⁰ The administration of polyplexes carrying mRNA encoding for neprilysin (NEP)—an enzyme involved in the clearance of amyloid-beta ($A\beta$)—showed a reduction in the cerebral concentration of $A\beta$, which had previously been artificially supplemented in the brains of the mice. Luc mRNA polyplexes demonstrated strong protein expression in a diffuse manner surrounding the ventricular space at 4 h post intracerebroventricular injection, followed by a gradual decrease over 48 h.

4.2.2. Systemic administration. As the protein vascular cell adhesion molecule 1 (VCAM-1) is overexpressed in the BBB under inflammatory conditions, the IV injection of VCAM-1-targeting LNPs could allow their accumulation in the brains of mice experiencing cerebral inflammation, potentially achieving a brain/blood ratio of VCAM-1 more than 300-fold greater than through untargeted delivery.²⁰¹ Furthermore, upon the IV injection of fluorescently labeled LNPs, flow cytometry analysis of ECs in an artificially induced mouse model of brain edema revealed predominant targeting of these cells, with more than half of the population displaying fluorescence. VCAM-1-targeted LNPs encapsulating mRNA encoding for thrombomodulin (TM, a natural endothelial inhibitor of thrombosis, inflammation, and vascular leakage) were able to mediate expression in the brain EC population, restoring normal integrity of the BBB and leading to diminished brain edema in a mouse model. This study successfully illustrates the potential of this approach for the cerebrovascular targeting of inflamed brain endothelial tissues.

4.3. mRNA delivery to the eyes

Over the past decade, interest has grown in the development of nucleic acid drugs for the treatment of ocular diseases. The straightforward accessibility and immune-privileged status of

the eyes has resulted in a plethora of published works and clinical trials, leading in 2017 to the FDA approval of an adeno-associated virus (AAV2)-based complementary DNA gene augmentation therapy, voretigene neparvovec (Luxturna[®]).²⁰² LNPs have been used to deliver mRNA to the eyes *via* two routes of local administration: subretinal (SR) and intravitreal injection. While SR injection delivers the LNPs in close proximity to the retinal pigment epithelium (RPE) in the outer retina, intravitreal administration requires the vehicle to move through the vitreous humor and penetrate a complex network composed of tight junctions and fibronectin, thereby restricting the permeation of nanoparticles prior to reaching the RPE. An initial study demonstrated that the SR injection of Cy5-labeled GFP mRNA encapsulated in Lipofectamine[™]2000 displayed localization in the RPE layer and specific uptake into photoreceptor cells.²⁰³ GFP protein expression was found to be co-localized with the Cy5-mRNA signal in the RPE layer and photoreceptor cells. Similarly, another study, conducted in mice, evaluated the SR injection of a series of LNP formulations containing ionizable lipids with distinct pK_a values.²⁰⁴ Examination of Luc expression demonstrated that lipids displaying low pK_a values (such as MC3) and containing unsaturated alkyl chains generated the brightest luminescence in the RPE, in comparison to cationic or ionizable lipids with high pK_a values such as *N,N*-dimethyl-2,2-di-(9*Z*,12*Z*)-9,12-octadecadien-1-yl-1,3-dioxolane-4-ethanamine and 1,2-dioleoyloxy-3-dimethylaminopropane (DODMA) potentially due to the superior ability of MC3 to escape the endosomal lumen. Upon SR injection of MC3 LNPs, mRNA delivery was shown to be cell-type specific with the majority of expression observed in the RPE and in the Müller cells. Owing to the crucial role of RPE cells and Müller cells in the pathological development of several retinal disorders, including macular degeneration,²⁰⁵ the delivery of mRNA to the retinal epithelium might offer new treatment opportunities for these conditions.

While SR injection is a very efficient retinal drug delivery route, this technique requires careful manipulation in order to avoid damage to the retinal layer.²⁰⁶ In contrast, intravitreal injection presents a less invasive and safer method of reaching the retina, though the need to travel through the vitreous humor could potentially lower the transfection efficiency of the injected complexes.²⁰⁷ To investigate this approach, a recent work evaluated the influence of particle size and PEG content (0.5–5%) on the penetration and transfection efficiency of LNPs upon intravitreal injection.²⁰⁸ It was found that LNPs with a PEG content of 0.5 mol% and a particle size of 150 nm yielded optimal Luc activity and expression in Müller cells, the optic nerve head, and the trabecular meshwork, but failed to reach the RPE, possibly due to the low quantity of nanoparticles able to reach the retina after diffusion through the vitreous humor. Consequently, the route of administration is a key factor to consider for ocular mRNA delivery, with intravitreal injection enabling transfection of the Müller glia and the optic nerve head in the inner retinal layer, while SR injection is required to reach the RPE in the deeper retinal layer. The FDA-approved gene therapy Luxturna[®] is

administered *via* SR injection, highlighting the potential of this approach, though the high level of precision required for this procedure should still be emphasized. Future developments enabling transfection of the neural retina through intravitreal delivery, which is less invasive and allows for repeated administration, could broaden the scope of therapeutic applications of mRNA for the treatment of Mendelian eye disorders.

4.4. mRNA delivery to the heart

Myocardial infarction and heart failure are leading causes of death in industrialized nations, with 300 000 individuals per year experiencing recurring heart attacks in the United States alone.^{209,210} Myocardial infarction leads to a loss of cardiomyocytes (CMs), which are replaced with non-CM cells, leading to scarring and, in most cases, heart failure.²¹¹ Current therapies such as cell-based treatments using exogenous cells, cardiac progenitor cells, or stem cells have been developed to improve heart function, however, poor clinical improvement has generally been reported.²¹² With this in mind, there has been a recent focus on the enhancement of angiogenesis and revascularization of the myocardium through direct VEGF administration in both preclinical and clinical studies.^{213,214} Initial studies have demonstrated that intramyocardial injection of VEGF mRNA complexed with a commercial transfection agent (RNAiMAX[®]) results in the expansion and directed differentiation of endogenous heart progenitor cells toward cardiovascular cell types, improving heart function in a mouse model of myocardial infarction.^{215,216} Intramyocardial injection and intracoronary delivery have also been assessed using eGFP-encoding mRNA formulated in LNPs.^{217,218} Direct intramyocardial injection led to strong eGFP expression in the subepicardial areas of injection and extended to the myocardium, with subsequent biodistribution analyses showing low off-target accumulation (below 10%) in the liver, spleen, and lungs. As a more clinically suitable minimally invasive delivery approach, intracoronary delivery has been investigated in this study. Nonetheless, this approach demonstrated lower levels of protein expression than direct myocardial injection and a more pronounced off-target expression profile, particularly in the spleen. Interestingly, while naked RNA is rapidly degraded in the bloodstream, recent reports have demonstrated that the direct injection of naked mRNA into the myocardium resulted in prolonged VEGF levels in cardiac tissue. In one study, the encapsulation of mRNA with nanoparticles hindered its effective translation, whereas naked m1 ψ -modified mRNA in sucrose-citrate buffer was translated very efficiently, with protein expression detected within 10 min of administration in cardiac muscle.²¹⁹ These findings were supported by another study, which reported efficient intracardiac transfection and protein expression following the delivery of naked Luc mRNA in saline citrate buffer.²²⁰ Translation efficiency in mouse hearts was found to be highest with 100 mg of naked mRNA modified with m5C and m1 ψ , delivered in a sucrose-citrate buffer. The cause of this prolonged protein expression may be explained by a combination of the interstitial localization of mRNA along the cardiac sarcolemma, potentially

acting as a protected reservoir of VEGF mRNA, and the direct local administration into muscle cells, avoiding RNase-mediated degradation in the bloodstream. Building upon these findings, the development of mRNA therapies for cardiac ischemia has been pursued, leading to a first-in-human study of this treatment using VEGF-A mRNA, which has recently been completed (NCT02935712). Overall, these reports indicate that the intramyocardial administration of mRNA-based therapeutics for the induction of cardioprotection and vascular or cardiac regeneration following myocardial infarction is very efficient and shows low off-target biodistribution.

5. Most advanced pre-clinical and clinical nanoparticle-based mRNA therapeutics

The transient nature of mRNA drugs necessitates a chronic administration regimen over an extended period of time. Thus, the ability to achieve long-term efficacy and safety upon repeated dosage is a prerequisite for clinical maturity. To fulfill the task of mRNA delivery, while polymeric nanocarriers have been shown to be effective agents, LNPs have been at the forefront of preclinical and clinical investigations.²²¹ A key component involved in the tolerability and efficacy of these LNP formulations is the ionizable lipid component.²²² The insertion of ester functionalities at specific positions on the lipid tail is a feasible strategy for preserving high *in vivo* transfection efficiency and a favorable metabolic profile, as illustrated by the development of the optimized ionizable lipid "Lipid 5".⁸⁹ Evaluation of repeated EPO mRNA dosing in primates showed a consistent expression profile and no increase in liver function biomarkers such as alanine transferase (ALT) or aspartate aminotransferase (AST), illustrating the ability of this lipid to safely deliver mRNA in a chronic dosage regimen. Consequently, recent developments in the design of ionizable lipids and their formulations have enabled preclinical studies and, in some cases, reached the stage of clinical investigations, as highlighted in Tables 2 and 3. Hereafter, we highlight preclinical studies and clinical investigations of mRNA-based protein supplementation therapy explored in the liver, lungs, lymphoid organs, heart, and brain.

5.1. Genetic liver disorders

mRNA-based protein replacement therapy in the liver has been explored for the treatment of various rare genetic disorders involving the metabolism of amino acids, heme synthesis, and glucose homeostasis for which either no treatment is approved, or where management of the condition restricts quality of life. For example, methylmalonic acidemia is caused by a partial or complete loss of the enzyme methylmalonyl-CoA mutase (MUT) responsible for the catabolism of amino acids, and leads to the accumulation of toxic metabolites such as methylmalonic acid.²²³ Presently, there is no enzyme-re-

Table 2 Selected list of preclinical studies discussed in this review of nanoparticle-based mRNA protein replacement therapy

Disease	mRNA	Formulation	Route of administration	Ref.
<i>Lung</i>				
Cystic fibrosis	CFTR	Polyplex	IT	152 and 164
Cystic fibrosis	CFTR	LNP	Nebulization	234
Cystic fibrosis	CFTR	LNP	Intranasal	235
SP-B deficiency	ZFN	Polyplex	IT	150
Influenza, SARS-COV-2 infection	Cas13 and sgRNA	Polyplex	Nebulization	165
Alpha-1-antitrypsin deficiency	SERPINA	LNP	IV	250 and 236
<i>Liver</i>				
Urea cycle disease	OTC	GalNac polymer-conjugated LNP, LUNAR-LNP	IV	75
Methylmalonic acidemia	MUT	LNP	IV	88 and 224
Propionic acidemia	PCCA and PCCB	LNP	IV	251
Glycogen storage disorder	G6Pase- α	LNP	IV	228 and 252
Acute intermittent porphyria	Human PBGD	LNP	IV	87
Arginase deficiency	ARG1	LNP	IV	226
Hemophilia	hFIX	LNP	IV	253 and 254
Thrombotic thrombocytopenic purpura	ADAMTS13	LNP	IV	255
Anemia	EPO	LNP	IV	89
Fulminant hepatitis	Bcl-2	Polyplex	IV	110
<i>Brain</i>				
Friedreich's ataxia	FXN	LNP	Intrathecal	195
Alzheimer disease	NEP	Polyplex	Intracerebroventricular	200
Inflammatory disorders	TM	Active-targeted LNP	IV	201
<i>Other organs</i>				
Cardiovascular diseases	VEGF	Naked	Cardiac injection	220
Lymphedema	VEGF	LNP	ID	185
Inflammatory bowel disease	IL-10	Active-targeted LNP	IV	238

placement treatment available for this condition, and patients must follow a strict diet, alongside carnitine supplementation. In contrast, a single IV bolus injection of MUT mRNA encapsulated in LNPs (formulated with Lipid 5) demonstrated a 75% decrease in plasma levels of methylmalonic acid in MUT $^{-/-}$ mice.⁸⁸ A subsequent long-term study evaluated the chronic dosing of this formulation *via* IV injection every two weeks for 12 weeks at various dosages. The dose-dependent response profile indicated that an mRNA dosage below 0.5 mg kg $^{-1}$ resulted in fluctuating plasma levels of methylmalonic acid with increases between injections, whereas doses from 0.5 mg kg $^{-1}$ to 2 mg kg $^{-1}$ resulted in a more stable profile. Safety evaluations showed no difference in liver toxicity markers, including AST and ALT, nor in other inflammatory markers (*e.g.*, interleukin-6, IFN- γ), indicating that the injection of human MUT mRNA-LNPs did not induce liver toxicity.^{88,224} Another critical liver condition is arginase deficiency, a disorder resulting in the accumulation of ammonia and arginine in the liver,²²⁵ with available treatment options limited to ammonia scavenging and strict dietary regimens. The delivery of arginase-encoding mRNA encapsulated in LNPs every 3 days demonstrated consistent arginine control, without elevation of plasma ammonia, and maintained long-term survival in Arg1 $^{-/-}$ mice.²²⁶ A safety evaluation in hepatic tissues

detected no pathological hepatic abnormalities or lymphocyte infiltration, suggesting the strong tolerability of this approach. Aside from liver inflammation, another safety concern is the development of anti-drug antibodies (ADAs) against the mRNA-encoded protein. In conventional protein replacement therapy, the induction of ADAs upon repeated systemic administration of exogenous recombinant protein is of great concern, as this can activate an immune response, thereby mitigating the efficacy of the treatment.²²⁷ In contrast, the repeated dosing of mRNA-LNPs in various studies has shown no substantial increase in induced ADAs in treated mice, indicating that mRNA-based approaches might result in superior long-term efficacy.^{87,88,228} Indeed, mRNA uses endogenous translation machinery within cells to replace the missing protein, whereas exogenous recombinant proteins injected into the systemic circulation are exposed to immune cells, potentially engaging in complement activation and promoting rapid clearance of the therapeutic protein. Nonetheless, concerns have been raised about the generation of anti-PEG antibodies, which bind to either the backbone or the terminal methoxy group of PEG, as this polymer is commonly used in mRNA nanocarrier formulations and can trigger activation of the complement pathway in humans.²²⁹ At present, there are no data available on the repeated dosing of mRNA-LNPs in

Table 3 List of current industry clinical trials involving mRNA delivery system for protein replacement therapy (situation as of May 2022)

Product (sponsor)	Gene mRNA and formulation	Indication	Administration route	Clinical stage
<i>Heart</i>				
mRNA AZD-8601 (Astrazeneca/ Moderna Tx)	VEGF-A mRNA, naked in citrate buffer	Cardiovascular disease, heart failure	Epicardial injection	Phase I (completed) NCT02935712 Phase II (completed) NCT03370887
<i>Lung</i>				
MRT5005 (Translate Bio)	CFTR mRNA, LNP	Cystic fibrosis	Nebulization	Phase I/II (recruiting) NCT 03375047
<i>Liver</i>				
MRT5201 (Translate Bio)	OTC mRNA, LNP	OTC deficiency	IV	Phase I/II (withdrawn) NCT03767270
mRNA-3704 (Moderna Tx)	MUT mRNA, LNP	MUT deficiency	IV	Phase I/II (withdrawn) NCT03810690
mRNA-3927 (Moderna Tx)	PCCA and PCCB mRNA, dispersion	Propionic acidemia	IV	Phase I/II (recruiting) NCT04159103 NCT05130437 (recruiting)
ARCT-810 (Arcturus Tx)	OTC mRNA, LNP	OTC deficiency	IV	Phase I (completed) NCT04416126 NCT04442347 (recruiting)
mRNA-3745 (ModernaTx)	(G6Pase) mRNA, LNP	Glycogen Storage Disease	IV	Phase I (recruiting) NCT05095727

humans. Clinical evaluation of repeated dosing of Onpattro[®] over 24 months in 29 patients revealed that, despite the presence of DMG-PEG in the formulation, anti-PEG antibodies were infrequently detected and did not affect the pharmacokinetic exposure or the transthyretin (TTR) reduction effect of the drug.²³⁰

Though most preclinical and clinical applications of LNPs use passive targeting to traffic particles to the liver, active targeting has also been evaluated, using a hybrid formulation consisting of a combination of LNPs mixed with a GalNAc-targeted polymer. The delivery of ornithine transcarbamylase (OTC) mRNA in hybrid nanoparticles induced a normalization of plasma ammonia levels and urinary orotic acid levels, and led to prolonged survival in a murine model of OTC deficiency, for two different dosing frequencies.⁷⁵ A twice-per-week dosing regimen led to enhanced survival and normalization of plasma levels of ammonia and orotic acid, whereas for weekly dosing, urinary orotic acid levels became elevated after 20 days, resulting in death shortly thereafter. The twice-per-week dosing regimen also led to a substantial increase in body weight and superior survival, demonstrating the necessity of frequent dosing. In spite of these results, the preclinical study was discontinued in 2018 for unknown reasons. Nonetheless, another clinical study conducted by Arcturus Bio, consisting of an OTC-replacement program using its proprietary lipid formulation platform LUNAR (LUNAR-OTC) without any additional targeting moiety, has successfully completed a Phase I clinical trial (ARCT-810) in healthy adults. The company is currently recruiting participants for a Phase I/II OTC deficiency study,

including stable patients with OTC deficiency (Table 3). We note that the first FDA-approved siRNA-LNP-based therapeutic (Onpattro[®]) did not include a targeting ligand, and a clinical evaluation did not observe any added performance in gene silencing by the GalNAc-conjugated formulation over its non-conjugated counterpart.²³¹ Though very promising results have been achieved in animal models for various genetic metabolic liver disorders, clinical investigations remain in early stages, and no clinical data has thus far been provided. Currently, one of the most advanced clinical studies involves the treatment of OTC deficiency, developed by Arcturus Bio, with primary outcomes expected by the end of 2022. Another clinical study conducted by Moderna investigating propionic acidemia is currently recruiting participants, and initial outcomes are expected by 2025 for its first-in-human Phase I/II trial, at which point another study will begin, evaluating the long-term clinical safety of this pharmaceutical candidate (Table 3). Similarly, a study on glycogen storage disorders will begin by the end of 2022. The large number of upcoming clinical trials suggests the great promise of this technology for the development of potential patient treatments, while providing crucial information on clinically suitable dosing regimens.

5.2. Genetic lung disorders

Gene therapy is a promising treatment approach for a range of lung diseases displaying resistance to current treatments. CF, which is caused by mutations in the CFTR gene, has long been a subject at the forefront of lung-disease research. Although several gene therapies have shown potential for treatment of

this condition, the correction of CFTR defects using viral or non-viral vectors has thus far remained unsuccessful in clinical trials, largely due to delivery issues.^{232,233} The local administration of polyplexes containing mRNA encoding for CFTR has been evaluated in a mouse model of CF using chitosan-coated PLGA polyplexes, poloxamine-based polyplexes, and LNPs. It has been found that administration of 40 µg of mRNA complexed with PLGA polyplexes *via* the IT route significantly improved lung function, specifically enhancing forced expiratory volume (FEV1). Interestingly, the same group also considered IV administration, finding this delivery route to be more efficient for the same dosage, likely due to the poor penetration ability of the polyplexes into CF mucus following IT administration.¹⁵⁰ Similarly, the IT administration of peptide-poloxamine nanoparticles encapsulating CFTR gene insertion tools led to the successful knock-in of the CFTR gene in a murine model of CF.¹⁶⁴ However, more detailed long-term safety evaluations in larger animal models, such as pigs, as well as in pertinent CF animal models with thicker pulmonary mucus layers, are required before conclusions can be drawn. The nebulization of SORT LNPs including positively charged helper lipid has also been tested for treatment of CF, demonstrating significant rescue of CFTR expression and function in multiple genotypes,²³⁴ with immunofluorescent analysis revealing CFTR mRNA expression in several relevant cell types, including basal cells and ionocytes. As an alternative to nebulization and IT administration, the nasal administration of CFTR mRNA-LNPs has also been shown to be capable of mediating chloride secretion restoration in the airway epithelia of CFTR knockout mice for at least 14 days post-treatment. CFTR activity was found to peak on day 3, recovering up to 55% of the net chloride efflux observed in healthy mice.²³⁵ The company Translate Bio began the first study on nebulized mRNA-LNP supplementation therapy for CF in 2018 to evaluate the safety and tolerability of single and multiple escalating doses in adult CF patients. Results from the second interim data analysis revealed that, in a single ascending dose study including 16 patients, 20 mg administrations were safe and well tolerated with no marked increases in percent predicted forced expiratory volume (ppFEV1), which would indicate pulmonary exacerbation. Interestingly, patients had no detectable LNP lipid levels in their blood, and neither anti-PEG nor anti-CFTR antibodies were found. In the multiple ascending dose study for doses ranging from 8–16 mg, an analysis of 12 patients found similar safety results, indicating that the nebulization of mRNA was well tolerated among the patients tested. However, the same interim results indicated that no pattern of improvement in lung function was measured, which could be due to the mRNA candidate—which contained no base modifications—used for the clinical investigation.³⁷ Aside from CF treatment, the delivery of mRNA to the lung was also evaluated for the ability to encode a therapeutic antibody with the potential to protect from viral infection. The nebulization of LNPs encapsulating mRNA encoding for membrane-anchored FI6 (aFI6), an antibody binding hemagglutinin, resulted in mice protected from a lethal challenge by the H1N1 subtype of the

influenza A virus, whereas control mice progressively died.¹⁶⁵ Despite displaying promising transfection efficiencies for lung epithelial cells and ECs, IV injection has not yet been evaluated in a therapeutic model of a lung-specific gene disorder, though one clinical indication affecting both the liver and lungs has been tested, namely alpha-1-antitrypsin deficiency.²³⁶ Overall, mRNA-based protein supplementation therapy for the treatment of genetic lung disorders displays clear potential, but future work is required, including a focus on improving delivery tools, which could include pre-treatment with mucolytic agents in order to increase transfection efficiency in epithelial cells in the airways of CF patients.

5.3. Cancer immunotherapy and immunomodulation

The delivery of mRNA to immune cells can be used to engage or mitigate the immune response. mRNA has emerged as an attractive cancer vaccine format, as it provides both antigen delivery and innate immune activation.²³⁷ This has led to numerous cancer vaccine clinical trials, potentially offering promising alternatives to traditional cancer treatments. Reports have described mRNA-induced tumor-antigen cancer vaccines which can be administered either *via* the IV route or locally, directly into the lymph nodes or tumor tissue. For example, the SC injection of an optimized mRNA LNP has been shown to efficiently transfect immune cells, eliciting a strong T cell response.¹⁸⁸ To evaluate the antitumor function of this approach, the delivery of mRNA coding for tumor-associated antigens in a mouse model of melanoma was investigated. Upon administration, strong T cell activation resulted in a reduction in tumor size and extended the overall survival of the treated mice, which suggests that an mRNA-mediated immune response could act as an effective antitumor strategy. A major limitation of local administration is that only lymph nodes in the vicinity of the injection site can be accessed and participate in T cell activation. In comparison, the IV administration of mRNA to secondary lymphoid organs such as the spleen—as the largest agglomeration of immune cells—could be more potent, potentially holding significant therapeutic potential. As an example, Kranz *et al.* administered negatively charged mRNA-LPX vaccines in mice resulting in strong T cell stimulation, particularly in the spleen, resulting in tumor shrinkage and improved survival.¹²¹ Similarly, in a Phase I clinical trial (NCT02410733), bioimaging studies highlighted the rapid targeting and transient activation of lymphoid-tissue-resident immune cells in the spleen upon IV injection of mRNA-LPXs.¹⁹⁰ Melanoma patients were later vaccinated with the same formulation used by Kranz *et al.*, encoding for tumor-associated antigens prevalent in melanoma patients. Interim analysis showed that the vaccine, alone or in combination with PD1 antibody, mediated the induction of strong CD4+ and CD8+ T cell immunity against vaccine antigens, promoting stable disease status. A Phase II study is currently ongoing for the same application (NCT04526899). Similar approaches using other tumor-specific antigens are being evaluated in various Phase I and I/II clinical trials in patients with

triple-negative breast cancer (TNBC; NCT02316457), ovarian cancer (NCT04163094), and prostate cancer (NCT04382898).

In an opposite approach, mRNA-based therapeutics can be used to downregulate autoimmune responses by expressing anti-inflammatory proteins. Inflammatory bowel disease (IBD) is characterized by elevated and sustained pro-inflammatory expression in the colon and, as such, its treatment and management would benefit from an effective immunosuppressive strategy. To evaluate this, the targeted delivery of mRNA encoding the anti-inflammatory cytokine IL-10 to activated leukocytes (Ly6c+) was conducted in a mouse model of IBD, resulting in a pronounced reduction of proinflammatory cytokines TNF α and IL6 in the colon, when compared to the untreated group.²³⁸ Pathological features including inflammatory infiltration of the colon and erythema were significantly reduced, highlighting the therapeutic potential of mRNA as an immunomodulatory approach for inflammation-related diseases.

5.4. Other organs

Lymphedema refers to tissue swelling caused by an accumulation of extracellular fluid normally drained through the body's lymphatic system. Current treatment approaches such as manual lymph drainage and compression therapy have significant limitations and provide only symptomatic relief.²³⁹ Studies in a murine model of secondary lymphedema demonstrated that the administration of VEGF mRNA-LNPs effectively induced the growth of lymphatic vessels.¹⁸⁵ Consequently, the drainage of extracellular fluid was enhanced, and reduced paw thickness and fibroadipose area were observed. Although more work is needed to investigate the long-term effects of this treatment, mRNA therapy may represent a feasible therapeutic alternative to current approaches.

While most mRNA-based therapeutics use nanocarriers to protect the nucleic acids from endonuclease-mediated degradation, an ongoing clinical program is investigating the use of naked mRNA (candidate AZD8601) encoding for VEGF directly injected into the myocardium of patients undergoing elective coronary artery bypass surgery (CABG) surgery to promote the formation of new blood vessels. This study asserts that the direct administration of VEGF-A mRNA to the heart could promote cardioprotective effects and reduce myocardial damage following heart infarction.²²⁰ AZD8601 has been investigated for safety and tolerability in patients with impaired systolic function undergoing coronary artery bypass grafting. At present, Phase II trials have been completed, rendering this the most advanced clinical study of mRNA-based therapeutics conducted by Moderna.

5.5. Gene editing

Gene editing technologies could represent an outstanding advancement in the treatment of many genetic disorders through the knock-out or knock-in of a targeted gene with the substantial advantage of an infrequent administration regimen. The mRNA-mediated expression of gene-editing endonucleases is very attractive, as this strategy induces transient and limited expression of endonucleases, thus reducing

the probability of off-target genome editing and unwanted effects.²⁴⁰ Various approaches for this have been explored including CRISPR/Cas9-based methodologies, as well as ZFNs. *In vivo* gene editing using nanoparticles has also been evaluated in different organs including the liver,²⁴¹⁻²⁴⁴ the lungs (by local¹⁵⁰ and IV administration),^{122,172,173} the muscles,¹⁷² and the spleen.¹²² An initial study demonstrated successful homology directed-repair (HDR) mediated by an mRNA-encoded ZFN in the lungs of a transgenic mouse model of SP-B deficiency upon IT administration.¹⁵⁰ The HDR rate was found to be ~9%, which in turn prevented the decline of lung function, lung edema, and neutrophilia, all of which were observed in the untreated group. Another study delivering a combination of Cas9 mRNA and sgRNA in a single formulation achieved an editing rate of ~6% of phosphatase and tensin homolog (PTEN) in lung tissues upon IV administration in wild type C57BL/6 mice. While there are limited works describing gene editing in the lungs, HDR-based gene editing holds great promise for the treatment of genetic lung disorders and will doubtless be explored in future works. Further, HDR-mediated gene editing *in vivo* has also been shown to be feasible in tumor tissues. The intratumoral injection of LNPs containing Cas9 mRNA, sgRNA, and an ssDNA template was able to achieve HDR editing of up to 23% in tumor tissues.²⁴⁵ Studies investigating gene knockout in the liver are currently under clinical evaluation, showing potent gene silencing of the hepatic protein TTR. Results from a Phase I study in 6 patients demonstrated a dose-dependent response, with the highest dose (0.3 mg kg⁻¹ body weight) achieving a ~90% reduction of protein, with only mild adverse events.²⁴⁶

6. Conclusions

mRNA therapeutics show great potential for the treatment of a multitude of disorders. Nevertheless, important challenges faced in the development of mRNA drugs have been the effective delivery to target cells and the proportion of transfected cells capable of achieving a therapeutic degree of protein expression. mRNA sequences can be engineered to provide increased protein expression and specific localization, but this approach remains insufficiently explored, warranting the further development of safe and efficient nanocarriers for *in vivo* delivery. In this review, we focused on the biodistribution of both lipid- and polymer-based nanocarriers and their associated parameters which led to preferential biodistribution and expression in the main organs for which mRNA-based drugs hold promise.

mRNA delivery has mostly been conducted using passive targeting by modulating the physicochemical properties of the nanocarriers. One predictive physicochemical parameter required for effective *in vivo* mRNA delivery that has been identified is the surface pK_a of nanocarriers. In particular, LNPs with a surface pK_as of 6-7 yielded liver-selective mRNA delivery, while achieving high transfection efficiency in a range of hepatic cell subtypes. Transfection amongst these cells can

also be modulated using modified cholesterol derivatives. Spleen-specific mRNA delivery has been shown to be feasible through the incorporation of negatively charged phospholipids into LNP formulations, which in turn results in altered surface pK_a values below 6. Additionally, optimization of the structure of the ionizable lipids used in LNPs has been demonstrated as an effective approach to favor mRNA delivery to the spleen. In contrast, lung-specific mRNA delivery can be achieved through the introduction of positively charged lipids into LNPs, generating surface pK_a values above 7. While surface pK_a appears to be a potential predictive parameter for the biodistribution of mRNA nanocarriers, other physicochemical properties of the nanocarriers can influence this value in ways that remain unclear. Future works should attempt to evaluate the relationship between pK_a and the surface charge of the nanoparticle, as this is not currently well-understood. Though it seems that liver-targeting mRNA formulations do not require active targeting for efficient delivery, this strategy may prove valuable for cell-specific mRNA delivery in the lungs and spleen. A recent study utilized CD5-targeted LNPs to deliver mRNA encoding a CAR binding to fibroblast activation protein to T cells *in vivo*.²⁴⁷ The production of transient effective CAR T cells reduced fibrosis and restored cardiac function after injury, indicating that this targeted platform may be a feasible approach for the generation of CAR T cells *in vivo*. Although these targeting strategies can mediate organ-specific mRNA delivery, future work is required to determine the full relationship between mRNA biodistribution and subsequent mRNA-induced protein expression. A thorough understanding of this phenomenon will provide meaningful insights into the interactions between nanoparticles and cells and may give rise to new opportunities for improved cell-targeted strategies.

Though less clinically advanced, polymer nanocarriers have also been shown to promote substantial mRNA expression in various tissues, but have not yet reached the stage of clinical investigation. On the other hand, several clinical studies have been initiated using LNPs, mainly as a strategy for the treatment of genetic liver diseases. Clinical investigations of mRNA-based protein supplementation therapies in other organs have been less thoroughly explored, with the only studies in progress being limited to local administration to the lungs and heart. A notable disadvantage of mRNA-based treatments is the requirement for repeated dosing which, while demonstrated to be safe in preclinical models, remains an impediment in comparison to DNA-based therapeutics or gene-editing approaches with infrequent administration regimens. Indeed, gene-editing approaches have yielded promising results for gene silencing, though knock-in editing for protein replacement therapy remains far less explored in preclinical models, owing to safety concerns regarding unwanted genetic modifications. Accordingly, mRNA-induced protein replacement approaches yielding prolonged expression over time, while generating fewer safety concerns than gene editing, are a research area of utmost importance. Another strategy for extended protein expression, without the potential risk of insertional mutagenesis, is the delivery of episomal pDNA,

which remains in the nucleus for a long period as an extra-chromosomal element.^{248,249} Though this approach has mostly been studied using viral delivery systems, non-viral delivery vectors could also easily be applied.

It is our belief that the foundational works described in this review will continue to be built upon to further enhance the efficacy and tolerability of mRNA nanocarriers, unlocking effective treatments for various Mendelian diseases. Concomitant research on the elucidation of the interactions between surface pK_a , surface charge, and their impact on the protein corona formed in circulation, as well as on nanoparticle-cell interactions, can be leveraged to optimize the targeting of diverse cell types and are key factors to be considered in the screening process for nanoformulations. Based on this, we envision that future investigations evaluating the interconnection of these parameters will serve to increase efficacy, while reducing side-effects, for next generation nanoparticle-based mRNA gene therapies.

Author contributions

Matthias Zadory: conceptualization, literature collection and analysis, article writing. Elliot Lopez: figures and article writing. Samuel Babity: manuscript revision and editing. Simon-Pierre Gravel: manuscript revision and editing. Davide Brambilla: conceptualization, supervision, manuscript revision.

Conflicts of interest

“There are no conflicts to declare”.

Acknowledgements

This work was supported by grants from the Servier foundation of the Faculté de Pharmacie de l'Université de Montréal, the Natural Sciences and Engineering Research Council of Canada, the Canadian Generic Pharmaceutical Association and Biosimilars Canada and funding from the Canada First Research Excellence Fund through the TransMedTech Institute.

References

- 1 A. L. Hopkins and C. R. Groom, The druggable genome, *Nat. Rev. Drug Discovery*, 2002, **1**(9), 727–730.
- 2 K. D. Warner, C. E. Hajdin and K. M. Weeks, Principles for targeting RNA with drug-like small molecules, *Nat. Rev. Drug Discovery*, 2018, **17**(8), 547–558.
- 3 G. F. Jirikowski, P. P. Sanna, D. Maciejewski-Lenoir and F. E. Bloom, Reversal of diabetes insipidus in Brattleboro rats: intrahypothalamic injection of vasopressin mRNA, *Science*, 1992, **255**(5047), 996–998.

- 4 J. A. Wolff, R. W. Malone, P. Williams, W. Chong, G. Acsadi, A. Jani, *et al.*, Direct Gene-Transfer into Mouse Muscle In vivo, *Science*, 1990, **247**(4949), 1465–1468.
- 5 S. F. Dowdy, Overcoming cellular barriers for RNA therapeutics, *Nat. Biotechnol.*, 2017, **35**(3), 222–229.
- 6 E. Dolgin, The tangled history of mRNA vaccines, *Nature*, 2021, **597**(7876), 318–324.
- 7 X. Hou, T. Zaks, R. Langer and Y. Dong, Lipid nanoparticles for mRNA delivery, *Nat. Rev. Mater.*, 2021, **6**, 1078–1094.
- 8 R. W. Malone, P. L. Felgner and I. M. Verma, Cationic liposome-mediated RNA transfection, *Proc. Natl. Acad. Sci. U. S. A.*, 1989, **86**(16), 6077–6081.
- 9 F. Martinon, S. Krishnan, G. Lenzen, R. Magne, E. Gomard, J. G. Guillet, *et al.*, Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA, *Eur. J. Immunol.*, 1993, **23**(7), 1719–1722.
- 10 K. A. Hajj and K. A. Whitehead, Tools for translation: non-viral materials for therapeutic mRNA delivery, *Nat. Rev. Mater.*, 2017, **2**(10), 17056.
- 11 K. Paunovska, D. Loughrey and J. E. Dahlman, Drug delivery systems for RNA therapeutics, *Nat. Rev. Genet.*, 2022, **23**, 265–280.
- 12 A. Wadhwa, A. Aljabbari, A. Lokras, C. Foged and A. Thakur, Opportunities and Challenges in the Delivery of mRNA-based Vaccines, *Pharmaceutics*, 2020, **12**(2), DOI: [10.3390/pharmaceutics12020102](https://doi.org/10.3390/pharmaceutics12020102).
- 13 L. Schoenmaker, D. Witzigmann, J. A. Kulkarni, R. Verbeke, G. Kersten, W. Jiskoot, *et al.*, mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability, *Int. J. Pharm.*, 2021, **601**, 120586.
- 14 U. Sahin, K. Kariko and O. Tureci, mRNA-based therapeutics—developing a new class of drugs, *Nat. Rev. Drug Discovery*, 2014, **13**(10), 759–780.
- 15 C. H. June, R. S. O'Connor, O. U. Kawalekar, S. Ghassemi and M. C. Milone, CAR T cell immunotherapy for human cancer, *Science*, 2018, **359**(6382), 1361–1365.
- 16 I. Sahu, A. Haque, B. Weidensee, P. Weinmann and M. S. D. Kormann, Recent Developments in mRNA-Based Protein Supplementation Therapy to Target Lung Diseases, *Mol. Ther.*, 2019, **27**(4), 803–823.
- 17 H. Tourriere, K. Chebli and J. Tazi, mRNA degradation machines in eukaryotic cells, *Biochimie*, 2002, **84**(8), 821–837.
- 18 K. Kariko, H. Muramatsu, F. A. Welsh, J. Ludwig, H. Kato, S. Akira, *et al.*, Incorporation of Pseudouridine Into mRNA Yields Superior Nonimmunogenic Vector With Increased Translational Capacity and Biological Stability, *Mol. Ther.*, 2008, **16**(11), 1833–1840.
- 19 K. Kariko, M. Buckstein, H. Ni and D. Weissman, Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA, *Immunity*, 2005, **23**(2), 165–175.
- 20 Y. Li and M. Kiledjian, Regulation of mRNA decapping, *Wiley Interdiscip. Rev.: RNA*, 2010, **1**(2), 253–265.
- 21 M. Mockey, C. Goncalves, F. P. Dupuy, F. M. Lemoine, C. Pichon and P. Midoux, mRNA transfection of dendritic cells: synergistic effect of ARCA mRNA capping with Poly (A) chains in cis and in trans for a high protein expression level, *Biochem. Biophys. Res. Commun.*, 2006, **340**(4), 1062–1068.
- 22 P. M. Rabinovich, M. E. Komarovskaya, Z. J. Ye, C. Imai, D. Campana, E. Bahceci, *et al.*, Synthetic messenger RNA as a tool for gene therapy, *Hum. Gene Ther.*, 2006, **17**(10), 1027–1035.
- 23 E. Grudzien-Nogalska, J. Jemielity, J. Kowalska, E. Darzynkiewicz and R. E. Rhoads, Phosphorothioate cap analogs stabilize mRNA and increase translational efficiency in mammalian cells, *RNA*, 2007, **13**(10), 1745–1755.
- 24 J. Kowalska, M. Lewdorowicz, J. Zuberek, E. Grudzien-Nogalska, E. Bojarska, J. Stepinski, *et al.*, Synthesis and characterization of mRNA cap analogs containing phosphorothioate substitutions that bind tightly to eIF4E and are resistant to the decapping pyrophosphatase Dcp5, *RNA*, 2008, **14**(6), 1119–1131.
- 25 D. R. Gallie, The cap and poly(A) tail function synergistically to regulate mRNA translational efficiency, *Genes Dev.*, 1991, **5**(11), 2108–2116.
- 26 M. Ikegami, S. Uchida, H. Uchida, K. Nagata, K. Kataoka and K. Itaka, Enhanced Transfection of mRNA Transcribed From Elongated-poly(A/T) Tail-Containing Vector, *Mol. Ther.*, 2014, **22**, S43.
- 27 P. Arbutnot, A. Ely and K. Bloom, A convenient method to generate and maintain poly(A)-encoding DNA sequences required for in vitro transcription of mRNA, *BioTechniques*, 2019, **66**(1), 37–39.
- 28 C. Zeng, X. Hou, J. Yan, C. Zhang, W. Li, W. Zhao, *et al.*, Leveraging mRNA Sequences and Nanoparticles to Deliver SARS-CoV-2 Antigens In Vivo, *Adv. Mater.*, 2020, **32**(40), e2004452.
- 29 G. Tushev, C. Glock, M. Heumuller, A. Biever, M. Jovanovic and E. M. Schuman, Alternative 3' UTRs Modify the Localization, Regulatory Potential, Stability, and Plasticity of mRNAs in Neuronal Compartments, *Neuron*, 2018, **98**(3), 495–511.
- 30 L. Lu, F. Zhang, Y. Li, A. Yang, C. Guan, X. Ding, *et al.*, Dendritic targeted mRNA expression via a cis-acting RNA UTR element, *Biochem. Biophys. Res. Commun.*, 2019, **509**(2), 402–406.
- 31 M. A. Valencia-Sanchez, J. Liu, G. J. Hannon and R. Parker, Control of translation and mRNA degradation by miRNAs and siRNAs, *Genes Dev.*, 2006, **20**(5), 515–524.
- 32 B. D. Brown, B. Gentner, A. Cantore, S. Colleoni, M. Amendola, A. Zingale, *et al.*, Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state, *Nat. Biotechnol.*, 2007, **25**(12), 1457–1467.
- 33 C. Coulouarn, V. M. Factor, J. B. Andersen, M. E. Durkin and S. S. Thorgeirsson, Loss of miR-122 expression in liver cancer correlates with suppression of the hepatic

- phenotype and gain of metastatic properties, *Oncogene*, 2009, **28**(40), 3526–3536.
- 34 R. Jain, J. P. Frederick, E. Y. Huang, K. E. Burke, D. M. Mauger, E. A. Andrianova, *et al.*, MicroRNAs Enable mRNA Therapeutics to Selectively Program Cancer Cells to Self-Destruct, *Nucleic Acid Ther.*, 2018, **28**(5), 285–296.
- 35 X. Mu and S. Hur, Immunogenicity of In Vitro-Transcribed RNA, *Acc. Chem. Res.*, 2021, **54**(21), 4012–4023.
- 36 K. J. Kauffman, F. F. Mir, S. Jhunjunwala, J. C. Kaczmarek, J. E. Hurtado, J. H. Yang, *et al.*, Efficacy and immunogenicity of unmodified and pseudouridine-modified mRNA delivered systemically with lipid nanoparticles in vivo, *Biomaterials*, 2016, **109**, 78–87.
- 37 J. R. Melamed, K. A. Hajj, N. Chaudhary, D. Strelkova, M. L. Arral, N. Pardi, *et al.*, Lipid nanoparticle chemistry determines how nucleoside base modifications alter mRNA delivery, *J. Controlled Release*, 2022, **341**, 206–214.
- 38 P. S. Kowalski, A. Rudra, L. Miao and D. G. Anderson, Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery, *Mol. Ther.*, 2019, **27**(4), 710–728.
- 39 C. Lorenz, M. Fotin-Mleczek, G. Roth, C. Becker, T. C. Dam, W. P. Verdurmen, *et al.*, Protein expression from exogenous mRNA: uptake by receptor-mediated endocytosis and trafficking via the lysosomal pathway, *RNA Biol.*, 2011, **8**(4), 627–636.
- 40 M. Diken, S. Kreiter, A. Selmi, C. M. Britten, C. Huber, O. Tureci, *et al.*, Selective uptake of naked vaccine RNA by dendritic cells is driven by macropinocytosis and abrogated upon DC maturation, *Gene Ther.*, 2011, **18**(7), 702–708.
- 41 B. Dalby, S. Cates, A. Harris, E. C. Ohki, M. L. Tilkins, P. J. Price, *et al.*, Advanced transfection with Lipofectamine 2000 reagent: primary neurons, siRNA, and high-throughput applications, *Methods*, 2004, **33**(2), 95–103.
- 42 Y. Sato, H. Hatakeyama, Y. Sakurai, M. Hyodo, H. Akita and H. Harashima, A pH-sensitive cationic lipid facilitates the delivery of liposomal siRNA and gene silencing activity in vitro and in vivo, *J. Controlled Release*, 2012, **163**(3), 267–276.
- 43 Y. Zhang, C. Sun, C. Wang, K. E. Jankovic and Y. Dong, Lipids and Lipid Derivatives for RNA Delivery, *Chem. Rev.*, 2021, **121**(20), 12181–12277.
- 44 H. Li, T. Lee, T. Dziubla, F. M. Pi, S. J. Guo, J. Xu, *et al.*, RNA as a stable polymer to build controllable and defined nanostructures for material and biomedical applications, *Nano Today*, 2015, **10**(5), 631–655.
- 45 O. S. Fenton, K. J. Kauffman, J. C. Kaczmarek, R. L. McClellan, S. Jhunjunwala, M. W. Tibbitt, *et al.*, Synthesis and Biological Evaluation of Ionizable Lipid Materials for the In Vivo Delivery of Messenger RNA to B Lymphocytes, *Adv. Mater.*, 2017, **29**(33), 1606944.
- 46 X. Cheng and R. J. Lee, The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery, *Adv. Drug Delivery Rev.*, 2016, **99**(Pt A), 129–137.
- 47 K. J. Kauffman, J. R. Dorkin, J. H. Yang, M. W. Heartlein, F. DeRosa, F. F. Mir, *et al.*, Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in Vivo with Fractional Factorial and Definitive Screening Designs, *Nano Lett.*, 2015, **15**(11), 7300–7306.
- 48 Q. Cheng, T. Wei, Y. Jia, L. Farbiak, K. Zhou, S. Zhang, *et al.*, Dendrimer-Based Lipid Nanoparticles Deliver Therapeutic FAH mRNA to Normalize Liver Function and Extend Survival in a Mouse Model of Hepatorenal Tyrosinemia Type I, *Adv. Mater.*, 2018, **30**(52), e1805308.
- 49 W. V. Rodriguez, J. J. Wheeler, S. K. Klimuk, C. N. Kitson and M. J. Hope, Transbilayer Movement and Net Flux of Cholesterol and Cholesterol Sulfate between Liposomal Membranes, *Biochemistry*, 1995, **34**(18), 6208–6217.
- 50 Y. Sato, N. Okabe, Y. Note, K. Hashiba, M. Maeki, M. Tokeshi, *et al.*, Hydrophobic scaffolds of pH-sensitive cationic lipids contribute to miscibility with phospholipids and improve the efficiency of delivering short interfering RNA by small-sized lipid nanoparticles, *Acta Biomater.*, 2020, **102**, 341–350.
- 51 M. Herrera, J. Kim, Y. Eygeris, A. Jozic and G. Sahay, Illuminating endosomal escape of polymorphic lipid nanoparticles that boost mRNA delivery, *Biomater. Sci.*, 2021, **9**(12), 4289–4300.
- 52 S. Patel, N. Ashwanikumar, E. Robinson, Y. Xia, C. Mihai, J.3 Griffith, *et al.*, Naturally-occurring cholesterol analogues in lipid nanoparticles induce polymorphic shape and enhance intracellular delivery of mRNA, *Nat. Commun.*, 2020, **11**(1), 983.
- 53 Y. Eygeris, S. Patel, A. Jozic and G. Sahay, Deconvoluting Lipid Nanoparticle Structure for Messenger RNA Delivery, *Nano Lett.*, 2020, **20**(6), 4543–4549.
- 54 H. Hatakeyama, H. Akita and H. Harashima, The poly-ethyleneglycol dilemma: advantage and disadvantage of PEGylation of liposomes for systemic genes and nucleic acids delivery to tumors, *Biol. Pharm. Bull.*, 2013, **36**(6), 892–899.
- 55 I. Vlatkovic, Non-Immunotherapy Application of LNP-mRNA: Maximizing Efficacy and Safety, *Biomedicines*, 2021, **9**(5), 530.
- 56 C. D. Sago, M. P. Lokugamage, G. N. Lando, N. Djeddar, N. N. Shah, C. Syed, *et al.*, Modifying a Commonly Expressed Endocytic Receptor Retargets Nanoparticles in Vivo, *Nano Lett.*, 2018, **18**(12), 7590–7600.
- 57 C. D. Sago, B. R. Krupczak, M. P. Lokugamage, Z. Gan and J. E. Dahlman, Cell Subtypes Within the Liver Microenvironment Differentially Interact with Lipid Nanoparticles, *Cell. Mol. Bioeng.*, 2019, **12**(5), 389–397.
- 58 S. K. Asrani, H. Devarbhavi, J. Eaton and P. S. Kamath, Burden of liver diseases in the world, *J. Hepatol.*, 2019, **70**(1), 151–171.
- 59 O. A. Almazroo, M. K. Miah and R. Venkataramanan, Drug Metabolism in the Liver, *Clin. Liver Dis.*, 2017, **21**(1), 1–20.
- 60 F. S. Wang, J. G. Fan, Z. Zhang, B. Gao and H. Y. Wang, The Global Burden of Liver Disease: The Major Impact of China, *Hepatology*, 2014, **60**(6), 2099–2108.

- 61 D. Witzigmann, J. A. Kulkarni, J. Leung, S. Chen, P. R. Cullis and R. van der Meel, Lipid nanoparticle technology for therapeutic gene regulation in the liver, *Adv. Drug Delivery Rev.*, 2020, **159**, 344–363.
- 62 G. Gonzalez-Aseguinolaza and J. Prieto, Gene therapy of liver diseases: a 2011 perspective, *Clin. Res. Hepatol. Gastroenterol.*, 2011, **35**(11), 699–708.
- 63 N. Pardi, A. J. Secreto, X. Shan, F. Debonera, J. Glover, Y. Yi, *et al.*, Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge, *Nat. Commun.*, 2017, **8**, 14630.
- 64 Y. Rybakova, P. S. Kowalski, Y. Huang, J. T. Gonzalez, M. W. Heartlein, F. DeRosa, *et al.*, mRNA Delivery for Therapeutic Anti-HER2 Antibody Expression In Vivo, *Mol. Ther.*, 2019, **27**(8), 1415–1423.
- 65 M. Thran, J. Mukherjee, M. Ponisch, K. Fiedler, A. Thess, B. L. Mui, *et al.*, mRNA mediates passive vaccination against infectious agents, toxins, and tumors, *EMBO Mol. Med.*, 2017, **9**(10), 1434–1447.
- 66 C. R. Stadler, H. Bahr-Mahmud, L. Celik, B. Hebich, A. S. Roth, R. P. Roth, *et al.*, Elimination of large tumors in mice by mRNA-encoded bispecific antibodies, *Nat. Med.*, 2017, **23**(7), 815–817.
- 67 K. M. Tsoi, S. A. MacParland, X. Z. Ma, V. N. Spetzler, J. Echeverri, B. Ouyang, *et al.*, Mechanism of hard-nanomaterial clearance by the liver, *Nat. Mater.*, 2016, **15**(11), 1212–1221.
- 68 A. J. Debacker, J. Voutila, M. Catley, D. Blakey and N. Habib, Delivery of Oligonucleotides to the Liver with GalNAc: From Research to Registered Therapeutic Drug, *Mol. Ther.*, 2020, **28**(8), 1759–1771.
- 69 J. K. Nair, J. L. Willoughby, A. Chan, K. Charisse, M. R. Alam, Q. Wang, *et al.*, Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing, *J. Am. Chem. Soc.*, 2014, **136**(49), 16958–16961.
- 70 J. A. Kulkarni, D. Witzigmann, S. B. Thomson, S. Chen, B. R. Leavitt, P. R. Cullis, *et al.*, The current landscape of nucleic acid therapeutics, *Nat. Nanotechnol.*, 2021, **16**(6), 630–643.
- 71 Y. Sato, H. Matsui, N. Yamamoto, R. Sato, T. Munakata, M. Kohara, *et al.*, Highly specific delivery of siRNA to hepatocytes circumvents endothelial cell-mediated lipid nanoparticle-associated toxicity leading to the safe and efficacious decrease in the hepatitis B virus, *J. Controlled Release*, 2017, **266**, 216–225.
- 72 A. Akinc, M. A. Maier, M. Manoharan, K. Fitzgerald, M. Jayaraman, S. Barros, *et al.*, The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs, *Nat. Nanotechnol.*, 2019, **14**(12), 1084–1087.
- 73 Y. Dong, J. R. Dorkin, W. Wang, P. H. Chang, M. J. Webber, B. C. Tang, *et al.*, Poly(glycoamidoamine) Brushes Formulated Nanomaterials for Systemic siRNA and mRNA Delivery in Vivo, *Nano Lett.*, 2016, **16**(2), 842–848.
- 74 S. T. Crowley, J. A. Poliskey, N. J. Baumhover and K. G. Rice, Efficient expression of stabilized mRNA PEG-peptide polyplexes in liver, *Gene Ther.*, 2015, **22**(12), 993–999.
- 75 M. G. Prieve, P. Harvie, S. D. Monahan, D. Roy, A. G. Li, T. L. Blevins, *et al.*, Targeted mRNA Therapy for Ornithine Transcarbamylase Deficiency, *Mol. Ther.*, 2018, **26**(3), 801–813.
- 76 A. Akinc, W. Querbes, S. M. De, J. Qin, M. Frank-Kamenetsky, K. N. Jayaprakash, *et al.*, Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based Mechanisms, *Mol. Ther.*, 2010, **18**(7), 1357–1364.
- 77 Y. Z. Dong, K. T. Love, J. R. Dorkin, S. Sirirungruang, Y. L. Zhang, D. L. Chen, *et al.*, Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates (vol 111, pg 3955, 2014), *Proc. Natl. Acad. Sci. U. S. A.*, 2014, **111**(15), 5753.
- 78 K. T. Love, K. P. Mahon, C. G. Levins, K. A. Whitehead, W. Querbes, J. R. Dorkin, *et al.*, Lipid-like materials for low-dose, in vivo gene silencing, *Proc. Natl. Acad. Sci. U. S. A.*, 2010, **107**(5), 1864–1869.
- 79 P. R. Cullis and M. J. Hope, Lipid Nanoparticle Systems for Enabling Gene Therapies, *Mol. Ther.*, 2017, **25**(7), 1467–1475.
- 80 A. Thess, S. Grund, B. L. Mui, M. J. Hope, P. Baumhof, M. Fotin-Mleczek, *et al.*, Sequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an Effective Protein Therapy in Large Animals, *Mol. Ther.*, 2015, **23**(9), 1456–1464.
- 81 M. Sedic, J. J. Senn, A. Lynn, M. Laska, M. Smith, S. J. Platz, *et al.*, Safety Evaluation of Lipid Nanoparticle-Formulated Modified mRNA in the Sprague-Dawley Rat and Cynomolgus Monkey, *Vet. Pathol.*, 2018, **55**(2), 341–354.
- 82 H. Yin, C. Q. Song, S. Suresh, Q. Wu, S. Walsh, L. H. Rhym, *et al.*, Structure-guided chemical modification of guide RNA enables potent non-viral in vivo genome editing, *Nat. Biotechnol.*, 2017, **35**(12), 1179–1187.
- 83 K. A. Whitehead, J. R. Dorkin, A. J. Vegas, P. H. Chang, O. Veiseh, J. Matthews, *et al.*, Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity, *Nat. Commun.*, 2014, **5**, 4277.
- 84 J. Zhang, H. Fan, D. A. Levorse and L. S. Crocker, Ionization behavior of amino lipids for siRNA delivery: determination of ionization constants, SAR, and the impact of lipid pKa on cationic lipid-biomembrane interactions, *Langmuir*, 2011, **27**(5), 1907–1914.
- 85 J. Heyes, L. Palmer, K. Bremner and I. MacLachlan, Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids, *J. Controlled Release*, 2005, **107**(2), 276–287.
- 86 M. Jayaraman, S. M. Ansell, B. L. Mui, Y. K. Tam, J. Chen, X. Du, *et al.*, Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo, *Angew. Chem., Int. Ed.*, 2012, **51**(34), 8529–8533.

- 87 L. Jiang, P. Berraondo, D. Jerico, L. T. Guey, A. Sampedro, A. Frassetto, *et al.*, Systemic messenger RNA as an etiological treatment for acute intermittent porphyria, *Nat. Med.*, 2018, **24**(12), 1899–1909.
- 88 D. An, J. L. Schneller, A. Frassetto, S. Liang, X. L. Zhu, J. S. Park, *et al.*, Systemic Messenger RNA Therapy as a Treatment for Methylmalonic Acidemia, *Cell Rep.*, 2017, **21**(12), 3548–3558.
- 89 S. Sabnis, E. S. Kumarasinghe, T. Salerno, C. Mihai, T. Ketova, J. J. Senn, *et al.*, A Novel Amino Lipid Series for mRNA Delivery: Improved Endosomal Escape and Sustained Pharmacology and Safety in Non-human Primates, *Mol. Ther.*, 2018, **26**(6), 1509–1519.
- 90 C. Delehedde, L. Even, P. Midoux, C. Pichon and F. Perche, Intracellular Routing and Recognition of Lipid-Based mRNA Nanoparticles, *Pharmaceutics*, 2021, **13**(7), DOI: [10.3390/pharmaceutics13070945](https://doi.org/10.3390/pharmaceutics13070945).
- 91 L. Miao, J. Lin, Y. Huang, L. Li, D. Delcassian, Y. Ge, *et al.*, Synergistic lipid compositions for albumin receptor mediated delivery of mRNA to the liver, *Nat. Commun.*, 2020, **11**(1), 2424.
- 92 K. Zhou, L. H. Nguyen, J. B. Miller, Y. Yan, P. Kos, H. Xiong, *et al.*, Modular degradable dendrimers enable small RNAs to extend survival in an aggressive liver cancer model, *Proc. Natl. Acad. Sci. U. S. A.*, 2016, **113**(3), 520–525.
- 93 K. A. Hajj, R. L. Ball, S. B. Deluty, S. R. Singh, D. Strelkova, C. M. Knapp, *et al.*, Branched-Tail Lipid Nanoparticles Potently Deliver mRNA In Vivo due to Enhanced Ionization at Endosomal pH, *Small*, 2019, **15**(6), 1805097.
- 94 K. A. Hajj, J. R. Melamed, N. Chaudhary, N. G. Lamson, R. L. Ball, S. S. Yerneni, *et al.*, A Potent Branched-Tail Lipid Nanoparticle Enables Multiplexed mRNA Delivery and Gene Editing In Vivo, *Nano Lett.*, 2020, **20**(7), 5167–5175.
- 95 R. D. Harvey, N. Ara, R. K. Heenan, D. J. Barlow, P. J. Quinn and M. J. Lawrence, Stabilization of distearoylphosphatidylcholine lamellar phases in propylene glycol using cholesterol, *Mol. Pharm.*, 2013, **10**(12), 4408–4417.
- 96 R. Zhang, R. El-Mayta, T. J. Murdoch, C. C. Warzecha, M. M. Billingsley, S. J. Shepherd, *et al.*, Helper lipid structure influences protein adsorption and delivery of lipid nanoparticles to spleen and liver, *Biomater. Sci.*, 2021, **9**(4), 1449–1463.
- 97 E. Ikonen, Cellular cholesterol trafficking and compartmentalization, *Nat. Rev. Mol. Cell Biol.*, 2008, **9**(2), 125–138.
- 98 K. Paunovska, C. J. Gil, M. P. Lokugamage, C. D. Sago, M. Sato, G. N. Lando, *et al.*, Analyzing 2000 in Vivo Drug Delivery Data Points Reveals Cholesterol Structure Impacts Nanoparticle Delivery, *ACS Nano*, 2018, **12**(8), 8341–8349.
- 99 J. Poisson, S. Lemoine, C. Boulanger, F. Durand, R. Moreau, D. Valla, *et al.*, Liver sinusoidal endothelial cells: Physiology and role in liver diseases, *J. Hepatol.*, 2017, **66**(1), 212–227.
- 100 G. Kolios, V. Valatas and E. Kouroumalis, Role of Kupffer cells in the pathogenesis of liver disease, *World J. Gastroenterol.*, 2006, **12**(46), 7413–7420.
- 101 P. Harvie, F. M. Wong and M. B. Bally, Use of poly(ethylene glycol)-lipid conjugates to regulate the surface attributes and transfection activity of lipid-DNA particles, *J. Pharm. Sci.*, 2000, **89**(5), 652–663.
- 102 S. Chen, Y. Y. C. Tam, P. J. C. Lin, M. M. H. Sung, Y. K. Tam and P. R. Cullis, Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA, *J. Controlled Release*, 2016, **235**, 236–244.
- 103 M. Zhao, M. Li, Z. Zhang, T. Gong and X. Sun, Induction of HIV-1 gag specific immune responses by cationic micelles mediated delivery of gag mRNA, *Drug Delivery*, 2016, **23**(7), 2596–2607.
- 104 M. Li, M. Zhao, Y. Fu, Y. Li, T. Gong, Z. Zhang, *et al.*, Enhanced intranasal delivery of mRNA vaccine by overcoming the nasal epithelial barrier via intra- and paracellular pathways, *J. Controlled Release*, 2016, **228**, 9–19.
- 105 A. A. Eltoukhy, D. Chen, C. A. Alabi, R. Langer and D. G. Anderson, Degradable terpolymers with alkyl side chains demonstrate enhanced gene delivery potency and nanoparticle stability, *Adv. Mater.*, 2013, **25**(10), 1487–1493.
- 106 K. Hadinoto, A. Sundaresan and W. S. Cheow, Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review, *Eur. J. Pharm. Biopharm.*, 2013, **85**(3 Pt A), 427–443.
- 107 J. C. Kaczmarek, A. K. Patel, L. H. Rhym, U. C. Palmiero, B. Bhat, M. W. Heartlein, *et al.*, Systemic delivery of mRNA and DNA to the lung using polymer-lipid nanoparticles, *Biomaterials*, 2021, **275**, 120966.
- 108 J. C. Kaczmarek, A. K. Patel, K. J. Kauffman, O. S. Fenton, M. J. Webber, M. W. Heartlein, *et al.*, Polymer-Lipid Nanoparticles for Systemic Delivery of mRNA to the Lungs, *Angew. Chem., Int. Ed.*, 2016, **55**(44), 13808–13812.
- 109 C. Schumann, D. X. Nguyen, M. Norgard, Y. Bortnyak, T. Korzun, S. Chan, *et al.*, Increasing lean muscle mass in mice via nanoparticle-mediated hepatic delivery of follistatin mRNA, *Theranostics*, 2018, **8**(19), 5276–5288.
- 110 A. Matsui, S. Uchida, T. Ishii, K. Itaka and K. Kataoka, Messenger RNA-based therapeutics for the treatment of apoptosis-associated diseases, *Sci. Rep.*, 2015, **5**, 15810.
- 111 P. S. Kowalski, U. Capasso Palmiero, Y. Huang, A. Rudra, R. Langer and D. G. Anderson, Ionizable Amino-Polyesters Synthesized via Ring Opening Polymerization of Tertiary Amino-Alcohols for Tissue Selective mRNA Delivery, *Adv. Mater.*, 2018, 1801151.
- 112 J. Zhou, J. Liu, C. J. Cheng, T. R. Patel, C. E. Weller, J. M. Piepmeier, *et al.*, Biodegradable poly(amine-co-ester) terpolymers for targeted gene delivery, *Nat. Mater.*, 2011, **11**(1), 82–90.
- 113 S. M. Lewis, A. Williams and S. C. Eisenbarth, Structure and function of the immune system in the spleen, *Sci. Immunol.*, 2019, **4**(33), 1–12.

- 114 Y. Zhang and Z. Zhang, The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications, *Cell. Mol. Immunol.*, 2020, **17**(8), 807–821.
- 115 P. Serra and P. Santamaria, Antigen-specific therapeutic approaches for autoimmunity, *Nat. Biotechnol.*, 2019, **37**(3), 238–251.
- 116 M. M. Billingsley, N. Singh, P. Ravikumar, R. Zhang, C. H. June and M. J. Mitchell, Ionizable Lipid Nanoparticle-Mediated mRNA Delivery for Human CAR T Cell Engineering, *Nano Lett.*, 2020, **20**(3), 1578–1589.
- 117 P. Castiglioni, M. Gerloni and M. Zanetti, Genetically programmed B lymphocytes are highly efficient in inducing anti-virus protective immunity mediated by central memory CD8 T cells, *Vaccine*, 2004, **23**(5), 699–708.
- 118 C. J. McKinlay, N. L. Benner, O. A. Haabeth, R. M. Waymouth and P. A. Wender, Enhanced mRNA delivery into lymphocytes enabled by lipid-varied libraries of charge-altering releasable transporters, *Proc. Natl. Acad. Sci. U. S. A.*, 2018, **115**(26), E5859–E5866.
- 119 H. H. Gustafson, D. Holt-Casper, D. W. Grainger and H. Ghandehari, Nanoparticle Uptake: The Phagocyte Problem, *Nano Today*, 2015, **10**(4), 487–510.
- 120 P. W. Bisso, S. Gaglione, P. P. G. Guimaraes, M. J. Mitchell and R. Langer, Nanomaterial Interactions with Human Neutrophils, *ACS Biomater. Sci. Eng.*, 2018, **4**(12), 4255–4265.
- 121 L. M. Kranz, M. Diken, H. Haas, S. Kreiter, C. Loquai, K. C. Reuter, *et al.*, Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy, *Nature*, 2016, **534**(7607), 396–401.
- 122 Q. Cheng, T. Wei, L. Farbiak, L. T. Johnson, S. A. Dilliard and D. J. Siegwart, Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing, *Nat. Nanotechnol.*, 2020, **15**(4), 313–320.
- 123 S. A. Dilliard, Q. Cheng and D. J. Siegwart, On the mechanism of tissue-specific mRNA delivery by selective organ targeting nanoparticles, *Proc. Natl. Acad. Sci. U. S. A.*, 2021, **118**(52), e2109256118.
- 124 E. Alvarez-Benedicto, L. Farbiak, M. Márquez Ramírez, X. Wang, L. T. Johnson, O. Mian, *et al.*, Optimization of phospholipid chemistry for improved lipid nanoparticle (LNP) delivery of messenger RNA (mRNA), *Biomater. Sci.*, 2022, **10**(2), 549–559.
- 125 S. T. LoPresti, M. L. Arral, N. Chaudhary and K. A. Whitehead, The replacement of helper lipids with charged alternatives in lipid nanoparticles facilitates targeted mRNA delivery to the spleen and lungs, *J. Controlled Release*, 2022, **345**, 819–831.
- 126 S. Liu, Q. Cheng, T. Wei, X. Yu, L. T. Johnson, L. Farbiak, *et al.*, Membrane-destabilizing ionizable phospholipids for organ-selective mRNA delivery and CRISPR-Cas gene editing, *Nat. Mater.*, 2021, **20**(5), 701–710.
- 127 O. S. Fenton, K. J. Kauffman, R. L. McClellan, J. C. Kaczmarek, M. D. Zeng, J. L. Andresen, *et al.*, Customizable Lipid Nanoparticle Materials for the Delivery of siRNAs and mRNAs, *Angew. Chem., Int. Ed.*, 2018, **57**(41), 13582–13586.
- 128 C. D. Sago, M. P. Lokugamage, K. Paunovska, D. A. Vanover, C. M. Monaco, N. N. Shah, *et al.*, High-throughput in vivo screen of functional mRNA delivery identifies nanoparticles for endothelial cell gene editing, *Proc. Natl. Acad. Sci. U. S. A.*, 2018, **115**(42), E9944–E9952.
- 129 I. Tombacz, D. Laczko, H. Shah Nawaz, H. Muramatsu, A. Natesan, A. Yadegari, *et al.*, Highly efficient CD4+ T cell targeting and genetic recombination using engineered CD4 + cell-homing mRNA-LNPs, *Mol. Ther.*, 2021, **29**(11), 3293–3304.
- 130 M. Li, S. Li, Y. Huang, H. Chen, S. Zhang, Z. Zhang, *et al.*, Secreted Expression of mRNA-Encoded Truncated ACE2 Variants for SARS-CoV-2 via Lipid-Like Nanoassemblies, *Adv. Mater.*, 2021, **33**(34), e2101707.
- 131 Z. H. Liu, Z. Y. Zhang, C. R. Zhou and Y. P. Jiao, Hydrophobic modifications of cationic polymers for gene delivery, *Prog. Polym. Sci.*, 2010, **35**(9), 1144–1162.
- 132 X. Yu, S. Liu, Q. Cheng, S. M. Lee, T. Wei, D. Zhang, *et al.*, Hydrophobic Optimization of Functional Poly(TPAE-co-suberoyl chloride) for Extrahepatic mRNA Delivery following Intravenous Administration, *Pharmaceutics*, 2021, **13**(11), 1–13.
- 133 S. Liu, X. Wang, X. Yu, Q. Cheng, L. T. Johnson, S. Chatterjee, *et al.*, Zwitterionic Phospholipidation of Cationic Polymers Facilitates Systemic mRNA Delivery to Spleen and Lymph Nodes, *J. Am. Chem. Soc.*, 2021, **143**(50), 21321–21330.
- 134 L. M. Caffrey, B. M. deRonde, L. M. Minter and G. N. Tew, Mapping Optimal Charge Density and Length of ROMP-Based PTDMs for siRNA Internalization, *Biomacromolecules*, 2016, **17**(10), 3205–3212.
- 135 B. M. deRonde, J. A. Torres, L. M. Minter and G. N. Tew, Development of Guanidinium-Rich Protein Mimics for Efficient siRNA Delivery into Human T Cells, *Biomacromolecules*, 2015, **16**(10), 3172–3179.
- 136 Collaborators GBDCRD, Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017, *Lancet Respir. Med.*, 2020, **8**(6), 585–596.
- 137 A. A. Aslam, C. Higgins, I. P. Sinha and K. W. Southern, Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic fibrosis, *Cochrane Database Syst. Rev.*, 2017, **1**, CD012040.
- 138 R. H. Pfister and R. F. Soll, New synthetic surfactants: the next generation?, *Biol. Neonate*, 2005, **87**(4), 338–344.
- 139 N. Bertrand and J. C. Leroux, The journey of a drug-carrier in the body: an anatomo-physiological perspective, *J. Controlled Release*, 2012, **161**(2), 152–163.
- 140 T. Wang, J. R. Upponi and V. P. Torchilin, Design of multi-functional non-viral gene vectors to overcome physiological barriers: dilemmas and strategies, *Int. J. Pharm.*, 2012, **427**(1), 3–20.

- 141 S. P. Newman, Aerosol deposition considerations in inhalation therapy, *Chest*, 1985, **88**(2 Suppl), 152S–160S.
- 142 J. J. Wine, The genesis of cystic fibrosis lung disease, *J. Clin. Invest.*, 1999, **103**(3), 309–312.
- 143 J. G. Widdicombe, Airway liquid: a barrier to drug diffusion?, *Eur. Respir. J.*, 1997, **10**(10), 2194–2197.
- 144 M. Dawson, D. Wirtz and J. Hanes, Enhanced viscoelasticity of human cystic fibrotic sputum correlates with increasing microheterogeneity in particle transport, *J. Biol. Chem.*, 2003, **278**(50), 50393–50401.
- 145 N. N. Sanders, S. C. De Smedt, E. Van Rompaey, P. Simoens, F. De Baets and J. Demeester, Cystic fibrosis sputum - A barrier to the transport of nanospheres, *Am. J. Respir. Crit. Care*, 2000, **162**(5), 1905–1911.
- 146 J. S. Suk, S. K. Lai, Y. Y. Wang, L. M. Ensign, P. L. Zeitlin, M. P. Boyle, *et al.*, The penetration of fresh undiluted sputum expectorated by cystic fibrosis patients by non-adhesive polymer nanoparticles, *Biomaterials*, 2009, **30**(13), 2591–2597.
- 147 S. Ferrari, C. Kitson, R. Farley, R. Steel, C. Marriott, D. A. Parkins, *et al.*, Mucus altering agents as adjuncts for nonviral gene transfer to airway epithelium, *Gene Ther.*, 2001, **8**(18), 1380–1386.
- 148 N. Sanders, C. Rudolph, K. Braeckmans, S. C. De Smedt and J. Demeester, Extracellular barriers in respiratory gene therapy, *Adv. Drug Delivery Rev.*, 2009, **61**(2), 115–127.
- 149 N. Ernst, S. Ulrichskotter, W. A. Schmalix, J. Radler, R. Galneder, E. Mayer, *et al.*, Interaction of liposomal and polycationic transfection complexes with pulmonary surfactant, *J. Gene Med.*, 1999, **1**(5), 331–340.
- 150 A. Dewerth, A. Mahiny, L. E. Mays, M. Alkahled, B. Mothes, E. Malaeksefat, *et al.*, In vivo genome editing using nuclease-encoding mRNA corrects SP-B deficiency, *Eur. Respir. J.*, 2016, **48**, 584–586.
- 151 L. M. Noguee, Alterations in SP-B and SP-C expression in neonatal lung disease, *Annu. Rev. Physiol.*, 2004, **66**, 601–623.
- 152 A. Haque, A. Dewerth, J. S. Antony, J. Riethmuller, G. R. Schweizer, P. Weinmann, *et al.*, Chemically modified hCFTR mRNAs recuperate lung function in a mouse model of cystic fibrosis, *Sci. Rep.*, 2018, **8**(1), 16776.
- 153 A. K. Patel, J. C. Kaczmarek, S. Bose, K. J. Kauffman, F. Mir, M. W. Heartlein, *et al.*, Inhaled Nanoformulated mRNA Polyplexes for Protein Production in Lung Epithelium, *Adv. Mater.*, 2019, **31**(8), e1805116.
- 154 A. Jarzebinska, T. Pasewald, J. Lambrecht, O. Mykhaylyk, L. Kummerling, P. Beck, *et al.*, A Single Methylene Group in Oligoalkylamine-Based Cationic Polymers and Lipids Promotes Enhanced mRNA Delivery, *Angew. Chem., Int. Ed.*, 2016, **55**(33), 9591–9595.
- 155 S. E. Beck, B. L. Laube, C. I. Barberena, A. C. Fischer, R. J. Adams, K. Chesnut, *et al.*, Deposition and expression of aerosolized rAAV vectors in the lungs of Rhesus macaques, *Mol. Ther.*, 2002, **6**(4), 546–554.
- 156 C. L. Densmore, F. M. Orson, B. Xu, B. M. Kinsey, J. C. Waldrep, P. Hua, *et al.*, Aerosol delivery of robust polyethyleneimine-DNA complexes for gene therapy and genetic immunization, *Mol. Ther.*, 2000, **1**(2), 180–188.
- 157 G. McLachlan, H. Davidson, E. Holder, L. A. Davies, I. A. Pringle, S. G. Sumner-Jones, *et al.*, Pre-clinical evaluation of three non-viral gene transfer agents for cystic fibrosis after aerosol delivery to the ovine lung, *Gene Ther.*, 2011, **18**(10), 996–1005.
- 158 L. G. Johnson, J. C. Olsen, B. Sarkadi, K. L. Moore, R. Swanstrom and R. C. Boucher, Efficiency of gene transfer for restoration of normal airway epithelial function in cystic fibrosis, *Nat. Genet.*, 1992, **2**(1), 21–25.
- 159 A. E. Potash, T. J. Wallen, P. H. Karp, S. Ernst, T. O. Moninger, N. D. Gansemer, *et al.*, Adenoviral gene transfer corrects the ion transport defect in the sinus epithelia of a porcine CF model, *Mol. Ther.*, 2013, **21**(5), 947–953.
- 160 J. T. Huckaby and S. K. Lai, PEGylation for enhancing nanoparticle diffusion in mucus, *Adv. Drug Delivery Rev.*, 2018, **124**, 125–139.
- 161 N. N. Sanders, S. C. De Smedt, S. H. Cheng and J. Demeester, Pegylated GL67 lipoplexes retain their gene transfection activity after exposure to components of CF mucus, *Gene Ther.*, 2002, **9**(6), 363–371.
- 162 K. Maisel, M. Reddy, Q. Xu, S. Chattopadhyay, R. Cone, L. M. Ensign, *et al.*, Nanoparticles coated with high molecular weight PEG penetrate mucus and provide uniform vaginal and colorectal distribution in vivo, *Nanomedicine*, 2016, **11**(11), 1337–1343.
- 163 G. Conte, G. Costabile, D. Baldassi, V. Rondelli, R. Bassi, D. Colombo, *et al.*, Hybrid Lipid/Polymer Nanoparticles to Tackle the Cystic Fibrosis Mucus Barrier in siRNA Delivery to the Lungs: Does PEGylation Make the Difference?, *ACS Appl. Mater. Interfaces*, 2022, 7565–7578.
- 164 S. Guan, A. Munder, S. Hedtfeld, P. Braubach, S. Glage, L. Zhang, *et al.*, Self-assembled peptide-podoxamine nanoparticles enable in vitro and in vivo genome restoration for cystic fibrosis, *Nat. Nanotechnol.*, 2019, **14**(3), 287–297.
- 165 E. L. Blanchard, D. Vanover, S. S. Bawage, P. M. Tiwari, L. Rotolo, J. Beyersdorf, *et al.*, Treatment of influenza and SARS-CoV-2 infections via mRNA-encoded Cas13a in rodents, *Nat. Biotechnol.*, 2021, **39**(6), 717–700.
- 166 R. Y. K. Chang and H. K. Chan, Lipid nanoparticles for the inhalation of mRNA, *Nat. Biomed. Eng.*, 2021, **5**(9), 949–950.
- 167 M. P. Lokugamage, D. Vanover, J. Beyersdorf, M. Z. C. Hatit, L. Rotolo, E. S. Echeverri, *et al.*, Optimization of lipid nanoparticles for the delivery of nebulized therapeutic mRNA to the lungs, *Nat. Biomed. Eng.*, 2021, **5**(9), 1059–1068.
- 168 E. Schrom, M. Huber, M. Aneja, C. Dohmen, D. Emrich, J. Geiger, *et al.*, Translation of Angiotensin-Converting Enzyme 2 upon Liver- and Lung-Targeted Delivery of Optimized Chemically Modified mRNA, *Mol. Ther. – Nucleic Acids*, 2017, **7**, 350–365.
- 169 D. A. Chistiakov, A. N. Orekhov and Y. V. Bobryshev, Endothelial PECAM-1 and its function in vascular physi-

- ology and atherogenic pathology, *Exp. Mol. Pathol.*, 2016, **100**(3), 409–415.
- 170 J. Han, V. V. Shuvaev and V. R. Muzykantov, Targeted interception of signaling reactive oxygen species in the vascular endothelium, *Ther. Delivery*, 2012, **3**(2), 263–276.
- 171 H. Parhiz, V. V. Shuvaev, N. Pardi, M. Khoshnejad, R. Y. Kiseleva, J. S. Brenner, *et al.*, PECAM-1 directed re-targeting of exogenous mRNA providing two orders of magnitude enhancement of vascular delivery and expression in lungs independent of apolipoprotein E-mediated uptake, *J. Controlled Release*, 2018, **291**, 106–115.
- 172 T. Wei, Q. Cheng, Y. L. Min, E. N. Olson and D. J. Siegwart, Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue specific genome editing, *Nat. Commun.*, 2020, **11**(1), 3232.
- 173 J. B. Miller, S. Zhang, P. Kos, H. Xiong, K. Zhou, S. S. Perelman, *et al.*, Non-Viral CRISPR/Cas Gene Editing In Vitro and In Vivo Enabled by Synthetic Nanoparticle Co-Delivery of Cas9 mRNA and sgRNA, *Angew. Chem., Int. Ed.*, 2017, **56**(4), 1059–1063.
- 174 Y. Rui, D. R. Wilson, S. Y. Tzeng, H. M. Yamagata, D. Sudhakar, M. Conge, *et al.*, High-throughput and high-content bioassay enables tuning of polyester nanoparticles for cellular uptake, endosomal escape, and systemic in vivo delivery of mRNA, *Sci. Adv.*, 2022, **8**(1), eabk2855.
- 175 Y. Yan, H. Xiong, X. Zhang, Q. Cheng and D. J. Siegwart, Systemic mRNA Delivery to the Lungs by Functional Polyester-based Carriers, *Biomacromolecules*, 2017, **18**(12), 4307–4315.
- 176 J. C. Kaczmarek, K. J. Kauffman, O. S. Fenton, K. Sadtler, A. K. Patel, M. W. Heartlein, *et al.*, Optimization of a Degradable Polymer-Lipid Nanoparticle for Potent Systemic Delivery of mRNA to the Lung Endothelium and Immune Cells, *Nano Lett.*, 2018, **18**(10), 6449–6454.
- 177 C. D. Walkey, J. B. Olsen, F. Song, R. Liu, H. Guo, D. W. Olsen, *et al.*, Protein corona fingerprinting predicts the cellular interaction of gold and silver nanoparticles, *ACS Nano*, 2014, **8**(3), 2439–2455.
- 178 J. Huotari and A. Helenius, Endosome maturation, *EMBO J.*, 2011, **30**(17), 3481–3500.
- 179 F. Morfousse and A. Noel, Lymphatic and blood systems: Identical or fraternal twins?, *Int. J. Biochem. Cell Biol.*, 2019, **114**, 105562.
- 180 Y. Xie, T. R. Bagby, M. S. Cohen and M. L. Forrest, Drug delivery to the lymphatic system: importance in future cancer diagnosis and therapies, *Expert Opin. Drug Delivery*, 2009, **6**(8), 785–792.
- 181 P. Y. von der Weid, S. Rehal and J. G. Ferraz, Role of the lymphatic system in the pathogenesis of Crohn's disease, *Curr. Opin. Gastroenterol.*, 2011, **27**(4), 335–341.
- 182 W. F. Richter, S. G. Bhansali and M. E. Morris, Mechanistic determinants of biotherapeutics absorption following SC administration, *AAPS J.*, 2012, **14**(3), 559–570.
- 183 K. E. Lindsay, S. M. Bhosle, C. Zurla, J. Beyersdorf, K. A. Rogers, D. Vanover, *et al.*, Visualization of early events in mRNA vaccine delivery in non-human primates via PET-CT and near-infrared imaging, *Nat. Biomed. Eng.*, 2019, **3**(5), 371–380.
- 184 S. N. Thomas, N. A. Rohner and E. E. Edwards, Implications of Lymphatic Transport to Lymph Nodes in Immunity and Immunotherapy, *Annu. Rev. Biomed. Eng.*, 2016, **18**, 207–233.
- 185 D. Szoke, G. Kovacs, E. Kemecei, L. Balint, K. Szotak-Ajtay, P. Aradi, *et al.*, Nucleoside-modified VEGFC mRNA induces organ-specific lymphatic growth and reverses experimental lymphedema, *Nat. Commun.*, 2021, **12**(1), 3460.
- 186 V. Manolova, A. Flace, M. Bauer, K. Schwarz, P. Saudan and M. F. Bachmann, Nanoparticles target distinct dendritic cell populations according to their size, *Eur. J. Immunol.*, 2008, **38**(5), 1404–1413.
- 187 S. T. Reddy, A. Rehor, H. G. Schmoekel, J. A. Hubbell and M. A. Swartz, In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles, *J. Controlled Release*, 2006, **112**(1), 26–34.
- 188 M. A. Oberli, A. M. Reichmuth, J. R. Dorkin, M. J. Mitchell, O. S. Fenton, A. Jaklenec, *et al.*, Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy, *Nano Lett.*, 2017, **17**(3), 1326–1335.
- 189 U. Sahin, E. Derhovanessian, M. Miller, B. P. Kloke, P. Simon, M. Lower, *et al.*, Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer, *Nature*, 2017, **547**(7662), 222–226.
- 190 U. Sahin, P. Oehm, E. Derhovanessian, R. A. Jabulowsky, M. Vormehr, M. Gold, *et al.*, An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma, *Nature*, 2020, **585**(7823), 107–112.
- 191 L. F. Wong, L. Goodhead, C. Prat, K. A. Mitrophanous, S. M. Kingsman and N. D. Mazarakis, Lentivirus-mediated gene transfer to the central nervous system: therapeutic and research applications, *Hum. Gene Ther.*, 2006, **17**(1), 1–9.
- 192 S. Yang, R. Chang, H. Yang, T. Zhao, Y. Hong, H. E. Kong, *et al.*, CRISPR/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington's disease, *J. Clin. Invest.*, 2017, **127**(7), 2719–2724.
- 193 S. Ohta, E. Kikuchi, A. Ishijima, T. Azuma, I. Sakuma and T. Ito, Investigating the optimum size of nanoparticles for their delivery into the brain assisted by focused ultrasound-induced blood-brain barrier opening, *Sci. Rep.*, 2020, **10**(1), 18220.
- 194 K. T. Householder, S. Dharmaraj, D. I. Sandberg, R. J. Wechsler-Reya and R. W. Sirianni, Fate of nanoparticles in the central nervous system after intrathecal injection in healthy mice, *Sci. Rep.*, 2019, **9**(1), 12587.
- 195 J. F. Nabhan, K. M. Wood, V. P. Rao, J. Morin, S. Bhamidipaty, T. P. LaBranche, *et al.*, Intrathecal delivery of frataxin mRNA encapsulated in lipid nanoparticles to dorsal root ganglia as a potential therapeutic for Friedreich's ataxia, *Sci. Rep.*, 2016, **6**, 20019.

- 196 A.J. Atkinson Jr., Intracerebroventricular drug administration, *Transl. Clin. Pharmacol.*, 2017, **25**(3), 117–124.
- 197 H. Tanaka, T. Nakatani, T. Furihata, K. Tange, Y. Nakai, H. Yoshioka, *et al.*, In Vivo Introduction of mRNA Encapsulated in Lipid Nanoparticles to Brain Neuronal Cells and Astrocytes via Intracerebroventricular Administration, *Mol. Pharm.*, 2018, **15**(5), 2060–2067.
- 198 R. E. Pitas, J. K. Boyles, S. H. Lee, D. Hui and K. H. Weisgraber, Lipoproteins and Their Receptors in the Central-Nervous-System - Characterization of the Lipoproteins in Cerebrospinal-Fluid and Identification of Apolipoprotein-B,E(Ldl) Receptors in the Brain, *J. Biol. Chem.*, 1987, **262**(29), 14352–14360.
- 199 R. L. Rungta, H. B. Choi, P. J. Lin, R. W. Ko, D. Ashby, J. Nair, *et al.*, Lipid Nanoparticle Delivery of siRNA to Silence Neuronal Gene Expression in the Brain, *Mol. Ther.–Nucleic Acids*, 2013, **2**, e136.
- 200 C. Y. Lin, F. Perche, M. Ikegami, S. Uchida, K. Kataoka and K. Itaka, Messenger RNA-based therapeutics for brain diseases: An animal study for augmenting clearance of beta-amyloid by intracerebral administration of neprilysin mRNA loaded in polyplex nanomicelles, *J. Controlled Release*, 2016, **235**, 268–275.
- 201 O. A. Marcos-Contreras, C. F. Greineder, R. Y. Kiseleva, H. Parhiz, L. R. Walsh, V. Zuluaga-Ramirez, *et al.*, Selective targeting of nanomedicine to inflamed cerebral vasculature to enhance the blood-brain barrier, *Proc. Natl. Acad. Sci. U. S. A.*, 2020, **117**(7), 3405–3414.
- 202 D. A. Prado, M. Acosta-Acero and R. S. Maldonado, Gene therapy beyond luxturna: a new horizon of the treatment for inherited retinal disease, *Curr. Opin. Ophthalmol.*, 2020, **31**(3), 147–154.
- 203 J. Devoldere, K. Peynshaert, H. Dewitte, C. Vanhove, L. De Groef, L. Moons, *et al.*, Non-viral delivery of chemically modified mRNA to the retina: Subretinal versus intravitreal administration, *J. Controlled Release*, 2019, **307**, 315–330.
- 204 S. Patel, R. C. Ryals, K. K. Weller, M. E. Pennesi and G. Sahay, Lipid nanoparticles for delivery of messenger RNA to the back of the eye, *J. Controlled Release*, 2019, **303**, 91–100.
- 205 S. Veleri, C. H. Lazar, B. Chang, P. A. Sieving, E. Banin and A. Swaroop, Biology and therapy of inherited retinal degenerative disease: insights from mouse models, *Dis. Models Mech.*, 2015, **8**(2), 109–129.
- 206 R. Ladha, L. E. Caspers, F. Willermain and M. D. de Smet, Subretinal Therapy: Technological Solutions to Surgical and Immunological Challenges, *Front. Med.*, 2022, **9**, 846782.
- 207 J. Mains and C. G. Wilson, The vitreous humor as a barrier to nanoparticle distribution, *J. Ocul. Pharmacol. Ther.*, 2013, **29**(2), 143–150.
- 208 R. C. Ryals, S. Patel, C. Acosta, M. McKinney, M. E. Pennesi and G. Sahay, The effects of PEGylation on LNP based mRNA delivery to the eye, *PLoS One*, 2020, **15**(10), e0241006.
- 209 H. Dargie, Heart failure post-myocardial infarction: a review of the issues, *Heart*, 2005, **91**(Suppl 2), ii3–ii6.
- 210 A. S. Go, D. Mozaffarian, V. L. Roger, E. J. Benjamin, J. D. Berry, M. J. Blaha, *et al.*, Heart disease and stroke statistics–2014 update: a report from the American Heart Association, *Circulation*, 2014, **129**(3), e28–e292.
- 211 H. Hashimoto, E. N. Olson and R. Bassel-Duby, Therapeutic approaches for cardiac regeneration and repair, *Nat. Rev. Cardiol.*, 2018, **15**(10), 585–600.
- 212 A. Magadam, K. Kaur and L. Zangi, mRNA-Based Protein Replacement Therapy for the Heart, *Mol. Ther.*, 2019, **27**(4), 785–793.
- 213 K. Sato, T. Wu, R. J. Laham, R. B. Johnson, P. Douglas, J. Li, *et al.*, Efficacy of intracoronary or intravenous VEGF165 in a pig model of chronic myocardial ischemia, *J. Am. Coll. Cardiol.*, 2001, **37**(2), 616–623.
- 214 D. J. Stewart, M. J. Kutryk, D. Fitchett, M. Freeman, N. Camack, Y. Su, *et al.*, VEGF gene therapy fails to improve perfusion of ischemic myocardium in patients with advanced coronary disease: results of the NORTHERN trial, *Mol. Ther.*, 2009, **17**(6), 1109–1115.
- 215 K. O. Lui, L. Zangi, E. A. Silva, L. Bu, M. Sahara, R. A. Li, *et al.*, Driving vascular endothelial cell fate of human multipotent Isl1 + heart progenitors with VEGF modified mRNA, *Cell Res.*, 2013, **23**(10), 1172–1186.
- 216 L. Zangi, K. O. Lui, A. von Gise, Q. Ma, W. Ebina, L. M. Ptaszek, *et al.*, Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction, *Nat. Biotechnol.*, 2013, **31**(10), 898–907.
- 217 I. C. Turnbull, A. A. Eltoukhy, D. G. Anderson and K. D. Costa, Lipidoid mRNA Nanoparticles for Myocardial Delivery in Rodents, *Methods Mol. Biol.*, 2017, **1521**, 153–166.
- 218 I. C. Turnbull, A. A. Eltoukhy, K. M. Fish, M. Nonnenmacher, K. Ishikawa, J. Chen, *et al.*, Myocardial Delivery of Lipidoid Nanoparticle Carrying modRNA Induces Rapid and Transient Expression, *Mol. Ther.*, 2016, **24**(1), 66–75.
- 219 N. Sultana, A. Magadam, Y. Hadas, J. Kondrat, N. Singh, E. Youssef, *et al.*, Optimizing Cardiac Delivery of Modified mRNA, *Mol. Ther.*, 2017, **25**(6), 1306–1315.
- 220 L. Carlsson, J. C. Clarke, C. Yen, F. Gregoire, T. Albery, M. Billger, *et al.*, Biocompatible, Purified VEGF-A mRNA Improves Cardiac Function after Intracardiac Injection 1 Week Post-myocardial Infarction in Swine, *Mol. Ther.–Methods Clin. Dev.*, 2018, **9**, 330–346.
- 221 T. T. H. Thi, E. J. A. Suys, J. S. Lee, D. H. Nguyen, K. D. Park and N. P. Truong, Lipid-Based Nanoparticles in the Clinic and Clinical Trials: From Cancer Nanomedicine to COVID-19 Vaccines, *Vaccines*, 2021, **9**(4), 1–29.
- 222 M. A. Maier, M. Jayaraman, S. Matsuda, J. Liu, S. Barros, W. Querbes, *et al.*, Biodegradable Lipids Enabling Rapidly Eliminated Lipid Nanoparticles for Systemic Delivery of RNAi Therapeutics, *Mol. Ther.*, 2013, **21**(8), 1570–1578.

- 223 X. Zhou, Y. Cui and J. Han, Methylmalonic acidemia: Current status and research priorities, *Intractable Rare Dis. Res.*, 2018, **7**(2), 73–78.
- 224 D. An, A. Frassetto, E. Jacquinet, M. Eybye, J. Milano, C. DeAntonis, *et al.*, Long-term efficacy and safety of mRNA therapy in two murine models of methylmalonic acidemia, *EBioMedicine*, 2019, **45**, 519–528.
- 225 T. Uchino, S. E. Snyderman, M. Lambert, I. A. Qureshi, S. K. Shapira, C. Sansaricq, *et al.*, Molecular basis of phenotypic variation in patients with argininemia, *Hum. Genet.*, 1995, **96**(3), 255–260.
- 226 B. Truong, G. Allegri, X. B. Liu, K. E. Burke, X. L. Zhu, S. D. Cederbaum, *et al.*, Lipid nanoparticle-targeted mRNA therapy as a treatment for the inherited metabolic liver disorder arginase deficiency, *Proc. Natl. Acad. Sci. U. S. A.*, 2019, **116**(42), 21150–21159.
- 227 S. Song, L. Yang, W. L. Trepicchio and T. Wyant, Understanding the Supersensitive Anti-Drug Antibody Assay: Unexpected High Anti-Drug Antibody Incidence and Its Clinical Relevance, *J. Immunol. Res.*, 2016, **2016**, 3072586.
- 228 J. Cao, M. Choi, E. Guadagnin, M. Soty, M. Silva, V. Verzieux, *et al.*, mRNA therapy restores euglycemia and prevents liver tumors in murine model of glycogen storage disease, *Nat. Commun.*, 2021, **12**(1), 3090.
- 229 J. Szebeni, G. Storm, J. Y. Ljubimova, M. Castells, E. J. Phillips, K. Turjeman, *et al.*, Applying lessons learned from nanomedicines to understand rare hypersensitivity reactions to mRNA-based SARS-CoV-2 vaccines, *Nat. Nanotechnol.*, 2022, **17**(4), 337–346.
- 230 X. Zhang, V. Goel and G. J. Robbie, Pharmacokinetics of Patisiran, the First Approved RNA Interference Therapy in Patients With Hereditary Transthyretin-Mediated Amyloidosis, *J. Clin. Pharmacol.*, 2019, **60**(5), 573–585.
- 231 J. S. Butler, A. Chan, S. Costelha, S. Fishman, J. L. S. Willoughby, T. D. Borland, *et al.*, Preclinical evaluation of RNAi as a treatment for transthyretin-mediated amyloidosis, *Amyloid*, 2016, **23**(2), 109–118.
- 232 K. M. Miah, S. C. Hyde and D. R. Gill, Emerging gene therapies for cystic fibrosis, *Expert Rev. Respir. Med.*, 2019, **13**(8), 709–725.
- 233 J. A. Lee, A. Cho, E. N. Huang, Y. Xu, H. Quach, J. Hu, *et al.*, Gene therapy for cystic fibrosis: new tools for precision medicine, *J. Transl. Med.*, 2021, **19**(1), 452.
- 234 M. Torres, D. Boudko, E. Meleshkevitch, M. Coquelin, X. Yu, J. Eby, *et al.*, Variant-agnostic CFTR rescue using aerosolized delivery of CFTR mRNA using the SORT-LNP in primary human bronchial epithelial cells derived from patients with cystic fibrosis, *J. Cystic Fibrosis*, 2021, **20**, S278.
- 235 E. Robinson, K. D. MacDonald, K. Slaughter, M. McKinney, S. Patel, C. Sun, *et al.*, Lipid Nanoparticle-Delivered Chemically Modified mRNA Restores Chloride Secretion in Cystic Fibrosis, *Mol. Ther.*, 2018, **26**(8), 2034–2046.
- 236 A. Karadagi, A. G. Cavedon, H. Zemack, G. Nowak, M. E. Eybye, X. L. Zhu, *et al.*, Systemic modified messenger RNA for replacement therapy in alpha 1-antitrypsin deficiency, *Sci. Rep.*, 2020, **10**(1), 7052.
- 237 J. D. Beck, D. Reidenbach, N. Salomon, U. Sahin, O. Tureci, M. Vormehr, *et al.*, mRNA therapeutics in cancer immunotherapy, *Mol. Cancer*, 2021, **20**(1), 69.
- 238 N. Veiga, M. Goldsmith, Y. Granot, D. Rosenblum, N. Dammes, R. Kedmi, *et al.*, Cell specific delivery of modified mRNA expressing therapeutic proteins to leukocytes, *Nat. Commun.*, 2018, **9**(1), 4493.
- 239 K. Radhakrishnan and S. G. Rockson, The clinical spectrum of lymphatic disease, *Ann. N. Y. Acad. Sci.*, 2008, **1131**, 155–184.
- 240 A. Da Silva Sanchez, K. Paunovska, A. Cristian and J. E. Dahlman, Treating Cystic Fibrosis with mRNA and CRISPR, *Hum. Gene Ther.*, 2020, **31**(17–18), 940–955.
- 241 X. Zhang, W. Zhao, G. N. Nguyen, C. Zhang, C. Zeng, J. Yan, *et al.*, Functionalized lipid-like nanoparticles for in vivo mRNA delivery and base editing, *Sci. Adv.*, 2020, **6**(34), eabc2315.
- 242 C. Jiang, M. Mei, B. Li, X. Zhu, W. Zu, Y. Tian, *et al.*, A non-viral CRISPR/Cas9 delivery system for therapeutically targeting HBV DNA and psck9 in vivo, *Cell Res.*, 2017, **27**(3), 440–443.
- 243 M. Qiu, Z. Glass, J. Chen, M. Haas, X. Jin, X. Zhao, *et al.*, Lipid nanoparticle-mediated codelivery of Cas9 mRNA and single-guide RNA achieves liver-specific in vivo genome editing of Angptl3, *Proc. Natl. Acad. Sci. U. S. A.*, 2021, **118**(10), e20204011.
- 244 J. D. Finn, A. R. Smith, M. C. Patel, L. Shaw, M. R. Youniss, J. van Heteren, *et al.*, A Single Administration of CRISPR/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing, *Cell Rep.*, 2018, **22**(9), 2227–2235.
- 245 L. Farbiak, Q. Cheng, T. Wei, E. Alvarez-Benedicto, L. T. Johnson, S. Lee, *et al.*, All-In-One Dendrimer-Based Lipid Nanoparticles Enable Precise HDR-Mediated Gene Editing In Vivo, *Adv. Mater.*, 2021, **33**(30), e2006619.
- 246 J. D. Gillmore, E. Gane, J. Taubel, J. Kao, M. Fontana, M. L. Maitland, *et al.*, CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis, *N. Engl. J. Med.*, 2021, **385**(6), 493–502.
- 247 J. G. Rurik, I. Tombacz, A. Yadegari, P. O. Méndez Fernández, S. V. Shewale, L. Li, *et al.*, CAR T cells produced in vivo to treat cardiac injury, *Science*, 2022, **375**(6576), 91–96.
- 248 A. Ehrhardt, R. Haase, A. Schepers, M. J. Deutsch, H. J. Lipps and A. Baiker, Episomal vectors for gene therapy, *Curr. Gene Ther.*, 2008, **8**(3), 147–161.
- 249 K. Paunovska, A. J. Da Silva Sanchez, C. D. Sago, Z. Gan, M. P. Lokugamage, F. Z. Islam, *et al.*, Nanoparticles Containing Oxidized Cholesterol Deliver mRNA to the Liver Microenvironment at Clinically Relevant Doses, *Adv. Mater.*, 2019, **31**(14), e1807748.
- 250 B. Connolly, C. Isaacs, L. Cheng, K. H. Asrani and R. R. Subramanian, SERPINA1 mRNA as a Treatment for

- Alpha-1 Antitrypsin Deficiency, *J. Nucleic Acids*, 2018, **2018**, 8247935.
- 251 L. Jiang, J. S. Park, L. Yin, R. Laureano, E. Jacquinet, J. Yang, *et al.*, Dual mRNA therapy restores metabolic function in long-term studies in mice with propionic acidemia, *Nat. Commun.*, 2020, **11**(1), 5339.
- 252 D. S. Roseman, T. Khan, F. Rajas, L. S. Jun, K. H. Asrani, C. Isaacs, *et al.*, G6PC mRNA Therapy Positively Regulates Fasting Blood Glucose and Decreases Liver Abnormalities in a Mouse Model of Glycogen Storage Disease 1a, *Mol. Ther.*, 2018, **26**(3), 814–821.
- 253 S. Ramaswamy, N. Tonnu, K. Tachikawa, P. Limphong, J. B. Vega, P. P. Karmali, *et al.*, Systemic delivery of factor IX messenger RNA for protein replacement therapy, *Proc. Natl. Acad. Sci. U. S. A.*, 2017, **114**(10), E1941–E1950.
- 254 F. DeRosa, B. Guild, S. Karve, L. Smith, K. Love, J. R. Dorkin, *et al.*, Therapeutic efficacy in a hemophilia B model using a biosynthetic mRNA liver depot system, *Gene Ther.*, 2016, **23**(10), 699–707.
- 255 S. Liu-Chen, B. Connolly, L. Cheng, R. R. Subramanian and Z. Han, mRNA treatment produces sustained expression of enzymatically active human ADAMTS13 in mice, *Sci. Rep.*, 2018, **8**(1), 7859.